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1 Introduction
1.1 Alzheimer’s Disease
1.1.1 Historical Background
The  disease  was  first  described  by  Alois  Alzheimer  (Fig.  1.1),  a  neurologist  and 
psychiatrist in Frankfurt am Main. He extensively investigated the pathology of the 
nervous system together with his colleague Franz Nissl. At the beginning of the last 
century,  he  reported  that  one  of  his  patients,  Auguste  D.,  suffered  from  severe 
memory  impairment  and  desorientation.  After  death,  he  dissected  the  brain  and 
described  histopathological  changes  which  are 
recognized  still  today  as  the  typical  hallmarks  of 
Alzheimer´s  Disease  (AD):  extracellular  senile  plaques 
and  intracellular  neurofibrillary  tangles.  Kraepelin,  who 
invited  Alzheimer  to  work  with  him  at  the  university  of 
Heidelberg  in  1902,  proposed  the  term  Alzheimer´s 
disease  for  this  illness.  His  monumental  work  on 
Alzheimer´s disease (Alzheimer 1907) was published In 
1907.
Figure 1.1: Alois Alzheimer (1864-1915).
1.1.2 Definition
Alzheimer´s  disease  (AD),  the  most  frequent  form  of  dementia,  is  a  progressive 
neurodegenerative  disorder  characterized  by  cognitive  deterioration,  progressive 
memory loss, impairment of activities of daily living and a variety of neuropsychiatric 
symptoms and behavioural disturbances evolving over several decades (Braak, H., 
Braak,  E.,  1991).  The  disease  first  destroys  a  person’s  ability  to  learn  and  to 
remember recent experiences, to reason, make judgements, communicate and carry 
out  daily  activities.  As  the  illness  progresses,  patients  also  experience  growing 
changes in behaviour and personality leading to anxiety, suspiciousness, agitation or 
hallucinations (www.alzorg.com). In the end-stage of the disease patients need the 
support of relatives or caregivers to handle basic functions such as eating, personal 
hygiene and dressing. This underlines the very helpless situation of affected persons Introduction
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being  bedridden,  incontinent  and  dependent  on  custodial  care.  Death  occurs,  on 
average,  about  nine  years  after  clinical  diagnosis, but  the  duration  can  vary  from 
three to twenty years.
1.1.3 Epidemiology
In Germany, 18% of the whole population, approximately 14.8 million people, are 65 
years or older. Currently, 1.2 million people in Germany suffer from AD, with about 
70% being supported by their relatives. Worldwide, more than 12 million individuals 
suffer  from  Alzheimer’s  disease  (AD),  and  it  accounts  by  far  for  most  cases  of 
dementia that are diagnosed beyond age 60. The disorder currently affects nearly 
2% of the entire population in industrialized countries; the risk of AD dramatically 
increases as a consequence of the longer life expectancy. Most patients are suffering 
from  the  so-called  late-onset  AD  (LOAD),  whose  biggest  known  risk  factor  is 
increasing  age  and  genetic  predisposition. The  likelihood  of  developing  LOAD 
approximately doubles every five years, and by the age of 85, the risk increases to 
nearly 35%. In contrast to LOAD, in early-onset AD (EOAD), symptoms can appear 
as early as age 40 or even younger. These individuals make up only 10% of all cases 
of AD. For this form, a hereditary background is believed to be of higher importance 
than  for  LOAD.  Each  year,  100.000  victims  die  and  360.000  new  cases  are 
diagnosed. By 2020, 30 million people will be affected by this devastating disorder 
worldwide and by 2050, the number could increase to 45 million. Today, the disease 
causes  enormous  health  care  expenses  and  lost  wages  of  both  patients  and 
caregivers which has an enormous impact on society. By 2030, when the entire baby 
boom generation is over 65, the number of people affected by AD could rise to levels 
that may exceed the ability of the population to absorb the added cost.
1.1.4 Diagnosis
Nowadays, dementia is a commonly recognized disease diagnosed by the use of the 
criteria  of  the  Diagnostic  and  Statistical  Manual  of  Mental  Disorders (DSM-IV)
(American Psychiatric Association 1994) (Watt, D. F., 1994) or ICD 10 (International 
Classification  of  Diseases).  Diagnosis  of  AD  is  most  often  based  on  the  criteria 
developed  by  the  National  Institute  of Neurological and Communicative  Disorders 
and  Stroke-Alzheimer’s  Disease  and  Related  Disorders  Association  (NINCDS–Introduction
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Normal AD brain
ADRDA),  according  to  which  it is  classified  as  definite  (histological  confirmation), 
probable  (typical  clinical  syndrome  without  histological  confirmation),  or  possible 
(atypical  clinical  features  but  no  alternative  diagnosis  apparent;  no  histological 
confirmation)  (Mckhann,  G.,  Drachman,  D.  et  al.,  1984).  Typical  sensitivity  and 
specificity values for the diagnosis of probable Alzheimer’s disease with the use of 
these criteria are 0.65 and 0.75 (Chui, H., Zhang, Q., 1997). Neuro-imaging methods 
play an increasingly important role in the diagnosis of AD: structural imaging of the 
brain with computed tomography (CT), magnetic resonance imaging (MRI), positron-
emission tomography (PET, Fig. 1.2) or single-photon-emission CT (Silverman, D. H. 
S., Small, G. W. et al., 2001). Above and beyond the improved diagnostic methods 
for AD, it should be emphasized that the low rates of recognition of dementia by 
family members and physicians (Callahan, J. J., 2004; Ross, G. W., Petrovitch, H. et 
al., 1997) constitute a major barrier to the appropriate care for many patients with 
AD. Additionally, scientists are facing the problem of clearly differentiate between the 
multiple forms of dementia, amongst which vascular dementia plays an important role 
as well as mixed forms of dementia.
Figure 1.2: Positron emission tomography scans (glucose utilisation).
Red  and  yellow  areas  indicate  high  glucose  uptake.  AD  brain  (right)  is  characterised  by  impaired  glucose 
metabolism in the frontal cortex and temporal lobes compared to healthy brain (left) (taken form Mattson, 2004). 
Red  and  yellow  areas  indicate  high  glucose  uptake.  AD  brain  (right)  show  a  strong  decrease  in  energy 
metabolism in the frontal cortex and temporal lobes compared to a healthy brain (left) (taken from Mattson, 2004).Introduction
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1.1.5 Risk factors
1.1.5.1 Age
For the late-onset AD (LOAD), the most important risk factor known is increasing age 
(Mayeux,  R.,  2003; Braak, H.,  Braak,  E.  et al., 1996).  Incidences  increase  about 
hundredfold between ages 65 and 90, which underlines the importance of the risk 
factor aging.
LOAD is a progredient illness developing over several decades with first symptoms 
appearing in an advanced age. Since women posses a higher life expectancy, they 
are consequently more affected by the disease than men.
1.1.5.2 Genetics
Inherited forms of AD are exceptionally rare, with only a few hundred families being 
affected  throughout  the  world.  In  this  case,  scientists  also  use  the  term  “Familial 
Alzheimer’s Disease” (FAD). Naturally, there is a 50% chance to inherit any single 
gene from either parent, and as half of any generation is affected, a characteristic 
pattern  of  inheritance  is  observed.  As  mentioned  above,  early-onset  AD  (EOAD) 
make up only 10% of all AD cases, including approximately 1% of FAD. Three genes 
are known to cause this rare familial form of EOAD: The amyloid precursor protein 
(APP) on chromosome 21, the presenilin-1 (PS-1) gene on chromosome 14 and the 
presenilin-2  (PS-2)  gene  on  chromosome  1.  Presenilin  genes  encode  polytopic 
transmembrane proteins, which are processed by proteolytic cleavage. Besides the 
processing  of  selected  proteins  including  APP,  they  have  been  suggested  to  be 
functionally  involved  in  developmental  morphogenesis  and  unfolded  protein 
responses (Suh, Y. H., Checler, F., 2002). Notably, all familial cases are very rare, 
but the PS-1 gene seems to be the most common and most probably there are other 
genes  causing  EOAD  remaining  to  be  discovered.  Nowadays,  more  than  120 
mutations in the PS-1 gene are identified, all leading to an extremely early onset of 
the  disease  before  age  40.  Most  interestingly,  all  known  presenilin  mutations 
increase  the  production  of  the  neurotoxic  A1-42 forming  the  core  of  the  senile 
plaques. In contrast to PS, mutations in the APP gene (Fig. 1.3) mainly increase total Introduction
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A levels (Scheuner, D., Eckman, C. et al., 1996; Citron, M., Oltersdorf, T. et al., 
1992; Suzuki, N., Cheung, T. T. et al., 1994). This strongly supports the “amyloid 
hypothesis” proposing that flaws in processes governing production, accumulation or 
disposal  of  A are  the  primary  cause  of  AD.  Patients  with  Down’s  syndrome, 
possessing three copies of chromosome 21, almost always develop AD in the middle 
age, most probably due to three copies of the APP gene and an elevated production 
of total A. The first FAD-associated mutation of the APP gene was discovered in 
1991. In this mutation, V717 was replaced by isoleucine (APP770 V717) (Goate, A., 
Chartierharlin, M. C. et al., 1991).
Figure 1.3: APP mutations
-secretory pathway: The processing of APP by -secretase leads to the secretion of a large soluble ectodomain 
of APP  (sAPP) and to the  retention of an  83-residue  COOH-terminal  fragment (C83)  in  the  membrane. -
secretory pathway: cleavage of APP by -secretase produces a membrane-bound C-terminal fragment (C99) 
which is further cleaved by a -secretase leading to the release and secretion of pathogenic A-peptide and a C-
terminal  fragment  (APP  intracellular  domain:  C57/C59,  AICD).  Missense  mutations  in  the  APP-gene  either 
interfere with - secretase or enhance - or -secretase cleavage, resulting in an increased production of the toxic 
A peptide (taken from Eckert, 2003).
In the “Swedish mutation” (APPsw), which results in an average onset of the disease 
at  age  53,  two  amino  acids  are  replaced  (APP770KM670/671NL)  next  to  the  N-
terminus of the A sequence (Haass, C., Lemere, C. A. et al., 1995b). In contrast to 
Aß
NH2----TEEISEVKM DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKK---COOH
1  10  20          30  40
-secretase -secretase -secretase
NL GQ I,G,F V Mutation:
APP
FAD FAD FAD FAD/CAA HCHWA-D phenotype:
codon:
name:
670/671 692 693 716  717  
„Swedish“ „Flemish“ „Dutch“ „Florida“ „London“
Plasma membrane
CT
Cytosol
AggregationIntroduction
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the mutation at V717, the processing of APPsw does not result in a relative over-
production of A1-42, but in an elevated production of total A (Cai, X. D., Golde, T. E. 
et al., 1993; Citron, M., Vigopelfrey, C. et al., 1994). Also, increased cleavage of the 
-secretase  site  was  found  in  distinct  subcellular  compartments  for  the  APPsw 
mutation (Haass, C., Lemere, C. A. et al., 1995b): It was found that wild-type APP 
(APPwt) was re-internalised prior to -secretase cleavage, while APPsw is cleaved 
earlier in secretory vesicles, leading to a six- to eightfold increase in A secretion 
(Cai, X. D., Golde, T. E. et al., 1993). 
ApoE4  is  the  only  gene  that  has  been  definitely  associated  with  late  onset  AD 
(LOAD) (Fig. 1.4). ApoE4 is located on chromosome 19, which has three common 
variants, E2, E3, E4. The E2 allele probably decreases the risk of developing AD or 
is protective, in contrast to E4, which is reported to be associated with an increased 
A metabolism (Saunders, A. M., Strittmatter, W. J. et al., 1993). Consequently, the 
presence of two copies of the ApoE4 allele leads to an increased risk for developing 
AD (Corder, E. H., Saunders, A. M. et al., 1993). 
Other  genes  probably  enhancing  the  risk  for  AD  include:  A  gene  encoded  on 
chromosome 10, insulin degrading enzyme (IDE), a metalloendopeptidase implicated 
in the A degradation (Bertram, L., Blacker, D. et al., 2000). Mutations of IDE are 
reported  to reduce  A degradation  for  15-30%  (Farris, W., Mansourian,  S.  et al., 
2004). Minor changes in the antichymotrypsin gene, various ApoE receptor genes, 
the serotonin transporter gene and the butyrylcholinesterase E gene are likely to be 
associated with AD, but to a lower extent than the association of ApoE4 with AD.Introduction
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Figure 1.4: Genetic risk factors of AD.
Mutations leading to early-onset familial AD (EOFAD) and to early-onset AD (EOAD) appear on the chromosomes 
21, 14 and 1, with APP and PS-1/2 being the affected genes. All mutations are dominantly inherited and lead to 
an increase in A levels. A risk factor for late-onset AD and late AD (LOAD) is the Apo E 4 allele. Polymorphisms 
of Apo E are encoded on chromosome 19 (taken from Eckert, 2003).
Effect
Chromosome Gene Mutations Onset Feature on Aß
EO FAD 21 APP 7 45-64 dominant Aß
14 PS 1 >120 28-55 dominant  Aß
1 PS 2 2 40-75 dominant  Aß
EO AD < 60
LO FAD 19 Apo E Poly- 61-65 Risk factor
morphism  4
 2,  3,  4
LO AD > 60Introduction
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1.2 Pathological hallmarks
Still today it is unknown which factors trigger LOAD, but scientists believe that the 
damage  of the brain  begins  years before  the  clinical symptoms  appear. As  other 
forms  of  dementia  also  cause  memory  loss,  the  definitive  diagnosis  of  AD  still 
requires post-mortem examination of the brain. Brain regions involved in learning and 
memory processes, including the temporal and frontal lobes and hippocampus, are 
reduced in size in AD patients as the result of degeneration of synapses and death of 
neurons leading to a massive reduction of total brain weight and cortex volume at the 
end-stage of the disease. The affected brain regions also contain significantly high 
numbers of so-called “plaques” and “tangles” to qualify as affected by AD (Dickson, 
D. W., 1997; Braak, H., Braak, E. et al., 1996). Plaques are extracellular deposits of 
fibrils and amorphous aggregates of various A isoforms. A was first isolated from 
blood vessels of Down’s syndrome and AD patients and then identified as the main 
constituent of amyloid plaques (Masters, C. L., Simms, G. et al., 1985).
Other proteins are found in the plaques such as ApoE, chymotrypsin, ubiquitin and 
inflammatory factors. Neurites associated with the plaques are often damaged, which 
lead  to  the  conclusion  that  A is  the  primary  toxic  species  in  AD  (“amyloid 
hypothesis”). The neurons to be particularly affected use glutamate or acetyl choline 
as  neurotransmitters  together  with  neurons  that  produce  serotonin  and 
norepinephrine.  Neurofibrillary  tangles  consist  of  microtubule-associated, 
hyperphosphorylated  tau  protein.  Plaques  and  tangles  are  present  mainly  in  the 
entorhinal  cortex,  hippocampus,  basal  forebrain  and  amygdala:  brain  regions 
involved in learning, memory and emotional behaviours.Introduction
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Figure 1.5: Amyloid plaques (left) and neurofibrillary tangles (right). 
Amyloid plaques (left) and neurofibrillary tangles are the pathological hallmarks in AD brain: The dense amyloid 
core mainly consisting of A1-42 is surrounded by an amyloid halo consisting of various A isoforms. Cytoskeletal 
changes, namely hyperphosphorylation of tau protein, cause neurofibrillary tangles (right) (Bogdanovic, N., 2000).
1.3 Neurofibrillary tangles
Neurofibrillary  tangles  are  found  in  many  neurologic  diseases,  summarized  as 
tauopathies,  indicating  that  they  are  not  a  specific  hallmark  of  AD.  Other 
degenerative disorders associated with hyperphosphorylated tau and the formation of 
neurofibrillary tangles are, amongst others, amyotrophic lateral sclerosis, corticobasal 
degeneration and supranuclear progressive paralysis. 
Neurofibrillary  tangles  are  intracellular  fibrillar  aggregates  of  the  microtubule-
associated protein tau that exhibit hyperphosphorylation and oxidative modifications. 
Functionally, microtubules are strongly involved in intracellular transport processes. 
Under  physiological  conditions,  tau  is  a  microtubule-associated  protein  (MAP)
regulating the  formation  of  axonal  microtubules  (Drubin,  D.,  Kobayashi,  S.  et al., 
1986), signal transduction (Jenkins, S. M., Johnson, G. V. W., 1998; Jenkins, S. M., 
Johnson,  G.  V.  W.,  1998) and  neurite  outgrowth  (Biernat,  J.,  Mandelkow,  E.  M., 
1999).  Hyperphosphorylation  of  tau  can  be  executed  by  various  proteins:  cyclin-
dependent kinase 5 (cdk 5), glycogen synthase kinase-3 (GSK-3), or extracellular 
signal-regulated kinases (ERKs) (Liu, F., Iqbal, K. et al., 2002; Noble, W., Olm, V. et 
al.,  2003;  Moran,  C.  M.,  Donnelly,  M.  et  al.,  2005).  Interestingly,  pronounced 
phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the 
repeat domain of tau protein by recombinant GSK-3 has been described recently 
(Godemann,  R.,  Biernat,  J.  et  al.,  1999).  Abnormally  hyperphosphorylated  tau 
accumulates  and  aggregates  to  paired  helical  filaments  (PHFs)  finally  leading  to Introduction
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neurodegeneration  (Garcia,  M.  L.,  Cleveland,  D.  V.,  2001).  Interestingly, 
hyperphosphorylation of tau also blocks APP trafficking, suggesting that this process 
might be the connecting link between the tau and amyloid theory (Mandelkow, E. M., 
Biernat, J. et al., 2004). 
1.4 APP processing
The  Alzheimer's  disease  APP  belongs,  together  with  the  amyloid  precursor-like 
protein  1  (APLP-1)  and 2  (APLP-2),  to  a  superfamily  of  proteins  that  appear 
functionally related (Coulson, E. J., Paliga, K. et al., 2000), as these transmembrane 
proteins type I are characterized by their orientation in the plasma membrane: the N 
terminus is directed to the extracellular space and the C terminus is located in the 
cytosol.  They  are  also  described  as  integral  membrane  proteins  with  a  single 
membrane-spanning domain. Although APLPs are highly homologous to APP in the 
N and C-terminal domains, they lack A, the main constituent of neuritic plaques in 
AD.  After  post-translational  modification,  mainly  N- and  O- glycolysation  and 
sulfatation  of  tyrosine,  APP  can  be  processed  proteolytically  (Georgopoulou,  N., 
McLaughlin, M. et al., 2001). APP is produced in several different isoforms ranging in 
size from 695 to 770 amino acids with APP695 being the most abundant form in 
brain produced mainly by neurons. APP695 differs from longer forms of APP in that it 
lacks  a  kunitztype  protease  inhibitor  sequence  in  its  ectodomain (Tanaka,  S., 
Nakamura, S. et al., 1988). The normal function of APP is not yet determined, but in 
the last years many insights about how APP might exert its function became clear. 
APP is widely expressed in cells throughout the body where the amount produced is 
influenced by the developmental and physiological state of the cells. Recent findings 
suggest  that  APP  plays  a  pivotal  role  in  extracellular  signal  transduction  by 
interacting with G0, a GTP-binding protein (Nishimoto, I., Okamoto, T. et al., 1993; 
Mahlapuu,  R.,  Viht,  K.  et  al.,  2003;  Karelson,  E.,  Fernaeus,  S.  et  al.,  2005). 
Furthermore, APP is reported to interact with kinesin I corroborating its potential role 
in axonal transport processes (Kamal, A., Stokin, G. B. et al., 2000). APP is mainly 
located at the cell surface or on the lumenal side of ER and Golgi membranes, with 
part of the peptide embedded in the membrane (Fig. 1.6). APP possesses critical 
components of the mitochondrial-targeting signal, with positively charged residues at 
40, 44, and 51, respectively. Introduction
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Chemical  cross-linking  together  with  immunoelectron  microscopy  show  that  the 
mitochondrial APP exists in NH2-terminal inside trans-membrane orientation and in 
contact with mitochondrial translocase proteins. Accumulation of full-length APP in 
the  mitochondrial  compartment  in  a  transmembrane-arrested  form  caused 
mitochondrial dysfunction and impaired energy metabolism (Anandatheerthavarada, 
H. K., Biswas, G. et al., 2003). 
Figure 1.6: APP processing and trafficking.
APP is mainly located at the cell surface or on the lumenal side of ER and Golgi membranes, with part of the 
peptide embedded in the membrane where it can be proteolytically processed by - , - and -secretases. Recent 
findings suggest that altered APP trafficking might contribute to the progress of the disease. 
Mature  APP  (N- and  O-glycosylated  forms)  is  phosphorylated  at  threonine  668 
(numbering for APP695 isoform), specifically in neurons (Ando, K., Ohmori, K. et al., 
2002). Phosphorylation of mature APP has been described during and after neuronal 
differentiation  in  PC12  cells.  The  phosphorylated  form  of  APP  is  specifically 
distributed in neurites as is mostly present in growth cones. This suggests that the 
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phosphorylated  form  of  APP  may  play  an  important  role  in  neurite  outgrowth  of 
differentiating neurons (Suzuki, T., Ando, K. et al., 1997; Lee, M. S., Kao, S. C. et al., 
2003). Most likely, glycogen synthase kinase-3 (GSK-3) phosphorylates APP, an 
enzyme which is also involved in the pathogenic hyperphosphorylation of tau. The 
phosphorylation site was confirmed by endoproteinase digestion of APP and peptide 
sequencing (Aplin, A. E., Jacobsen, J. S. et al., 1997). Enzyme activities involved in 
cleavage of APP at the -, - and -secretase sites are described in the following.
1.4.1 -secretase
The identity of -secretase remains unclear, although TACE (an enzyme cleaving 
members  of  the  TNF  receptor  family  at  the  cell  surface),  and  disintegrin  and 
metalloproteases, ADAM-9, -10, -17 respectively, are candidates (Asai, M., Hattori, 
C. et al., 2003; Buxbaum, J. D., Liu, K. N. et al., 1998; Lammich, S., Kojro, E. et al., 
1999). Most of the APP protein is cleaved by -secretase releasing sAPP (sAPP) 
into  the  extracellular  space  while  leaving  a  83-amino-acid  carboxy-terminal  APP 
fragment (C83, CTF) at the cell surface. C83 is cleaved by -secretase resulting in 
the formation of the fragments p3 and p7. Of note, production of sAPP increases in 
response to electrical activity and activation of muscarinic acetyl choline receptors, 
suggesting that neuronal activity increases -secretase cleavage of APP (Pascual, 
J., Fontan, A. et al., 1991). Another approach indicates that the treatment with acetyl 
cholinesterase inhibitors increases ADAM-10 activity by promoting its trafficking in 
neuroblastoma cell lines (Zimmermann, M., Gardoni, F. et al., 2004). sAPP, in turn, 
is  reported  to  be  neuroprotective  via  its  neurotrophic  properties  (Small,  D.  H., 
Nurcombe, V. et al., 1994; Furukawa, K., Sopher, B. L. et al., 1996). Biochemical, 
epidemiological, and genetic findings demonstrate a link between cholesterol levels, 
processing of APP and AD. The treatment of various peripheral and neuronal cell 
lines  with  either  cholesterol-extracting  agents  or  lovastatin  resulted  in  a  drastic 
increase of secreted -secretase-cleaved sAPP (Kojro, E., Gimpl, G. et al., 2001). Introduction
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1.4.2 -secretase
Altered proteolytic processing of APP by -secretase resulting in the production and 
aggregation of neurotoxic forms of A is central to several genetic forms of AD. The 
membrane-bound  aspartyl  protease  BACE-1,  -site  cleaving  enzyme,  has  been 
identified as -secretase encoded on chromosome 11 (Yan, R. Q., Bienkowski, M. J. 
et al., 1999; Vassar, R., Bennett, B. D. et al., 1999; Sinha, S., Anderson, J. P. et al., 
1999).  Tissue  culture  and  animal  studies  indicate  that  -secretase  BACE-1  is 
expressed in all  tissues  with highest levels in  neurons,  and -secretase  cleavage 
occurs mainly in the plasma  membrane, but also at the Golgi apparatus and ER. 
Three  recent  publications  report  increased  -secretase  activity  in  sporadic  AD
(Holsinger, R. M. D., Mclean, C. A. et al., 2004; Yang, L. B., Lindholm, K. et al., 
2003b;  Li,  R.,  Lindholm,  K.  et  al.,  2004c),  but  it  needs  to  be  confirmed  whether 
BACE-1  over-expression  is  crucial  in  the  pathogenic  cascade  of  sporadic  AD. 
Cleavage of APP by -secretase (BACE) liberates sAPP into the extracellular space 
and  leaves  a  C-terminal  fragment  (C99,  CTF)  bound  to  the  membrane.  C99  is 
internalised and further processed by -secretase to produce A1-40/42 in endocytic 
compartments (Evin, G., Zhu, A. Q. et al., 2003). Another isoform of BACE, BACE-2, 
shows -secretase activity and is located on chromosome 21 (Bennett, B. D., Babu-
Khan, S. et al., 2000). The enzyme is found in the Golgi apparatus and endosomes 
being highest expressed in neurons. The physiological role of BACE-2 is unknown, 
but  most  probably  the enzyme  has  no  key  role in  APP  processing,  and  it is  not 
considered to be a drug target for AD. Introduction
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1.4.3 -secretase
1.4.3.1 Presenilins
Recent studies strongly suggest the possible pathogenic interactions between APP 
and presenilins implicating a potential role for presenilins in -secretase cleavage. It 
is  supposed  that  high  molecular  complexes  of  presenilins  together  with  anterior 
pharynx  defective  (APH),  nicastrin  and presenilin  enhancer  2  (PEN-2)  exhibit  -
secretase activity under physiological conditions (Capell, A., Beher, D. et al., 2005). 
PS-1 and PS-2 are two homologous membrane-spanning proteins with two aspartyl 
residues in the transmembrane domains 6 and 7 potentially being responsible for the 
protease-like activity. It seems at least possible that presenilins are involved in  -
secretase  cleavage  since  numerous  missense  mutations  of  presenilins  are 
associated with the autosomal dominant form of familial AD (Fraser, P. E., Yang, D. 
S. et al., 2000; Chen, F. S., Yang, D. S. et al., 2000; Menendez, M., 2004; Finckh, U., 
Kuschel, C. et al., 2005).  Reduced  -secretase  activity  was  observed  in  neuronal 
cultures of PS-1 knockout mice. Of note, knockout of the -secretase component PS-
1 caused a lethal phenotype indicating that -secretase cleavage of Notch-1 must be 
of fundamental importance during embryonic development (Huppert, S. S., Ilagan, M. 
X. G. et al., 2005; Doerfler, P., Shearman, M. S. et al., 2001; Selkoe, D., Kopan, R., 
2003).Introduction
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1.4.3.2 -secretase cleavage
Expression of the four proteins APH, nicastrin, presenilin and PEN-2 in yeast lead to 
reconstituted -secretase activity (Fig. 1.7) (Edbauer, D., Winkler, E. et al., 2003). 
The entire biology of the enzyme is yet not fully understood, as the reconstitution 
from purified components has not yet been accomplished, and the structure of the 
active site remains unknown. As mentioned above, C83 and C99 are substrates of -
secretase: C83 cleavage results in the formation of p7 and p3, C99 cleavage results 
in  the  formation  of  various  A isoforms  and  AICD,  APP  intracellular  domain,  a 
fragment that translocates to the nucleus where it may regulate gene expression, 
including the induction of apoptotic genes (Leissring, M. A., Murphy, M.  P. et al., 
2002). It has been reported that AICD is neurotoxic by increasing the expression of 
GSK-3 (Kim, H. S., Kim, E. M. et al., 2003). The identification of the -secretase 
components and the generation 
of gene-targeted models quickly
lead  to  the  identification  of  -
secretase substrates other than 
APP,  including  the  notch 
receptor 1 (Notch-1), the Notch 
ligands  delta-like  protein  1 
(Delta-1) and Jagged 2 (Jag-2), 
v-erb-a erythroblastic leukaemia 
viral  oncogene  homologue  4 
(ErbB-4)  and  others  (Ni,  C.  Y., 
Murphy, M. P. et al., 2001) were 
rapidly found. 
Figure 1.7: -secretase complex.Introduction
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1.4.4 Amyloid 
Recent  data  suggest  that intracellular  or  extracellular  accumulation  and 
oligomerization  of A plays a central  role in  the pathogenesis  of the disease,  as 
previous findings suggest that A is a neurotoxic side product of APP processing 
(Canevari, L., Abramov, A. Y. et al., 2004; Hardy, J., Allsop, D., 1991). Generally, A
consists of 39-43 amino acids, whereas the A1-40 and A1-42 forms are the most 
prominent ones. Under physiological conditions, A1-42 makes up only 10% of the 
total brain A, but most of the gene mutations that segregate with the inherited forms 
of  AD  result  in  increasing  the  ratio  of  A1-42/A1-40 production,  and  A1-42 also 
accumulates in neurons of AD brains (Iwatsubo, T., Odaka, A. et al., 1994). This is 
very interesting since it has been reported that A1-40 and A1-42 are produced in 
distinct subcellular  compartments:  A1-40 is processed in the trans-Golgi,  A1-42 is 
from the ER (Hartmann, T., Bieger, S. C. et al., 1997). New data strongly suggest 
that  the  production  and  initial  accumulation  of  A takes  place  intracellularly  in 
neurons  of  human  brains  or  of  transgenic  mice  (Oddo,  S.,  Caccamo,  A.  et  al., 
2003b). Kienlen-Campard et al. demonstrated that although APP processing leads to 
production  of  extracellular  A1-40 and  soluble  APP  in  rat  cortical  neurons,  these 
extracellular derivatives do not induce neuronal death (Kienlen-Campard, P., Miolet, 
S.  et  al.,  2002).  In  their  setting,  neurons  undergo  apoptosis  as  soon  as  they 
accumulate  intracellular  A1-42 following  the expression of full-length  APP  or a C-
terminally deleted APP isoform. A is a hydrophobic peptide being able to aggregate 
and to form oligomers. A oligomers evolve over time, whereas spherical oligomer 
formation precedes the formation of the curvilinear strings or protofibrils (Harper, J. 
D., Wong, S.  S.  et al., 1999;  Kayed,  R.,  Head,  E.  et al., 2003). Then,  chains  of 
clusters  called  fibrils  together  with  -sheeted  structures  form  the  end-stage  of 
“plaques”. Recent reports suggest that the toxicity of A does not lie in the insoluble 
fibrils  that  accumulate  but  rather  in  the  soluble  oligomeric  intermediates,  as  their 
amount  correlates  best  with  the  progress  of  the  disease  monitored  by  cognitive 
function (Mclean, C. A., Cherny, R. A. et al., 1999; Lue, L. F., Kuo, Y. M. et al., 1999). 
These soluble oligomers include spherical particles and curvilinear structures called 
“protofibrils” that appear to represent strings of the spherical particles (Hartley, D. M., Introduction
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Walsh, D. M. et al., 1999). These neurotoxic A species comprise small diffusible A
oligomers (referred to as ADDLs, for A-derived diffusible ligands), which were found 
to kill mature neurons in organotypic central nervous system cultures at nanomolar 
concentrations. At cell surfaces, ADDLs bound to trypsin-sensitive sites and surface-
derived tryptic peptides blocked binding and afforded neuroprotection. Remarkably, 
neurological  dysfunction  evoked  by  ADDLs  occurred  well  in  advance  of  cellular 
degeneration. Without lag, and despite retention of evoked action potentials, ADDLs 
inhibited  hippocampal  long-term  potentiation,  indicating  an  immediate  impact  on 
signal transduction. Impaired synaptic plasticity and associated memory dysfunction 
during early stage of AD and severe cellular degeneration during the end stage could 
be  caused  by  the  biphasic  impact  of  ADDLs acting  upon particular  neural  signal 
transduction pathways (Lambert, M. P., Barlow, A. K. et al., 1998). Introduction
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1.5 Molecular mechanisms of cell death
1.5.1 Necrosis
Necrosis  can  occur  in  response  to  various  cytotoxic  stimuli,  like  acute  ischemia, 
exposure  to  excitotoxins  or  mechanical  injury  of  the  cell  membrane.  Necrosis  is 
highly  unregulated- no  active, energy-consuming  processes  are  involved.  The 
histological  features  of  necrotic  cell  death  are  mitochondrial  and  nuclear  swelling, 
dissolution  of  organelles,  and 
condensation of chromatin around 
the nucleus (Fig. 1.8). The rupture 
of  nuclear  and  cytoplasmic 
membranes follows these events. 
Degradation  of  DNA  by  random 
enzymatic  cuts  in  the  molecule 
begins.
Figure 1.8: Necrotic (left) and apoptotic cell (right).
(taken from The Cell, 2004).
1.5.2 Apoptosis (Programmed cell death)
The mitochondrial matrix contains numerous enzymes, including those that convert 
pyruvate and fatty acids to acetyl CoA and those of the citric acid cycle that oxidize 
this acetyl CoA to CO2. The energy available from combining molecular oxygen with 
the reactive  electrons  carried  by  NADH  and  FADH2 is harnessed  by  an electron-
transport chain (ETC) in the inner mitochondrial membrane. Protons are pumped out 
of  the  matrix  to  create  a  transmembrane  electrochemical  proton  gradient,  which 
includes  contributions  from  both  a  membrane  potential  and  a  pH  difference.  The 
large  amount  of  free  energy  released  when  protons  flow  back  across  the  inner 
membrane provides the basis for ATP production in the matrix by the ATP synthase 
(F1F0 ATPase). The transmembrane electrochemical gradient is also used to drive 
the  active  transport  of  selected  metabolites  across  the  mitochondrial  inner Introduction
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membrane, including an ATP-ADP exchange between mitochondria and the cytosol. 
The resulting high ratio of ATP to its hydrolysis products favours ATP hydrolysis, 
allowing to drive a large number of the cell's energy-requiring processes. In addition 
to their function as major energy-providing organelles of the cell, they accomplish a 
crucial  role in  apoptosis  (Gulbins,  E.,  Dreschers,  S.  et  al.,  2003;  Gottlieb,  R.  A., 
Granville, D. J., 2002). Mitochondria harbour several death factors that are released 
upon  apoptotic  stimuli.  Alterations  in  mitochondrial  functions,  increased  oxidative 
stress  and apoptosis  have been  observed in  various  diseases.  Mitochondria  may 
thus trigger the abnormal onset of cell death by at least three general mechanisms, 
and most probably their effects are interrelated: (i) disruption of electron transport, 
oxidative phosphorylation, ATP production, (ii) alteration of cellular redox potential, 
(iii) release of proteins that trigger activation of caspase family proteases, (Fig. 1.9). 
Figure 1.9: Mitochondria- executioners of cell death. 
At least three mechanisms lead to mitochondrial disturbances in apoptosis: 1. Disruption of electron transport 
(ETC= electron transport chain), 2. Alteration of cellular redox-potential, 3. Release of pro-apoptotic factors.
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Extrinsic and intrinsic pathways can initiate programmed cell death, apoptosis (Fig. 
1.10). The extrinsic pathway plays an important role in immune response and tumour 
suppression (Reed, J. C., 2000). The intrinsic pathway can be initiated by various 
stimuli like reactive oxygen species, ER stress, UV radiation, cytotoxic substances, 
and growth factor withdrawal (Newmeyer, D. D., Ferguson-Miller, S., 2003; Rudner, 
J., Jendrossek, V. et al., 2002).The mechanism can further be dissected into: (i) the 
initiation and  signalling  phase,  (ii)  the  signal  amplification  phase  and  (iii),  the 
execution  phase.  Apoptosis  involves  changes  in the cytoplasm,  ER,  mitochondria 
and nucleus as well as the activation of a group of cysteinases called caspases that 
cleave various protein substrates to sculpt morphological and biochemical aspects of 
the cell death process. Some groups propose a model for initiation of apoptosis in 
which  mitochondria  and  caspases  engage  in  a  self-amplifying  pathway  of  mutual 
activation (Green, D., Kroemer, G., 1998; Nicholson, D. W., 2001). In most of the 
apoptotic scenarios, impairment of mitochondrial function is an early event. In the 
final phase  of apoptosis,  executioner  caspases  (caspase-9 and  -3) are activated. 
More specifically, caspases have a dual function in the apoptotic process: first, as 
signal  transduction  molecules  that  act  as  facultative  inducers  of  mitochondrial 
membrane  changes  (initiator/signaling  caspases),  and  second,  as  processing 
enzymes that orchestrate the apoptotic phenotype (executioner caspases). In the last 
years, investigative work aimed at the inhibition of caspases to prevent apoptosis 
(Arnoult,  D.,  Karbowski,  M.  et  al.,  2003;  Riedout,  H.  J.,  Stefanis,  L.,  2001).  But 
recently, it has become clear that inhibition of caspases does not always prevent 
irreversible loss of cellular function, although it does prevent the acquisition of typical 
apoptotic morphology. Introduction
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Figure 1.10: Extrinsic and intrinsic signaling pathways of apoptosis.
Caspase-8  is  the  most  important  signaling  caspase  in  the  extrinsic  pathway  (blue  arrows)  activating  the 
executioner caspase-3 that finally leads to apoptosis. Caspase-2 is involved in the intrinsic apoptotic pathway (red 
arrows),  initiating  the  cleavage  of  Bid  to  t-Bid  which  in  turn  promotes  the  insertion  of  Bax  into  the  outer 
mitochondrial membrane. In the next step, pro-apoptotic factors, such as cytochrome c, are released into the 
cytosol. Cytochrome c forms the apoptosome together with Apaf-1, cleaving procaspase-9. Again, it comes to an 
activation of caspase-3 by caspase-9.
1.5.2.1 Members of the Bcl-2 family
Bcl-2 and related cytoplasmic proteins are key regulators of apoptosis (Adams, J. M., 
Cory, S., 1998). Those most similar to Bcl-2 (Bcl-2, Bcl-xL) promote cell survival by 
inhibiting  adapters  needed  for activation  of caspases  that dismantle  the cell  (Fig. 
1.11). More distant relatives, like Bax instead promote apoptosis apparently through 
displacing the adapters from the pro-survival proteins (Reed, J. C., 1997; Borner, C., 
2003; Festjens, N., van Gurp, M. et al., 2003). 
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Figure 1.11: Pro- and anti-apoptotic members of the Bcl-2 family.
Pro- and anti-apoptotic members of the family differ in the numbers and orientation of their domains. The anti-
apoptotic members (Bcl-2, Bcl-xL, Bcl-w) are characterized by the domains BH1-4 and a trans-membrane domain 
(TM).  Pro-apoptotic  members  can  be  sub-divided  in multi-domain  (Bax,  Bak)  and  BH3-only  (Bid,  Bad,  Bim) 
proteins (taken from Borner et al., 2003, modified).
Pro-apoptotic  members  of the  Bcl-2 family  (Bid,  Bax)  are  originally located in  the 
cytosol. Bid is activated when cleaved by caspase- 2 to truncated Bid (t-Bid) (Li, H. 
L.,  Zhu,  H.  et  al.,  1998).  Following  binding  to  the  BH3-domain-only  pro-apoptotic 
protein  t-Bid,  Bax  oligomerizes  and  then  integrates  in  the  outer  mitochondrial 
membrane,  where  it  triggers  cytochrome  c  release  (Fig. 1.12).  Bax  mitochondrial 
membrane  insertion  triggered  by  Bid-cleavage  represents  a  key  step in  pathways 
leading to apoptosis (Eskes, R., Desagher, S. et al., 2000; Sharpe, J. C., Arnoult, D. 
et al., 2004). In many types of apoptosis, the pro-apoptotic protein Bax additionally 
undergoes a change in conformation at the level of the mitochondria (Wei, M. C., 
Zong, W.  X.  et  al.,  2001).  Today  it is  unclear  how  Bax  promotes  the  release  of 
cytochrome c. It might be that Bax oligomers induce the opening of the permeability 
transition pore (PTP) in the outer mitochodrial membrane, a composite proteaceous 
channel that is involved in the regulation of mitochondrial membrane permeability, by 
which pro-apoptotic factors might be released: Bax binds to PTP, and PTP opening Introduction
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induced  by  Bax  results in the relase  of cytochrome  c  into the cytosol  (Marzo,  I., 
Brenner, C. et al., 1998). 
In contrast to this, it was also shown that Bax alone is sufficient to trigger the release 
of cytochrome c from isolated mitochondria and that this process cannot be blocked 
by PTP inhibitors. This is corroborated by the other studies investigating whether Bax 
promotes cell death directly through its putative function as a channel protein versus 
indirectly by inhibiting caspases (Jurgensmeier, J. M., Xie, Z. et al., 1998). In this 
experimental setting, Bax did not induce swelling of mitochondria in vitro unlike Ca
2+, 
a classical inducer of  mitochondrial permeability  transition.  The  organelle  swelling 
caused  by  permeability  transition  (inducer:  Ca
2+)  causes  a  non-selective  outer 
membrane rupture. These findings dissociate these two events, implying that Bax 
uses  an  alternative  mechanism  independent  from  Ca
2+ for  triggering  release  of 
cytochrome  c  from  mitochondria.  Concluding,  these  results  might  speak  for  the 
existence of at least two distinct mechanisms leading to cytochrome c release. Anti-
apoptotic  members  of the Bcl-2 family  (Bcl-2, Bcl-xL)  are located in the cytosolic 
compartment and in the outer mitochondrial membrane (Susin, S. A., Zamzami, N. et 
al., 1996). Their mode of action is very diverse, but Bcl-2 is known to not only inhibit 
the release of cytochrome c, but also of other mitochondrial pro-apoptotic factors. 
Bcl-xL in turn blocks the formation of the apoptosome (cytochrome c, Apaf-1 and 
procaspase-9 complex) and modulates Ca
2+ levels of the endoplasmatic reticulum 
(ER). It is possible that Bcl-2-family proteins can influence the levels of releasable 
Ca
2+ in  the  ER,  and  thus  determine  whether  the  released  Ca
2+ is  sufficient  to 
overload mitochondria and induce cell death (Kuwana, T., Newmeyer, D. D., 2003). Introduction
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Figure 1.12: Pro- and anti-apoptotic actions of Bcl-2 proteins.
Pro-apoptotic Bcl-2 proteins (red) are located downstream mitochondria in the apoptotic pathway. Truncated Bid 
(t-Bid) induces oligomerization of Bax into the outer mitochondrial membrane. Bax oligomers trigger PTP opening 
leading to the release of cytochrome c. Anti-apoptotic Bcl-2 proteins (blue) can block the release of cytochrome c 
and the formation of the apoptosome (Apaf-1, procaspase-9 and cytochrome c complex). Additionally, Bcl-xL 
inhibits the release of Ca
2+ from the endoplasmatic reticulum (ER).
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1.5.2.2 Pro-apoptotic mitochondrial proteins
Mitochondria  exert  their  important  role  during  cell  death  via  the  release  of  pro-
apoptotic  proteins  participating  in  the  degradation  phase  of  apoptosis:  Oxidative 
stress  induced  by  various  stimuli  results  in  the  release of  cytochrome  c  into  the 
cytoplasm  from  the  mitochondrial  intermembrane  space  where  it  initiates  the 
caspase-dependent  apoptosis  cascade  (Fig.  1.13)  (Newmeyer,  D.  D.,  Ferguson-
Miller, S., 2003). It is noteworthy that the main part of cytochrome c remains in the 
mitochondria  bound  to  the  electron  transport  chain  (ETC).  An  essential  role  of 
cytosolic cytochrome c in the execution of apoptosis was demonstrated by its direct 
microinjection into the cytosol, thus bypassing the need for cytochrome c release 
from the mitochondrial intermembrane space. Microinjection of cytochrome c caused 
caspase-dependent apoptosis (Takeyama, N., Miki, S. et al., 2002). First, cytochrome 
c binds to Apaf-1, a mammalian homologue of Ced-4, and procaspase-9 to form the 
apoptosome which then activates caspase-3 finally triggering apoptosis (Yoshida, H., 
2003;  Henshall,  D.  C.,  Bonislawski,  D.  P.  et  al.,  2001).  The  collapse  of  the 
mitochondrial membrane along with the release of cytochrome c from mitochondria is 
followed by the activation of caspases, nuclear fragmentation and cell death (Smaili, 
S. S., Hsu, Y. T. et al., 2003). The temporal and causal relationship of the release of 
Smac/DIABLO (in short named Smac), second mitochondrial activator of caspase, 
compared to cytochrome c was examined by several groups (Rehm, M., Dussmann, 
H. et al., 2003). The average duration of Smac/DIABLO release is greater than that 
of cytochrome c. However, there is no significant difference in the time to the onset of 
release,  and  both  cytochrome  c  and  Smac/DIABLO  release  coincided  with 
mitochondrial membrane potential depolarization. When Smac/DIABLO is released 
into the cytosol, it blocks inhibitor of apoptosis proteins (IAPs) (Adrain, C., Creagh, E. 
M.  et  al.,  2001).  IAP,  belonging  to  the  anti-apoptotic  cytosolic  factors,  inhibits 
caspase-9 activation. Over-expression of Smac/DIABLO increases cells sensitivity to 
apoptotic stimuli (Du, C., Fang, M. et al., 2000). Neutralization of Smac/DIABLO by 
inhibitors  of  apoptosis  (IAPs)  is  a  caspase-independent  mechanism  for  apoptotic 
inhibition  potentially  offering  a  new  therapeutic  strategy  in  apoptosis-mediated 
diseases (Wilkinson, J. C., Wilkinson, A. S. et al., 2004), while in turn inhibition of 
IAP's protection by Smac/DIABLO is discussed as a new therapeutic opportunity in Introduction
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cancer  therapy  (MacKenzie,  A.,  LaCasse,  E.,  2000).  The  third  factor  being  co-
released with cytochrome c and Smac/DIABLO is HtrA2/Omi, a caspase-dependent 
pro-apoptotic  protein.  Mature  HtrA2/Omi  is  released  together  with  mature 
Smac/DIABLO from the mitochondria into the cytosol upon disruption of the outer 
mitochondrial membrane during apoptosis. Mature HtrA2/Omi can induce apoptosis 
in human cells in a caspase-independent manner through its protease activity and in 
a caspase-dependent manner (Hegde, R., Srinivasula, S. M. et al., 2002). HtrA2/Omi 
is  largely  membrane-associated  in  healthy  cells,  with  a  significant  proportion 
observed  within  the  mitochondria.  Once  shifted  into  the  cytosol,  HtrA2/Omi  can 
interact with IAPs, preventing IAP inhibition of active caspase-3 (Verhagen, A. M., 
Silke, J. et al., 2002). 
The structure of AIF has been identified as a flavoprotein of relative molecular mass 
57.000 that shares homology with the bacterial oxidoreductases. The functions of 
apoptosis  inducing  factor  (AIF),  a  phylogenetically  ancient  mitochondrial 
intermembrane flavoprotein, appear to be much more diverse (Lorenzo, H. K., Susin, 
S.  A.  et  al.,  1999).  Under  physiological  circumstances,  AIF  is  located  behind  the 
outer mitochondrial membrane. In response to apoptotic stimuli, AIF translocates to 
the cytosol and then to the nucleus (Plesnila, N., Zhu, C. L. et al., 2004). 
Endowed  with  the  unique  capacity  to  induce  caspase-independent  peripheral 
chromatin condensation and large-scale DNA fragmentation when translocated to the 
nucleus, AIF is essential for programmed cell death during cavitation of embryoid 
bodies,  the  very  first  wave  of  (caspase-independent)  cell  death  indispensable  for 
morphogenesis (Cande, C., Cohen, I. et al., 2002). This has been confirmed by the 
finding  that  a  wide-ranging  caspase  inhibitor  prevents  none  of  the  AIF  effects. 
Paradoxically,  in  a  mouse  mutant  with  progressive  cerebellar  and  retinal 
degeneration, the down-regulation of AIF expression lead to apoptosis of neurons in 
association  with  an  imbalance  in  free  radical  metabolism  and  cell  cycle  re-entry 
(Bonni, A., 2003). In addition to its apoptogenic activity on nuclei, AIF participates in 
the regulation of apoptotic mitochondrial membrane permeabilization and exhibits an 
NADH  oxidase  activity.  Overexpression  of  Bcl-2,  which  controls  the  opening  of 
mitochondrial  permeability  transition  pores,  prevents  the  release  of  AIF  from  the 
mitochondrion but does not affect its apoptogenic activity (Susin, S. A., Lorenzo, H. 
K. et al., 1999a). Introduction
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Figure 1.13: Pro-apoptotic mitochondrial proteins. 
Apoptosis can  be  executed  in a  caspase-dependent  or independent  way. Cytochrome  c,  Smac/DIABLO  and 
HtrA2/Omi release directly or indirectly leads to the activation of caspases. In contrast to this, AIF induces nuclear 
condensation  and  chromatin  fragmentation  (red:  pro-apoptotic  factors/actions,  blue:  anti-apoptotic  factors/ 
actions).
1.5.3 Apoptosis and Alzheimer’s disease
Over the past 10 years, mitochondrial defects have been implicated in a wide variety 
of degenerative diseases, aging, and cancer. A growing body of data suggests that 
apoptosis  under  mitochondrial  control  is  implicated  in  neuronal  death  processes 
(Ghribi, O., DeWitt, D. A. et al., 2001). The essential serine protease HtrA2/Omi is 
discussed to be involved in A neurotoxicity in AD as it interacts with A in yeast two-
hybrid assays and cell culture experiments (Park, H. J., Seong, Y. M. et al., 2004). 
FAD mutations in presenilins render neurons vulnerable to apoptosis induced by A, 
trophic factor deprivation and other stimuli, suggesting that PS-1 in mitochondria is 
involved  by  regulating  HtrA2/Omi  activity  (Mattson,  M.  P.,  Chan,  S.  L.,  2003; 
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Popescu, B. O., Ankarcrona, M., 2004; Ankarcrona, M., Hultenby, K., 2002; Gupta, 
S., Singh, R. et al., 2004). APP mutations are ample to trigger apoptosis in cultured 
cells (McPhie, D. L., Lee, R. K. K. et al., 1997). It has been shown in our own group 
that  the  APPsw  mutation  increases  vulnerability  of  PC12  cells  against  oxidative 
stress (Eckert, A., Steiner, B. et al., 2001; Leutz, S., Steiner, B. et al., 2002; Marques, 
C. A., Keil, U. et al., 2003; Keil, U., Bonert, A. et al., 2004; Marques, C. A., Keil, U. et 
al., 2003; Marques, C. A., Keil, U. et al., 2003). Neurotoxic forms of A may be a 
trigger of  apoptosis  in  AD  because  pro-apoptotic  proteins  are associated  with  A
deposits  in  the  brains  of  AD  patients  and  A can  induce  apoptosis  of  cultured 
neurons. A causes increased oxidative stress in cell culture as could be shown by 
the induction of NF-B, a transcription factor thought to be regulated by oxidative 
stress (Behl, C., Davis, J. B. et al., 1994b). Oxidative stress-mediated neurotoxicity of 
A finally  results  in  mitochondrial  damage  (Pike,  C.  J.,  RamezanArab,  N.  et  al., 
1997).  A inhibited  cytochrome  c  oxidase  (COX-4)  activity  in  isolated  brain 
mitochondria (Canevari, L., Clark, J. B. et al., 1999). Furthermore, a selective defect 
in  cytochrome  c  oxidase has  been  observed in brains  of AD patients (Maurer, I., 
Zierz, S. et al., 2000). Activity changes in mitochondrial enzymes including pyruvate 
dehydrogenase  and  -ketoglutarate  dehydrogenase  have  been  described  in  AD 
brain (Gibson, G. E., Zhang, H. et al., 1998; Casley, C. S., Canevari, L. et al., 2002b). 
A-binding alcohol dehydrogenase (ABAD) might be a direct molecular link from A
to mitochondrial toxicity (Fig. 1.14). A interacts with ABAD in the mitochondria of AD
patients  and  transgenic  mice.  The  crystal  structure  of  A-bound  ABAD  shows 
substantial  deformation  of  the  active  site  that  prevents  nicotinamide  adenine 
dinucleotide  (NAD)  binding.  An  ABAD  peptide  specifically  inhibits  ABAD-A
interaction  and  suppresses  A-induced  apoptosis  and  free-radical  generation  in 
neurons (Lustbader, J. W., Cirilli, M. et al., 2004). Introduction
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Figure 1.14: Structure of A-bound ABAD.
Superposition  of A-bound  human  ABAD  (magenta) and  rat ABAD  in complex  with NAD  (cyan) (taken  from 
Lustbader, 2004).
Endoplasmic reticulum-associated A-binding protein (ERAB), L-3-hydroxyacyl-CoA 
dehydrogenase type II (HADH II), is expressed at high levels in Alzheimer's disease 
(AD)-affected  brain.  It  was  reported  that  L-3-hydroxyacyl-coenzyme  A 
dehydrogenase type II (ERAB) activity is implicated in A-induced cytotoxicity (Du 
Yan, S., Shi, Y. G. et al., 1999). 
Studies on patients with these diseases have revealed much about the complexities 
of  mitochondrial  genetics,  which  involves  interplay  between  mutations  in  the 
mitochondrial and nuclear genomes. However, the pathophysiology of mitochondrial 
diseases  has  remained  perplexing  (Wallace,  D.  C.,  Shoffner,  J.  M.  et  al.,  1995). 
Evidence that many neurons undergo apoptosis in AD includes the presence of high 
levels of activated apoptotic proteins such as caspase-3 and Bax in neurons that 
exhibit  neurofibrillary  tangle  pathology  (Engidawork,  E.,  Gulesserian,  T.  et  al., 
2001a). In addition, DNA-damage and up-regulation of the pro-apoptotic proteins p53 
and Bax occur in vulnerable neuronal populations at a relatively early stage in the 
disease process (Gomez-Lazaro, M., Fernandez-Gomez, F. J. et al., 2004; Culmsee, 
C., Mattson, M. P., 2005). The interaction of A with mitochondrial factors might give 
rise  to  new  targeting  sites  for  the  development  of  new  drugs  against 
neurodegenerative disorders. Not only a wide variety of apoptotic, but also of necrotic 
stimuli disrupt mitochondrial physiology in A-mediated toxicity (Behl, C., Davis, J. B. 
et al., 1994a). In coherence with this, data of our own group support the fact that 
necrosis and apoptosis do not necessarily exclude each other (Marques, C. A., Keil, Introduction
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U. et al., 2003). In frontal cortex and cerebellum of AD subjects, protein levels of 
caspase-3,  -8,  and  -9,  DFF45  (DNA  fragmentation  factor  45),  and  FLIP  (Fas 
associated  death  domain  (FADD)-like  interleukin-1-converting  enzyme  inhibitory 
proteins)  were  decreased,  while  those  of  ARC  (apoptosis repressor  with  caspase 
recruitment  domain)  and  RICK  (Receptor  interacting  protein  (RIP)-like  interacting 
CLARP  kinase)  were  increased.  In  contrast,  cytochrome  c  and  Apaf-1  were 
unchanged  (Engidawork,  E.,  Gulesserian,  T.  et  al.,  2001b).  The  current  findings 
showed that dysregulation of apoptotic proteins indeed exist in AD brain and support 
the  notion  that  it  may  contribute  to  neuropathology  of  AD.  Hence,  therapeutic 
strategies that ablate caspase activation may be of some benefit for AD sufferers.Introduction
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1.5.4 Neurotrophic factors
The neurotrophins  are  a family  of structurally  and  functionally related  small  basic 
proteins including nerve growth factor (NGF). All neurotrophins share a low affinity 
receptor, p75
NTR, but they transduct their specific actions mainly by interacting with 
the tyrosine kinase (Trk) family of transmembrane receptors including three subtypes, 
Trk A, B, and C. NGF preferably interacts with TrkA (Fig. 1.15) (Grimes, M. L., Zhou, 
J. et al., 1996). NGF, which is secreted 
by  the  target  and  interacts  with 
receptors  on  the  axon  tip,  regulates 
survival,  differentiation,  and 
maintenance  of  responsive  neurons. 
Yet it is uncertain how the NGF signal 
is  communicated  retrogradely  from 
distal axons to neuron cell bodies. 
Figure 1.15: Structure of homodimeric form of human NGF in complex with domain 5 of the Trk receptor.
(taken from The Cell, 2004)
Most probably, retrograde transport of activated receptors in endocytic vesicles could 
convey the signal. Some studies raise the possibility that NGF induces formation of 
signaling  endosomes  containing  activated  TrkA.  NGF  induces  transcription-
dependent neural differentiation, and the ERK family of MAPKs has been implicated 
as  the  dominant  signal  pathway  that  mediates  this  response.  Constitutive  active 
forms of c-Raf-1, MEKK1 and MKK6, proximal regulators of the ERKs, JNKs, and 
p38 MAPKs, respectively, were all stimulated by NGF. These findings indicate that 
the ERK and JNK pathways collaborate downstream of the NGF receptor. Besides 
the MAPK pathway the phosphoinositide 3-kinase (PI3K) pathway seems to play an 
important role (Fig. 1.16) (Jin, L., Hu, X. H. et al., 2005; Jones, D. M., Tucker, B. A. et 
al., 2003).  PI3K  activation  stimulates  Akt,  which  directly  phosphorylates  glycogen 
synthase kinase-3 (GSK-3) to switch off its catalytic activity. GSK-3 genes encode 
two  closely  related  proteins,  GSK-3 and  GSK-3,  both  of  which are  widely 
distributed in the brain. GSK-3 seems to play an important role in regulation of cell Introduction
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proliferation and neurite outgrowth. Inactivation of GSK-3 by phosphorylation results 
in the activation of pathways that are normally repressed by GSK-3 (Doble, B. W., 
Woodgett, J. R., 2003). Very interestingly, GSK-3 also seems to play an important 
role  in  AD  (Kaytor,  M.  D.,  Orr,  H.  T.,  2002),  being  implicated  in  amyloid  plaque 
formation associated with AD by influencing APP metabolism (Aplin, A. E., Gibb, G. 
M. et al., 1996). 
Figure 1.16: Mechanism of action of NGF. 
NGF binds to a high-affinity tyrosine kinase receptor, TrkA, on the plasma membrane to induce phosphorylation of 
TrkA at two different tyrosine residues. These phosphorylated tyrosines serve to bind various adapter proteins or 
phospholipase C (PLC). The adapter proteins, in turn, activate three major signaling pathways: the PI3 kinase 
pathway leading to activation of Akt kinase, the ras pathway leading to activation of MAP kinases and the PLC 
pathway  leading to release  of intracellular  Ca
2+ and  activation  of  PKC.  The  ras  and  PLC  pathways  primarily 
stimulate processes responsible for neuronal differentiation, while the PI3 kinase pathway is primarily involved in 
cell survival (taken from The Cell, 2004). Introduction
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1.6 Current therapy
Today,  there  is  no  known  treatment  to  cure  AD,  but  there  are  many  research 
programs running pursuing promising studies focused on halting or preventing the 
disease  process  (Carreiras,  M.  C.,  Marco,  J.  L.,  2004;  Breen,  K.  C.,  2004; 
Cummings, J. L., 2004). The current medications aim on helping to control symptoms 
of the disease as well as on managing agitation, depression, or psychotic symptoms, 
such as hallucinations or delusions. In Germany, acetyl cholinesterase inhibitors and 
memantine are specifically approved for the treatment of AD, and several other anti-
dementive  drugs  are  on  the  market,  amongst  which  standardized  Ginkgo  biloba 
extract (EGb 761) and Piracetam are the most important ones.
1.6.1 Acetyl cholinesterase inhibitors
The current standard of care for mild to moderate AD includes treatment with acetyl 
cholinesterase inhibitors to improve cognitive function. Aricept
 (donezepil), Exelon

(rivastigmine) and Reminyl
 (galantamine) belong to this group. It has been shown 
that  people  suffering  from  AD  have  low  brain  levels  of  acetyl  choline  due  to  a 
selective  loss  of  cholinergic  neurons  (Davies,  P.,  Maloney,  A.  J.  F.,  1976). 
Consequently, maintaining higher levels of the neurotransmitter in the postsynaptic 
area  of  intact  neurons  slows  the  progressive  cognitive impairment.  For  Reminyl

(galantamine), besides its action via nicotinic receptors, neuro-protective effects have 
been  reported  after  glucose- or  oxygen-deprivation  of  rat  hippocampal  neurons 
(Sobrado, M., Roda, J. M. et al., 2004; Chadwick, K. J., Rylett, R. J., 2004). 
1.6.2 NMDA antagonists
The  NMDA  receptor  is  possibly  involved  in  long  term  potentiation  of  disturbed 
memory processes in dementia (Lipton, S. A., Rosenberg, P. A., 1994; Bading, H., 
Segal, M. M. et al., 1995). An NMDA (N-methyl-D-aspartate) antagonist, memantine, 
has  been  approved  for  the  treatment  of  advanced  AD  (Molinuevo,  J.  L.,  2003; 
Moebius, H. J., Wirth, Y., 2005). Introduction
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In contrast to cholinesterase inhibitors being indicated for mild to moderate stages, 
memantine is approved for moderate and severe stages of the disease. The drug 
protects nerve cells against excess amounts of glutamate, a neurotransmitter whose 
release is probably increased in AD brain. Memantine is a drug considered to be 
neuro-protective. However, its benefit has been demonstrated in preclinical studies.
1.6.3 Ginkgo biloba extract
The  Gingko  biloba  extract  EGb  761  is  a  well-tolerated  drug  approved  for  the 
treatment  of  degenerative,  vascular  and  mixed  forms  of  dementia  (Kleijnen,  J., 
Knipschild, P., 1992; Kanowski, S., Herrmann, W. M. et al., 1996; Le Bars, P. L., 
Velasco,  F.  M.  et  al.,  2002;  Le  Bars,  P.  L.,  Kastelan,  J.,  2000).  It  has  been 
demonstrated by numerous studies and meta-analyses that EGb 761 is a prominent 
drug to treat AD (Andrieu, S., Gillette, S. et al., 2003). Evidence is provided that the 
extract  EGb  761  owns  antioxidant  and  neuroprotective  properties.  It  was 
demonstrated by our group that apoptosis was reduced in vitro by the treatment with 
Ginkgo biloba extract EGb 761. Mice feeded with the extract for two weeks exhibited 
significantly reduced ROS-induced apoptosis. Notably, this effect is most prominent 
in old mice (Schindowski, K., Leutner, S. et al., 2001). 
Additional data demonstrate that the extract reconstitutes mitochondrial membrane 
potential of PC12 cells, isolated brain mitochondria and dissociated brain cells after 
previous mitochondrial damage by sodium nitroprusside (Eckert, A., Keil, U. et al., 
2005). Furthermore, the ATP production was reversed by the extract. These findings 
strongly  support  that  protection  of  mitochondrial  function  is  a  very  specific  and 
sensitive property of the Gingko biloba extract EGb 761. Others found that Ginkgo 
biloba extracts exhibit anti-inflammatory, anti-oxidant and anti-coagulant properties 
and increase blood flow to the brain. Further studies emphasize that the benefit of 
the extract  in the treatment  of AD (Christen,  Y.,  2004; Kurz,  A.,  Van  Baelen, B., 
2004).  In  addition,  Ginkgo  biloba  extract  revealed  positive  effects  on  neuronal 
plasticity of adult mice indicating a direct interaction with the glutamatergic system 
and raise interesting implications with respect to a mechanism explaining its effect on 
cognitive  enhancement  in  human  subjects  experiencing  dementia  (Williams,  B., 
Watanabe, C. M. H. et al., 2004). Introduction
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1.6.4 Piracetam
Piracetam (2-oxo-1-pyrorolidine acteamide) is applied for the symptomatic therapy of 
cerebrovascular disturbances.  Due  to  its  nootropic  properties  (Giurgea,  C.  E., 
Greindl,  M.  G.  et  al.,  1983),  the  substance  improves  cognitive  functions  without 
causing undesirable side effects such as sedation. Extensive investigative work has 
been performed in our group in order to demonstate that the nootropic substance 
piracetam recovers mitochondrial function in cell culture models and in dissociated 
brain  cells of mice  (Keil, U.,  Scherping,  I.  et al., 2006). These  important  findings 
further emphasize the importance of the reconstitution of mitochondrial function in the 
therapy of cerebrovascular disturbances in dementia. Mitochondrial stabilization and 
protection  might  be  an  important  mechanism  to  explan  many  of  piracetam´s 
beneficial effects in elderly patients.
1.7 Disease-modifying strategies
New drugs are wanted that interfere with the neurodegenerative mechanisms to stop 
neuronal  cell  death.  As  mentioned  before,  one  strategic  option  could  be  the 
stabilization of mitochondrial membrane potential. Furthermore, modulation of APP 
and A metabolism as well as the promotion of neurotrophic pathways are under 
investigation.
1.7.1 Statins
ApoE4, playing a regulatory role in the transport of cholesterol, is a known risk factor 
for developing AD (see chapter 1.1.6.2). Epidemiological studies demonstrated that 
statin  therapy  was  associated  with  a  decreased  risk  for  the  development  of  AD 
(Wolozin,  B.,  Kellman,  W.  et  al.,  2000).  Notably,  statins  positively  regulated  -
secretase processing of APP, resulting in elevated amounts of the neuro-protective 
- APP (Kojro, E., Gimpl, G. et al., 2001; Fassbender, K., Masters, C. et al., 2001). 
Since  many  studies  suggest  a  strong  link  between  cholesterol  and  Alzheimer´s 
disease, studies were reviewed by our own group that have examined cholesterol 
levels in AD patients and control subjects. Of note, elevated cholesterol levels were 
not  identified  as  a  risk  factor  for  AD.  Thus,  alternative  hypotheses  have  to  be Introduction
37
discussed, including cholesterol  domains, e.g. (Eckert, G. P., Wood, W. G. et al., 
2005). This is underlined by our recent finding that statins have pleiotropic effects in 
addition  to lower  cholesterol  levels, and  that  they  may  act  on  different  pathways 
involving distinct gene expression patterns (Johnson-Anuna, L. N., Eckert, G. P. et 
al., 2005). Interestingly, simvastatin had the greatest influence on gene expression 
as  it  modified  the  expression  of  23  genes,  amongst  which  some  genes  were 
identified of being involved in apoptotic pathways. Currently, prospective clinical trials 
are underway to investigate the effect of statins on A production.
1.7.2 NSAIDS
Some studies suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may 
lower the risk of developing AD and slow its progression (Bradbury, J., 2004; Tuppo, 
E. E., Arias, H. R., 2005). As NSAIDs help by reducing inflammation, it is supposed 
that they might also slow the inflammatory response occurring during the progression 
of AD. It is well known that the treatment with NSAIDs is strongly associated with the 
risk factor liver and kidney damage as well as gastrointestinal bleeding. A trial called 
the Alzheimer’s disease prevention trial (ADAPT) sponsored by the National Institute 
of Aging (NIA), a part of the National Health Institute (NIH), was designed to assess 
the  potential  benefit  of  long-term  use  of  non-NSAIDs  in  decreasing  the  risk  of 
developing AD. The trial was stopped due to an apparent increase in cardiovascular 
and cerebrovascular events among the participants taking naproxen when compared 
with  those  on  placebo.  Thus,  further  studies  are  needed  before  general 
recommendations can be made concerning the use of NSAIDs.Introduction
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1.7.3 -secretase inhibitors
In the last years, -secretase inhibitors were designed to block A production and to 
explore whether -secretase may be a potential target for new AD therapeutics. The 
transmembrane domain is a new feature of a mammalian aspartic protease with its 
active site on the lumenal side of the membrane where -secretase cleaves APP. 
Three  groups,  reporting  that  -secretase-knockout  mice  are  deficient  in  A
production, independently provided the in-vivo validation of BACE-1 as -secretase. 
This  was  not  unexpected  but  it  additionally  demonstrated  that  there  is  no 
compensatory mechanism for -secretase cleavage in mice (Luo, Y., Bolon, B. et al., 
2001; Cai, H. B., Wen, H. J. et al., 2004; Roberds, S. L., Anderson, J. et al., 2001), 
an important predisposition for inhibitor development. Theoretically, there should be 
BACE-1  substrates  other  than  APP,  and  two  candidates  were  identified  recently 
(Kitazume, S., Nakagawa, K. et al., 2004; Lichtenthaler, S. F., Schobel, S. et al., 
2004), but the most important and unexpected finding of the knockout studies was 
the lack of serious vital problems due to -secretase ablation. A detailed analysis 
demonstrated that the knockout mice are normal in terms of gross morphology and 
anatomy,  tissue  histology,  haematology  and  clinical  chemistry and  also  on  gene 
expression  levels  and  phenotypic  assessment  of  older  BACE-1-knockout  mice. 
BACE-1-knockout over-expressing APP were engineered which did not develop any 
A deposits over life time supporting the fact that there is no alternative mechanism 
for APP cleavage that could drive plaque formation (Luo, Y., Bolon, B. et al., 2001). 
Also,  no  obvious  deficits  in  basal  neurological  and  physiological  functions  were 
observed by behavioural analysis of the knockout mice (Roberds, S. L., Anderson, J. 
et al., 2001). Concluding, the absence of A production and distinct pathology in the 
BACE-1-knockout mice is encouraging for -secretase drug development. Today, the 
therapeutical use of -secretase inhibitors is still restricted due to the unavoidable 
toxic  side  effects.  But  it  seems  at  least  probable  that  in  future  times,  promising 
candidates  will  be  developed  since  potent  and  specific  peptidic  inhibitors  are 
identified  for  aspartic  proteases.  Nevertheless,  the generation  of  small  molecules 
with the desired pharmacokinetic properties remains problematic (Middendorp, O., 
Ortler, C. et al., 2004; Polgar, T., Keseru, G. M., 2005; Stachel, S. J., Coburn, C. A. 
et al., 2004). Introduction
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1.7.4 -secretase inhibitors
The obvious lethality of the presenilin-knockout mice reinforces the serious concerns 
about mechanism-based toxicity of -secretase inhibitors. The effect of -secretase 
inhibitors  on  thymocyte  differentiation  (known  to  be  Notch  1-dependent)  in  organ 
culture systems was analysed, and indeed, -secretase inhibitors reduce thymocyte 
numbers and block thymocyte differentiation (Hadland, B. K., Manley, N. R. et al., 
2001; Doerfler, P., Shearman, M. S. et al., 2001). Currently, it is unclear whether 
therapeutically useful potent -secretase inhibitors can be generated. Regardless the 
serious concerns about -secretase inhibitor therapy, some intriguing findings offer 
new  perspectives:  It  was  shown  that,  at  very  high  concentrations,  certain  non-
steroidal anti-inflammatory drugs (NSAIDs) can modulate -secretase cleavage, such 
that  A1-42 is  reduced  and  the  production  of  a  smaller  isoform,  A1-38,  which  is 
expected to be less prone to aggregation than A1-42, is increased. In this setting, 
Notch cleavage (corresponding to the 49 position of A) was not blocked (Weggen, 
S.,  Eriksen,  J.  L.  et  al.,  2003).  These  compounds  could  possibly  modulate  -
secretase or its substrate, because the effect is observed in cells that lack the NSAID 
targets cyclo-oxygenase I (COX-1) and II (COX-2) (Beher, D., Clarke, E. E. et al., 
2004).  Other  known  non-COX  targets  of  NSAIDs,  such  as  lipoxygenases, 
peroxisome proliferative activated receptor- (PPAR-)                     B (NF-B)
are  not  affected.  Potent  compounds  using  this  A1-42 modulator  mechanism
circumventing the Notch-related side effects of total -secretase inhibition, could re-
emerge  as  promising  drug  targets.  Large  collections  of  compounds  to  identify 
molecules  that  reduce  A production  in  the  absence  of  overt  toxicity  have  been 
screened and it was determined whether - or -secretase activity had been inhibited 
by secondary assays. This approach only identified -secretase pathway inhibitors, 
and  the  potent  compounds  inhibited  the  production  of  all  A isoforms. Medicinal 
chemistry programs ultimately lead to drug-like molecules that could reduce plasma 
and soluble brain A in mice only a few hours after a single administration (Dovey, H. 
F., John, V. et al., 2001; Lanz, T. A., Himes, C. S. et al., 2003a). Bristol-Myers Squibb 
announced  that  the  first  -secretase  inhibitor  had  entered  Phase  II  clinical  trials 
(Molinoff, P. et al., unpublished data) in 2001. Also, most other companies have not Introduction
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disclosed  anything  about  the  development  status  of  their  -secretase-inhibitor 
programs.  The only  exception is Lilly,  recently  publishing  the results  of a 6-week 
Phase II trial of a functional -secretase inhibitor which demonstrated a significant 
decrease in A concentration in plasma, but not in cerebrospinal fluid, at a dose that 
was tolerated well during the short trial (Siemers, E., Dean, R. A. et al., 2004). The
safety,  tolerability  and  decrease  of  A levels  by  -secretase  inhibitor  was  further 
investigated  in  a  Phase  I  trial  (Siemers,  E.,  Skinner,  M.  et  al.,  2005).  A levels 
decreased  dose-dependently  after  multple  doses  for  14  days,  and  the  reported 
adverse events were described as manageable.Introduction
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1.7.5 Neurotrophins
One promising AD treatment strategy is to protect or repair the neurons affected by 
the disease process. Nerve growth factor (NGF) and other neurotrophic factors have 
been studied as potential therapeutic agents and attempts have been made to use 
NGF itself as a clinical therapy. However, these attempts have not been successful 
at least partly because NGF is rapidly degraded and lacks the ability to cross the 
blood  brain  barrier. While  there  is  widespread  interest  in  the  use  of  neurotrophic 
factors  to  prevent  and/or  reduce  the  neuronal  cell  loss  and  atrophy  observed  in 
neurodegenerative  disorders,  little  research  has  been  performed  examining  the 
expression and functional role of these factors in the normal and diseased human 
brain  (Connor,  B.,  Dragunow,  M.,  1998).  It  has  been  shown  recently  that  the 
activation of the high-affinity receptor for nerve growth factor (NGF), tyrosine kinase 
receptor  (TrkA),  results  in  increased  secretion  of  the  amyloid  precursor  protein 
(sAPP) into the culture medium. Interestingly, in the parietal cortex of AD patients a 
significant reduction in TrkA immunoreactivity has been reported suggesting a role of 
neurotrophins  in  the  process  of  neurodegeneration  in  AD  (Savaskan,  E.,  Muller-
Spahn, F. et al., 2000). Exogenous sAPP increased neuron viability in both short-
and long-term cortical neuron cultures grown in the absence of serum (Rossner, S., 
Ueberham, U. et al., 1998b). It has been supposed that the activation of mitogen 
activated protein (MAP) kinase alone is sufficient to promote APP secretion, whereas 
inhibition  of  MAP  kinase will  reduce  APP  secretion  only  when  phospholipase  C 
gamma  or  phosphatidylinositol  3-kinase  are  additionally  inhibited  (Rossner,  S., 
Ueberham,  U.  et  al.,  1999).  This  suggests  that  pharmacological  manipulations 
activating  the  MAP  kinase  pathway  may  result  in  increased  secretory  APP 
processing.  Furthermore,  much  attention  has  been  drawn  to  glycogen  synthase 
kinase 3 (GSK-3) and its implication in amyloid plaque formation associated with AD 
by influencing APP metabolism. The expression and secretion of APP is increased 
in  rat  cerebral  cortices  that  have  been  denervated  by  subcortical  lesions  of  the 
nucleus basalis of Meynert. It has been previously shown that sAPP produced by -
secretase  activity  potentiates  the  neuritogenic  activity  of  NGF  in  vitro.  The 
neurotrophic  interactions  of  NGF  and  sAPP have been  characterized  using 
differentiated  PC12  cells  and  rat  primary  cortical  neurons.  NGF  required  the Introduction
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expression of APP to maintain a neuronal phenotype (Luo, J. J., Wallace, M. S. et 
al., 2001). 
Moreover, in-vitro evidence is provided that NGF can abolish A-induced apoptosis 
(Kuner,  P.,  Schubenel,  R.  et  al.,  1998).  Substituted  pyrimidines  have  modest 
neurotrophin-like activities (Matsumoto, K., Yamamoto, K. et al., 2003; Fyfe, J. A., 
Beauchamp, L. M. et al., 2004) and their neuroprotective effect has been studied in 
models of cerebral ischemia, Parkinson and Huntington’s disease. Since it is known 
that PI3K  activation by  neurotrophins  stimulates  Akt  which in turn  phosphorylates 
GSK-3, a multifunctional serine/threonine kinase playing a pivotal role not only in the 
regulation of  cell proliferation  and neurite  outgrowth,  but also  in  APP  processing, 
post-translational modification and transport is considered to be the connecting link 
between the two main hallmarks of AD, as abnormal tau phosphorylation as well as 
altered APP  processing.  In siRNA  experiments (Phiel,  C.  J., Wilson, C.  A.  et al., 
2003),  reduced  GSK-3 protein  expression  levels  promote  A1-40 and  A1-42
secretion. Thus, the reduced phospho-GSK-3 expression in APPsw per se might be 
at least one regulatory factor leading to increased A levels in these cells.Introduction
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Figure 1.17: NGF signaling pathway and APP processing.
NGF interacts with TrkA in order to convey its signal intracellularly. TrkA receptor binding initiates MAP kinase, 
PI3K or PLC  signalling. Besides modulating the phosphorylation status of tau and APP, GSK-3 additionally 
blocks AP-1 leading to modified APP transcription.
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1.8 Aims of the thesis
Although  massive  investigative  work  has  been  accomplished  to  finally  reveal  the 
causes of AD, many pathways being involved in the Alzheimer’s disease progress 
remain obscure, which has fatal consequences for the disease’s therapy: The drugs 
currently used in the therapy of AD are effective, but most of them have only modest 
symptomatic  effects.  Actually,  no  effective  causative  disease-modifying  therapy  is 
available.
Among the approaches towards disease modifying treatment of Alzheimer's disease 
blocking the initial step of the amyloid cascade, A generation, has received most 
attention. A generation requires two proteases, - and -secretase, and inhibition of 
these enzymes is a key focus of AD drug development. Progress in this area has 
been slow,  because  these enzymes  were  not entirely identified.  After intracellular 
generation  of  A,  the  peptide  is  secreted  into  the  extracellular  space  where  it 
accumulates to form one characteristic hallmark of AD: amyloid plaques. Although 
the primary toxic species in sporadic AD is still unknown, neurotoxicity of A seems 
at  least  partly  to  be  associated  oxidative  stress,  mitochondrial  defects,  calcium 
dysregulation,  excitatory  toxicity  and  deficiency  of  survival  factors.  Missense 
mutations  located  within  the  APP-gene  close  to  the  A sequence  were  the  first 
familial AD-gene to be identified, but yet little is known of how these mutant genes 
lead to these  early  onset forms  of  AD.  Interestingly,  FAD  and sporadic  AD  have 
common clinical and neuropathological features. Therefore, using transgenic models 
expressing  FAD-mutations  are  promising  approaches  to  elucidate  the  underlying 
mechanisms of neuronal death in AD. On the basis of many studies in cell cultures, 
transgenic  animal  models,  and  patients,  we  know  that  FAD  mutations  alter  APP 
processing  with  respect  to  an  enhanced  A production.  However,  the  underlying 
mechanisms responsible for the massive neurodegeneration induced by A in the brain 
from AD patients are still not completely understood.
The  major  aim  of  this  thesis  was  therefore  to  elucidate  neurotoxic  biochemical 
pathways induced by A with special focus on the mitochondria-dependent cell death 
pathway, since recent data of our group indicate the pivotal role of mitochondria in 
the pathogenesis of AD. Introduction
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The first aim of this thesis was to characterize three different APP-expressing cell 
lines with regard to APP expression and localization, A production, secretion and 
intracellular distribution as well as - and -secretase activity. As cell models, the 
neuronal PC12 (rat pheochromocytoma), HEK (human embryonic kidney 293) and 
SY5Y (human neuroblastoma, APPwt only) cell lines were used, which have been 
transfected  with  human  wildtype  APP  or the human  APP  containing the Swedish 
double mutation. This mutation results in a three- to sixfold increased A production 
compared  to  wild-type  APP  (APPwt).  Compared  to  experiments  using  high 
concentrations of A at micromolar levels applied extracellularly to cells, these cell 
lines may allow to investigate chronic effects of intracellularly produced and secreted 
A in a dose-dependent manner. Thus, these cell models could represent a very 
suitable approach to elucidate the AD-specific cell death pathways mimicking various 
pathological conditions. Furthermore, the toxicity of different A species should be 
assessed, since evidence is provided that soluble, intracellular A species already 
reveal the maximum toxicity and that the insoluble, extracellular A aggregates, even 
though noxious,  do  not represent  the  main  toxic  species in AD. In particular,  the 
question  was  addressed  whether  A dimers  represent  already  the  neurotoxic 
correlate. Therefore, the effects of monomeric, dimeric and oligomeric/fibrillar A on 
the MTT reduction potential of SY5Y and PC12 cells were investigated. In addition, 
the effects of intracellularly produced A dimers of human neuroblastoma (SY5Y) 
cells  stably  transfected  with  APPK623C,  a  mutation  causing  the  intracellular 
formation of APP and A dimers, on the MTT reduction potential were investigated. 
Preceding  work  of  our  group  revealed  that  A can  induce  changes  in  the 
mitochondrial activity particularly after oxidative stress. It was shown that initiator-
and  executioner  caspases  were  activated  in  a  time-dependent  pattern  while 
mitochondrial membrane potential and ATP levels decreased significantly (Marques, 
C. A., Keil, U. et al., 2003; Keil, U., Bonert, A. et al., 2004). Therefore, the second 
aim  of  this  thesis  was  to  figure  out  alterations  in  protein  expression  of  pro-
/antiapoptotic factors associated with the mitochondria-dependent cell death pathway 
under baseline conditions and after oxidative stress. Thus, proteins up- and down-
stream  acting  of  mitochondria  that  are  involved  in  apoptosis  were  a  matter  of 
investigation. In order to assess the interplay of members of the Bcl-2 family during 
oxidative  stress,  protein expression  levels  and  subcellular  distribution  were Introduction
46
investigated. Furthermore, the time-dependent release of pro-apoptotic mitochondrial 
factors  was  investigated  in  order  to  characterize  caspase-dependent  and  -
independent mitochondrial apoptosis. This study should furthermore help to clarify 
whether Bcl-2 family proteins and other pro-apoptotic mitochondrial factors can serve 
as potentially new targets for AD disease modification or not. 
In  order  to  develop  new  AD-specific  drugs,  many  efforts  aim  at  the  inhibition  of 
secretases or at restoring and maintaining neuronal function. Therefore, in the last 
part of the thesis, two disease-modifying strategies should be investigated. Following 
the determination of baseline - and -secretase activity, the time- and concentration-
dependent decrease in A levels after treatment  with different - and -secretase 
inhibitors was characterised in cells stably transfected with APPwt and APPsw. In 
order  to  additionally  examine  their  beneficial  value,  the  effect  of  the  secretase 
inhibitors  on  mitochondrial  activity  mirroring  cellular  viability  was  determined. 
Furthermore,  evidence  is  provided  that  substituted  pyrimidines  have  mild  growth-
promoting activities. In particular, the substituted pyrimidine KP544 seems to be able 
to potentiate growth-promoting effect of NGF in primary neuronal cultures. In order to 
clarify the role of substituted pyrimidines as potential neuro-modulatory drugs in AD, 
we  investigated  the  effects  of KP544 on protein  expression,  APP  processing  and 
mitochondrial activity in PC12 cells with special regard to the APP Swedish double 
mutation.Introduction
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1.9 Ziele der Arbeit
In  den  letzten  Jahren  wurde  die  Entstehung  der  Alzheimer  Demenz  intensiv 
untersucht,  jedoch  liegen  noch  viele  Mechanismen,  die  an  der  Entstehung der 
Erkrankung  beteiligt  sind,  im  Dunkeln.  Dies  hat  fatale  Konsequenzen  für  die 
Therapie: Die Arzneimittel, welche zur Zeit zur Behandlung der Alzheimer Demenz 
eingesetzt werden sind effektiv, aber viele haben nur bescheidene symptomatische 
Wirkungen.  Momentan  gibt  es  keine  kausale  krankheitsmodulierende 
Behandlungsoption. 
Unter  den  Therapieansätzen,  die  zu  einer  krankheitsmodulierenden  Behandlung 
führen sollen,  erhält  die  Blockade  des  initialen Schrittes  der  Amyloidkaskade,  die 
Bildung von A, die meiste Aufmerksamkeit. Zur Bildung von A bedarf es zweier 
Proteasen, - und -Sekretase, und die Inhibition dieser Enzyme repräsentiert ein 
Hauptaugenmerk  der  Alzheimer-Forschung.  Die  Fortschritte  auf  diesem  Gebiet 
erfolgten nur langsam, da die Enzyme lange nicht identifiziert werden konnten. Nach 
der intrazellulären Bildung von A wird das Peptid in den Extrazellularraum sekretiert, 
wo  es  zu  einem  Hauptmerkmal  der  Alzheimer  Demenz  akkumuliert:  Amyloid-
Plaques. Bis heute sind die primären toxischen Spezies der sporadischen Alzheimer 
Erkrankung  noch  nicht  bekannt.  Es  scheint  jedoch  die  Neurotoxizität  von  A, 
assoziiert mit oxidativem Stress, mitochondrialen Defekten, Kalzium-Dysregulierung, 
exzitatorischer Toxizität und Mangel von Survivalfaktoren eine wesentliche Rolle zu 
spielen. Auf dem APP-Gen lokalisierte Mutationen nahe der A-Sequenz waren die 
ersten  familiären  Alzheimer-Gene,  die  identifiziert  wurden.  Heute  ist  immer  noch 
wenig  darüber  bekannt,  wie  diese  Genmutationen  zu  dem  frühen  Beginn  der 
Alzheimer  Demenz  führen.  Interessanterweise  haben  familiäre  und  sporadische 
Alzheimer-Formen  gemeinsame  klinische  und  neuropathologische  Charakteristika. 
Aus  diesem  Grund  stellen  transgene  Tier- oder  Zellkulturmodelle,  die  familiäre 
Mutationen exprimieren, vielversprechende Optionen dar, um die Mechanismen der 
Alzheimer Erkrankung aufzuklären.
Basierend  auf  vielen  Studien  in  Zellkultur,  an  transgenen  Tiermodellen  und  an 
Patienten  weiß  man  heute,  dass  familiäre  Alzheimer-Mutationen  die  APP-
Prozessierung beeinflussen und zu einer erhöhten A-Produktion führen.Introduction
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Frühere  Ergebnisse  unserer  Arbeitsgruppe demonstrieren,  dass  A die neuronale 
Empfindlichkeit gegenüber oxidativem Stress erhöht und so die Neurodegeneration 
und den Zelltod fördert. 
Basierend  auf  vielen  Studien  in  Zellkultur,  an  transgenen  Tiermodellen  und  an 
Patienten  weiß  man  heute,  dass  familiäre  Alzheimer-Mutationen  die  APP-
Prozessierung beeinflussen und zu einer erhöhten A-Produktion führen.
Frühere  Ergebnisse  unserer  Arbeitsgruppe demonstrieren,  dass  A die neuronale 
Empfindlichkeit gegenüber oxidativem Stress erhöht und so die Neurodegeneration 
und  den Zelltod  fördert.  Diese  Ergebnisse  waren  die  Grundlage  des  ersten  Ziels 
dieser  Arbeit,  die  zum  Ziel  hatte  A-induzierte,  neurotoxische,  biochemische 
Prozesse  aufzuklären.  Zu  diesem  Zweck  wurde  der  Effekt  der  Schwedischen 
Doppelmutation  (APPsw,  KM670/671NL)  auf  oxidativen  Stress-vermittelte 
Zelltodmechanismen untersucht. Die Schwedische Doppelmutation führt zu einer im 
Vergleich zur Wildtyp-Form (APPwt) drei- bis sechsfach erhöhten A-Produktion. Es 
wurden  PC12- (Rattenpheochromozytom-),  HEK- (humane  embryonale 
Nierenkarzinom-) und SY5Y- (humane Neuroblastom-) Zellen als Modell gewählt, die 
zu einem mit wildtyp APP (APPwt) oder mit der Schwedischen APP-Doppelmutation 
transfiziert wurden. APPsw-transfizierte PC12-Zellen sekretieren A in picomolaren 
Konzentrationen,  was  sehr  gut  die  physiologische  Situation  in  Gehirnen  von 
Alzheimer Patienten wiederspiegelt. Im Gegensatz dazu werden zur Untersuchung 
der  Toxizität  von  extrazellulärem  A unphysiologische  hohe  Konzentrationen  im 
mikromolaren Bereich appliziert. Dieses Zellkulturmodell ist somit sehr gut geeignet, 
um  Alzheimer-spezifische  Zelltodwege  zu  untersuchen,  die  unter  pathologischen 
Bedingungen auftreten und zu denen auch intrazelluläres A beiträgt.
Die verschiedenen Zelltypen, mit APPwt bzw. APPsw transfizierte PC12- und HEK-
Zellen erlauben die Untersuchung von APP- oder A-vermittelten dosisabhängigen 
Effekten.  APPsw-transfizierte  HEK-Zellen  zeigen  eine  dreißigfach  erhöhte  A-
Produktion im Vergleich zu APPsw-transfizierten PC12-Zellen. Somit steht hier ein 
Modell für die Untersuchung chronisch erhöhter A-Spiegel zur Verfügung. 
Humane  SY5Y-Zellen  sind  neuronalen  Ursprungs  und  wurden  stabil  mit  APPwt 
transfiziert.Introduction
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Ein  weiteres  Ziel  dieser  Arbeit  war  die  Untersuchung  der  Proteinexpression  und 
Sekretion in humanen Zelllinien (SY5Y, HEK) und der Ratten-Zellline (PC12), sowie 
der Vergleich beider Parameter in neuronalen (PC12, SY5Y) und nicht-neuronalen 
Zelllinien (HEK). 
Mitochondriales APP trägt möglicherweise zu der Neurozoxizität bei, wie kürzlich von 
einer  Arbeitsgruppe  demonstriert  wurde.  Um  die  Charakterisierung  der  APP-
Expression  und A-Sekretion  zu  vertiefen,  wurde  die intrazelluläre  Verteilung  von 
APP und A untersucht.
Es wird vermutet, dass lösliche, dimere und oligomere A- Spezies im Gegensatz zu 
unlöslichen, extrazellulären, fibrilläre A-Aggregaten die primären toxischen Spezies 
der Alzheimer Demenz darstellen und somit die höchste Toxizität aufweisen. Dehalb 
war  das  zweite  Ziel  dieser  Arbeit,  die  Toxizität  unterschiedlicher  A- Spezies  zu 
charakterisieren: Die Toxizität monomerer, dimerer und fibrillärer A- Spezies wurde 
durch  Bestimmung  des  MTT  Reduktionspotentials  von  SY5Y- und  PC12-Zellen 
wurde  untersucht.  Anhand  von  SY5Y-Zellen  (K623C  SY5Y),  die  mit  einem  APP-
Dimer-bildenden Konstrukt stabil transfiziert wurden, wurden diese Effekte mit denen 
von intrazellulär gebildeten A-Dimeren auf das MTT Reduktionspotential verglichen.
Frühere  Ergebnisse  unseres  Arbeitskreises  beschrieben  Caspase-Aktivierung  und 
mitochondriale Veränderungen nach Schädigung durch oxidativen Stress besonders 
im  Zusammenhang  mit  der  APPsw-Mutation  in  PC12-Zellen.  Initiator- und 
Executioner- Caspasen werden in einer zeitabhängigen Reihenfolge aktiviert, wobei 
zeitnah  das  mitochondriale  Membranpotential  und  die  ATP-Spiegel  signifikant 
sanken. 
Das dritte Ziel dieser Arbeit stellte die Charakterisierung weiterer Proteine dar, die 
eine wichtige Rolle in der Apoptose und bei oxidativem Stress spielen: Proteine der 
Bcl-2-Familie und pro-apoptotische, mitochondriale Faktoren. Die Expression und die 
subzelluläre  Verteilung  wurden  unter  Bedingungen  untersucht,  die  zur 
Charakterisierung der Caspasen analog sind. In diesem Zusammenhang wurde auch 
die  zeitabhängige Freisetzung  von  pro-apoptotischen  mitochondrialen Faktoren im 
Hinblick auf caspase-abhängige und -unabhängige Apoptose untersucht. Basierend 
auf  den  Ergebnissen  wurde  diskutiert,  ob  Bcl-2  Proteine  oder  pro-apoptotische 
mitochondriale Faktoren potentielle therapeutische Targets in der Alzheimer Demenz 
darstellen.Introduction
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Die Etablierung von geeigneten Immunisierungsmethoden zur Heilung der Alzheimer 
Demenz (Lemere, C. A., Spooner, E. T. et al., 2003; Selkoe, D. J., Schenk, D., 2003)
und die Inhibition von Sekretasen stellen zwei Ansätze dar, um die Akkumulation von 
neurotoxischen A-Formen entscheidend zu hemmen.
Somit  bestand  das  vierte  Ziel  dieser  Arbeit  darin,  krankheitsmodifizierende 
Therapiestrategien genauer zu untersuchen: Die basale - und -Sekretase-Aktivität 
wurde  bestimmt  um im  Anschluß die  Effekte  der Sekretase-Inhibition  in  Zellkultur 
näher  zu  untersuchen.  Es  gelang,  konzentrationsabhängige  Effekte  auf  die  A-
Spiegel nach  - und  -Sekretase- Behandlung  darzustellen.  Zusätzlich  wurde  der 
Einfluss von Sekretase-Inhibitoren auf die mitochondriale Aktivität von APPwt- und 
APPsw-transfizierten PC12- und HEK-Zellen untersucht.
Neurotrophe Faktoren als therapeutische Agentien zielen darauf ab, die neuronale 
Funktion bei neurodegenerativen Erkrankungen aufrecht zu erhalten. Zuvor wurde 
berichtet, dass  substituierte  Pyrimidine  leichte  wachstumsfördernde  Eigenschaften 
besitzen. 
KP544,  ein  substituiertes  Pyrimidin,  soll  die  wachstumsfördernde  Eigenschaft  von 
NGF verstärken. Hier wurde die Rolle von substituierten Pyrimidinen als potentielle 
neuromodulatorische Wirkstoffe in der Alzheimer Demenz untersucht. 
Die  Effekte  von  KP544  auf  Protein-Expression,  APP-Prozessierung  und 
mitochondriale Aktivität von PC12-Zellen wurden mit besonderem Augenmerk auf die 
APPsw-Mutation in PC12-Zellen charakterisiert.Materials and Methods
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals
dB-cyclic AMP Sigma, Munich, Germany
Bovine Serum Albumin (BSA) Sigma, Munich, Germany
Complete mini Sigma, Munich, Germany
DAPT Calbiochem, Schwalbach, Germany
Digitonin Sigma, Munich, Germany
Dithiotreitol (DTT) Sigma, Munich, Germany
Dulbecco´s modified eagle medium (DMEM) Life Technologies, Karlsruhe, Germany
Dulbecco´s Phosphate buffered saline (PBS) Life Technologies, Karlsruhe, Germany
ECL chemiluminescence reagent Amersham, Freiburg, Germany
EDTA Sigma, Munich, Germany
Fetal Calf Serum, mycoplasma-screened 
(FCS)
Life Technologies, Karlsruhe, Germany
Geneticine sulfate (G418) Life Technologies, Karlsruhe, Germany
Glycine Sigma, Munich, Germany
Horse Serum, mycoplasma-screened (HS) Life Technologies, Karlsruhe, Germany
Hybond P PVDF membrane Amersham, Freiburg, Germany
Hydrochloric acid Sigma, Munich, Germany
Hydrogen peroxide (H2O2) 30% Sigma, Munich, Germany
Hygromycine B Sigma, Munich, Germany
L-685458 Calbiochem, Schwalbach, Germany
Methanol (MeOH) Merck, Darmstadt, Germany
N,N-Dimethyformamide Sigma, Munich, Germany
Nerve growth factor, 7S (NGF) Calbiochem, Schwalbach, Germany
Nonidet P-40 Sigma, Munich, Germany
NuPAGE 4-20% Gradient gels Invitrogen, Karlsruhe, Germany
NuPAGE SDS Sample Buffer (4X) Invitrogen, Karlsruhe, GermanyMaterials and Methods
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NuPAGE MES SDS Running Buffer (20X) Invitrogen, Karlsruhe, Germany
NuPAGE Reducing Agent (10X) Invitrogen, Karlsruhe, Germany
NuPAGE Transfer Buffer (20X) Invitrogen, Karlsruhe, Germany
Optimem Life Technologies, Karlsruhe, Germany
Penicillin /Streptomycine- solution (PenStrep)Life Technologies, Karlsruhe, Germany
Phenoylmethylsulfonylfluoride (PMSF) Sigma, Munich, Germany
Poly-L-lysine hydrobromide Sigma, Munich, Germany
Ponceau Red Sigma, Munich, Germany
Sodium chloride (NaCl) Sigma, Munich, Germany
Sodium dodeyl sulfate (SDS) Sigma, Munich, Germany
-Secretase Inhibitor II Calbiochem, Schwalbach, Germany
Tris(hydroxymethyl)-aminomethane (Tris) Sigma, Munich, Germany
Triton X 100 Sigma, Munich, Germany
Trypsin Life Technologies, Karlsruhe, Germany
Tween 20 Sigma, Munich, Germany
Ultraglutamine Life Technologies, Karlsruhe, Germany
Western Breeze Blocker Diluent A Invitrogen, Karlsruhe, Germany
Western Breeze Blocker Diluent B Invitrogen, Karlsruhe, Germany
2.1.2 Kits
A1-40 ELISA Biosource, Solingen, Germany
A1-42 ELISA Biosource, Solingen, Germany
-secretase activity assay Calbiochem, Schwalbach, Germany
Cell Proliferation Kit I (MTT Assay)
Roche Diagnostics, Mannheim, 
Germany
Clontech cell fractionation kit BD Biosciences, Heidelberg, Germany
Cytotoxicity Detection Kit (LDH Assay)
Roche Diagnostics, Mannheim, 
Germany
DC Protein Assay BioRad, Munich, Germany
-secretase activity assay RnD, Wiesbaden, Germany
Quantikine M Cytochrome c ELISA RnD, Wiesbaden, GermanyMaterials and Methods
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2.1.3 Antibodies
2.1.3.1 Primary antibodies
Goat anti-Actin  Santa Cruz, Heidelberg, Germany
Mouse anti-APP/ A/CTF (W-02) Abeta, Heidelberg, Germany
Mouse anti-Bcl-2 BD Pharmingen, Heidelberg, Germany
Mouse anti-Calreticulin Chemicon, Wiesbaden, Germany
Mouse anti-COX-4 (Cell Fractionation Kit) BD Biosciences, Heidelberg, Germany
Mouse anti-Nitrotyrosine Chemicon, Wiesbaden, Germany
Rabbit anti-AIF  Chemicon, Wiesbaden, Germany
Rabbit anti-Bax CellSignaling, Frankfurt, Germany
Rabbit anti-Bcl-xL CellSignaling, Frankfurt, Germany
Rabbit anti-Cytochrome c 
(Cell Fractionation Kit)
BD Biosciences, Heidelberg, Germany
Rabbit anti-ERAB Chemicon, Wiesbaden, Germany
Rabbit anti-GSK-3 CellSignaling, Frankfurt, Germany
Rabbit anti-MEK 1 Abcam, Cambridge, UK
Rabbit anti-Na-K-ATPase
BD Transduction Labs, Heidelberg, 
Germany
Rabbit anti-phospho-GSK-3 CellSignaling, Frankfurt, Germany
Rabbit anti-Smac/DIABLO Chemicon, Wiesbaden, GermanyMaterials and Methods
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Antibodies were diluted in a total volume of 14 ml TBST containing 0.5% BSA and 
100  µl  sodium  azide (100x).  Appropriate  dilutions  ranged  from  1:100  to  1:10000, 
depending on the antibody. Optimal conditions were determined by dilution series 
according to manufacturer’s instructions. These dilutions were stored at 4-8°C and 
were used several times, 5-10 times on the average. Before the application of W-02 
on  PVDF  membranes,  the  membrane  was  boiled  for  5  min  in  ddH2O  to  achieve 
optimal results.
Figure 2.1: Schematic protein bands for the antibodies in use.
On the left side, typical bands for the Marker MagicMark
 (M, Invitrogen, Germany) are shown. The marker is 
horseradish peroxidase-coupled. Via the chemiluminescent reaction with ECL, the bands of the marker appear on 
the  film.  The  following  lanes  1-12  represent  schematic  protein  bands  for  the  antibodies  used  in  this  work. 
Schematic bands for APP, sAPP, CTF and A are shown in Fig. 2.8.
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2.1.3.2 Secondary antibodies
Anti-goat IgG secondary antibody Calbiochem, Schwalbach, Germany
Anti-mouse IgG secondary antibody Calbiochem, Schwalbach, Germany
Anti-rabbit IgG secondary antibody Calbiochem, Schwalbach, Germany
Generally, secondary antibodies were freshly diluted 1: 1000 with TBST prior to use.
2.1.4 Buffers and Solutions
Glycine stripping solution:
Glycine 8.0 g
ddH2O 1.0 l
HCl conc. 2.5 ml
MTT solubilization reagent (20% SDS/ 50% DMFA):
N,N-Dimethyformamide 90 ml
Solubilization Solution (kit) 90 ml
SDS 27 g
LDH reaction buffer:
1. Reconstitution of the catalyst (Diaphorase/NAD
+) with 1ml ddH2O
1 aliquot
2. Catalyst + dye (Iodo-tetrazolium chloride/ sodium lactate; kit)
45 aliquots
The reaction buffer was prepared freshly prior to usage.
PBS buffer:
Dulbecco´s phosphate buffered saline (10X) was diluted with ddH2O and stored at 
4°C until usage.Materials and Methods
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STEN lysis buffer:
Nonidet P-40 1%
Tris pH 7.6 50 mM
NaCl 150 mM
EDTA 2 mM
TBST (10X):
Tris 24.2 g
NaCl 80 g
HCl conc. 13 ml
Tween 20 5 ml
The solution was adjusted to pH 7.8. 100 ml were diluted with 900 ml ddH2O.
Tris Buffer 5 mM:
1.21 g/ml Tris was dissolved in 2 l ddH2O and pH was adjusted to 7.4.
Digitonin lysis buffer:
NaCl 75 mM
NaH
2PO
4 1 mM
Sucrose 250 mM
PMSF 1 mM
Digitonin 0.05 %
Formic acid lysis buffer:
Concentrated formic acid was diluted to 40% with ddH2O.
Mitochondria lysis buffer:
Triton X was diluted to 0.1% with ddH2O.Materials and Methods
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-secretase inhibitor stock solution:
-secretase inhibitors (DAPT, L-685458) were dissolved in DMSO resulting in a 1 mM 
stock solution. The stock solution was aliquoted and kept at -20°C until usage.
-secretase inhibitor stock solution:
-secretase inhibitor II was dissolved in DMSO resulting in a 1 mM stock solution. 
The stock solution was aliquoted and kept at -20°C until usage.
Caspase and JNK inhibitors:
The inhibitor were dissolved in DMSO resulting in 1 mM stock solutions. The stock 
solutions were aliquoted and kept at -20°C until usage.
Reconstitution of monomeric, dimeric and oligomeric/fibrillar A isoforms:
A stock solutions were adjusted to a final concentration of 0.5 mM with 25% NH3
(pH 9.8). Complete dissolution of A was achieved by sonification for 15 min and 
aliquoted to be stored unti usage. A stocks were diluted with 5 mM Tris (pH 7.4) to 
2.5 µM and kept in a waterbath (37°C) for 24h to aggregate before assay start.
NGF stock solution:
NGF was dissolved in PBS containing 2% serum (0.5% HS, 1.5% FCS) at a final 
concentration of 50 ng/ml. The stock solution was aliquoted and kept at -20°C until 
further usage.
Freezing medium:
FCS 40%
Medium (without supplements) 50%
DMSO 10%Materials and Methods
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NuPage Running buffer (Gradient gels):
MES SDS Running Buffer (20X) 50 ml
ddH2O 950 ml
NuPage Transfer buffer (Gradient gels):
Transfer buffer (20X) 50 ml
Methanol 100 ml
Antioxidant 1 ml
ddH2O 849 ml
Schaegger Running Buffer (Kathode, 5x):
Tris 0.5 M
Tricine 0.5 M
SDS 0.5%
Schaegger Running Buffer (Anode, 10x):
Tris (pH 6.8) 2 M
Schaegger Buffer for the preparation of Tricine gels:
Tris (pH 8.5) 3 M
SDS 0.3%
Sample Buffer (Reducing conditions):
Tris/Hcl (pH 6.8) 1.2 g
Gycerol 24 ml
SDS 8.0 g
DTT 3.1 g
Trypan blue 200 mlMaterials and Methods
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Tris-Acrylamide gels (18%):
Acrylamide (40%) 8.75 ml
Bis-acrylamide 4.82 ml
Tris (pH 8.8) 5.00 ml
SDS (10%) 0.20 ml
ddH2O 1.13 ml
TEMED 0.01 ml
Schaegger Tricine Gels (15%):
Acryl-/ Bisacrylamide solution (29:1) 7.50 ml
Schaegger Buffer (pH 8.5) 5.00 ml
ddH2O 0.75 ml
Gycerol (87%) 1.75 ml
APS (10%) 0.10 ml
TEMED 0.01 mlMaterials and Methods
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2.1.5 Apparatus
Arpege 70 tank for liquid nitrogen Air liquide, Paris, France
Asys Hightech Digiscan plate reader Asys, Eugendorf, Germany
Biorad PowerPac 300 BioRad, Munich, Germany
BioRad Sub Cell Model 96 BioRad, Munich, Germany
Centrifuge GS-6R Beckman, Munich, Germany
Combitips plus 0.1, 0.5, 1, 2.5, 5 ml
VWR International, Darmstadt, 
Germany
Coverslides for Neubauer chamber
VWR International, Darmstadt, 
Germany
Cryo S Greiner, Frickenhausen, Germany
Falcon 2050 Polystyrene tubes
Becton-Dickinson, Heidelberg, 
Germany
Freezer (-20°C)
Liebherr GmbH, Ochsenhausen, 
Germany
Freezer (-80°C)
Heraeus Instruments, Hanau, 
Germany
Hamilton syringe, 25+50 µl Hamilton, Bonaduz, Switzerland
IKA HS 250 basic Shaker IKA Labortechnik, Staufen, Germany
Incubator Heraeus Type BB 6220
Heraeus Instruments, Hanau, 
Germany
Laminar flow hood
Heraeus Instruments, Hanau, 
Germany
Microfuge R centrifuge Beckman, Munich, Germany
Microscope Modell TMS type 104 Nikon, Japan
Microtiter plates, 6, 96 wells flat bottom, 
sterile
Greiner, Frickenhausen, Germany
Milli Q Plus PF Millipore system  Millipore, Eschborn, Germany
Multical pH 526 pH meter  WTW, Weilheim, Germany
Multipette plus
Eppendorf, Wesseling-Berzdorf, 
GermanyMaterials and Methods
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Neubauer chamber superior
VWR International, Darmstadt, 
Germany
Pipette tips 10- 1000 µl and 5 ml Greiner, Frickenhausen, Germany
Pipettes 5, 10, 25 ml sterile Greiner, Frickenhausen, Germany
Pipettus akku Hirschmann, VWR, Germany
Polypropylene tubes 15, 50 ml Greiner, Frickenhausen, Germany
Promax 1020 Shaker Heidolph, Kelkheim, Germany
Transferpette 1, 10, 100, 5000 µl
Eppendorf, Wesseling-Berzdorf, 
Germany
Unitek HB-130 Heating Block CLF, Emershacker, Germany
Variomag mono Magnetic agitator
H+P Labortechnik, VWR, Darmstadt, 
Germany
Vortex model REAX 2000 Heidolph, Kelkheim, Germany
Wallac 1420 Victor2 plate reader
Perkin Elmer, Rodgau-Jürgesheim, 
Germany
X-Cell gel electrophoresis system Invitrogen, Karlsruhe, Germany
Ziegra ice machine Bader, Frankfurt, Germany
2.1.6 Computer software
Graph Pad Prism 3.0, GraphPad Software 
Microsoft Excel software 2000
Umax Vistascan software
ScionImage Software
Kodak ds1D software v. 2.03
Wallac 1420 Workstation version 2.09Materials and Methods
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2.2 Methods
2.2.1 Cell culture and transfection
2.2.1.1 Thawing cells
All cell clones were kept in liquid nitrogen until usage. Before thawing cells, medium 
was brought to room temperature. Then, a total volume of 10 ml was given into a 
falcon tube and a culture dish. After gently thawing cells in the water bath, they were 
added  to  the  falcon  tube  and  centrifuged  at  1000  x  g  for  5  min  to  remove  toxic 
DMSO. Medium was removed, the pellet consisting of cells was resuspended in 1 ml 
fresh  medium.  The  suspension  was  pipetted  into  the  culture  dish  medium  while 
gently shaking. Culture dishes were stored in the incubator for 24h. Then, depending 
on confluency of the cells, the first splitting step was undertaken or the medium was 
changed. First experiments were performed at passage 3, since at that time, growth 
rate of the clones was synchronized. In this way, false results due to differing growth 
rates  were  avoided.  Depending  on  incubation  periods,  growth  rates  were 
independently determined by counting the cells before assay start.
2.2.1.2 Freezing cells
Before  starting  the  freezing  procedure,  all  media  in  use  were  brought  to  4-8°C. 
Freezing  tubes  were  kept  on ice.  Then,  cells  were  collected  with  cool  and  fresh 
culture medium and centrifuged at 1000 x g for 5 min. In the next step, they were 
resuspended in 1 mL of freezing medium and transferred to the tubes. After overnight 
storage at -80°C in a freezing box containing isopropanol, cells were moved to the 
liquid nitrogen.Materials and Methods
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2.2.1.3 PC12 cells
PC12  cells were  transfected  with  DNA  constructs  harbouring  human  mutant  APP 
(APPsw, K670M/N671L) gene, wild-type APP (APPwt) gene, inserted downstream of 
a CMV promotor, using FUGENE technique 
(Roche  Diagnostics).  The  transfected  cells 
APPwt  PC12,  APPsw  PC12  and  control 
PC12 were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 
10%  heat-inactivated  fetal  calf  serum  and 
5%  heat-inactivated  horse  serum,  50 
units/ml  penicillin,  50  µg/ml  streptomycin, 
and 400 µg/ml G418 at 37°C in a humidified 
incubator containing 5% CO2.
Figure 2.2: APP-pCMV695 vector 
(taken from Marques C., 2004)
2.2.1.4 HEK cells
HEK cells were equally transfected with DNA constructs harbouring human mutant 
APP  (APPsw,  K670M/N671L)  gene,  wild-type  APP  (APPwt)  gene,  inserted 
downstream of a CMV promotor, using FUGENE technique (Roche Diagnostics). The 
transfected  cells  APPwt  HEK,  APPsw  HEK  and  control  HEK  were  cultured  in 
Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented  with  10%  heat-
inactivated fetal calf serum and 50 units/ml penicillin, 50 µg/ml streptomycin, and 400 
µg/ml G418 at 37°C in a humidified incubator containing 5% CO2. Materials and Methods
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2.2.1.5 SH-SY5Y cells
APP mutations were introduced by polymerase chain reaction amplification using the 
megaprimer  method.  Two  outside primers  spanned the  BglII (forward,  TCG GCC 
TCG TCA CGT GTT C) and XmnI sites (reverse, CAA CTG GCT AAG GGG CTA 
TGT G) in APP while the reverse mutagenic primers introduced mutations at position 
623  of  APP695  (  K623C,  CCA  ATG  ATT  GCA  CCA  CAA  TTC  GAA  CCC).  For 
cloning of the mutated DNA fragment the restriction enzymes XhoI and ClaI were 
used.  The  resulting  cDNAs  were  cloned  into  the  mammalian  expression  vector 
pCEP4 at SmaI and SalI sites. Stably expressing cell lines have been obtained by 
transfecting the human neuroblastoma SH-SY5Y with the plasmid K623C containing 
the entire coding region of APP. Human neuroblastoma SY5Y cells were grown at 
37°C in RPMI medium, supplemented with 10% fetal calf serum, 2 mM L-glutamine, 
minimal  essential  medium 
nonessential  amino  acid  mix, 
50 units/ml pencillin, 50 µg/ml 
streptomycin.  For  stable 
expression,  SY5Y  cells  were 
transfected  with  receptor 
cDNAs  individually  or  in 
combination,  selected  with 
hygromycin.
Figure 2.3: pCEP4 vector 
(taken from Invitrogen, Karlsruhe, Germany)
2.2.1.6 Cell Differentiation
For the determination of MTT reduction potential, PC12 cells were plated on Poly-L-
lysine (Sigma, Germany) coated 96 well plates at a density of 10.000 cells per well in 
DMEM supplemented with 5% fetal calf serum, 10% heat-inactivated horse serum 
and  50  µg/ml  penicillin/streptomycin.  Stably  transfected  clones  expressing  human 
mutant APP (APPsw) were additionally maintained with G418 (Gibco, Germany) at a Materials and Methods
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concentration of 400 µg/ml. Differentiation of PC12 cells was induced within 12h after 
addition of DMEM. Depending on the assay design, PC12 cells were treated with 
varying  concentrations  of  nerve  growth  factor  (NGF,  Sigma)  and  2´-O-
dibutyryladenosine  3´:  5´-cyclicmonophosphate  (db-cyclic  AMP,  Sigma)  Under 
standard conditions, full differentiation was achieved by the treatment with NGF (50 
ng/ml)  and  db-cyclic  AMP  (500  µM)  for  5d.  This  procedure  is  according  to  the 
protocol used by most workers in this field, and in this time, PC12 cells posses the 
maximal number of neurites. 
For western blot experiments, cells were plated in culture dishes (IWAKI, Germany) 
at a density of 5 x 10
6 cells. After incubation, cells were washed with ice-cold PBS 
and centrifuged at 800 x g for 5 min at 4°C. After centrifugation, PBS was removed, 
and cells were resuspended in lysis buffer (50 mM Tris pH 7.6, 150 mM NaCl, 2 mM 
EDTA, 1% Nonidet P-40) supplemented with the protease inhibitor cocktail Complete 
mini
 (Roche Diagnostics, Germany) and incubated at 4°C for 10 min. After removal 
of  cell  debris  by 
centrifugation at 800 x 
g at 4°C for 5 min, the 
total protein content of 
the  supernatant  was 
determined  by  the 
method  of  Lowry.  For 
the  following  western 
blot  procedure,  see 
chapter 2.2.8.
Figure 2.4: Terminally differentiated PC12 cells.
PC12 cells were treated with NGF (50 ng/ml, left) or with a combination of NGF and db-cyclic AMP (50 ng/ml, 500 
µM, right) in order to achieve full differentiation. For microscopic analysis, cells were plated at a density of 50.000 
cells/ chamber slide and treated with the above-mentioned concentrations of NGF and db-cyclic AMP.Materials and Methods
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2.2.2 Determination of cell number
Cells were collected from culture dishes and centrifuged at 1000 x g for 5 min. The 
supernatant  consisting  of  medium  was  removed  and  1  ml  of  fresh  medium  was 
added to gently resuspend the cells. 10 µl of cell suspension was given into a tube 
with  90 µl Trypan  blue  solution.  After  mixing,  10 µl  were  applied  on a Neubauer 
counting chamber. The chamber consists of 9 equally large squares, with 1 mm
2 area 
each square. The depth of a square is 0.1 mm resulting in a total volume of 0.1 µl. 
Viable cells appear white, as broken or damaged cells are stained blue by Trypan 
blue  entering  intracellular  compartments.  The  cell  number  of  4  squares  were 
determined and the mean was formed indicating the total cell number in 1 ml cell 
suspension. Then, cell number was adjusted at 1 x 10
6 cells/ml by the addition of 
fresh medium. After mixing, the adequate volume of cell suspension was pipetted 
into the corresponding wells or plates.
2.2.3 Determination of protein content
The  content  of  total  protein  was  determined  following  the  method  of  Lowry.  The 
assay principle is based on the reaction of an alkaline copper-tartrate solution with 
the protein, resulting in the formation of a copper-protein complex. In the following, 
the  complex  reduces  a  reagent  consisting  of  phospho-molybdate  and  phospho-
wolfram leading to the formation of a blue-coloured adduct. The absorption at 620 nm 
can be read with an ELISA microplate reader. In all assays, a standard curve using 
BSA and the appropriate lysis buffer is generated by which the total protein content 
of each pobe  was  calculated. For  general purpose,  the  standard  dilutions  ranged 
from 0.6 mg/ml to 2 mg/ml. were freshly prepared from BSA stocks (100 mg/ml) prior 
to each determination
2.2.4 Detection of A levels
For  the  detection  of  A1-40 and  A1-42,  a  specific  sandwich  enzyme-linked 
immunosorbent assay employing monoclonal antibodies was used. The ELISA was 
performed according to the instructions given in the A ELISA Kit by Biosource. The 
assay principle is that of a standard sandwich ELISA, which utilizes a monoclonal Materials and Methods
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mouse anti-human A1-16 capture antibody and a cleavage-site-specific rabbit anti-
human  A1-40  or  A1-42.  According  to  the  manufacturer´s  instructions,  the  ELISA 
specifically  recognizes  human  A,  thus  rat  A from  PC12  control  cells  is  barely 
detected. The minimum detection level for A1-40 is at 7.8 pg/ml, that of A1-42 is at 
15.6 pg/ml. In brief, 2 to 5 x 10
6 cells were plated on culture dishes the day before 
assay start. Then, medium was changed and the treatment (secretase inhibitors) was 
started.  At  the  end  of  the  incubation,  cells  were  visually  checked  for  potential 
contamination  and  confluency.  The  culture  supernatant  was  collected  by 
centrifugation at 800 x g for 5 min. 990 µl of culture supernatant was transferred to 
adequate freezing tubes, 10 µl of a 1mM PMSF stock solution was added and probes 
were gently mixed before immediate freezing at -80°C. For the determination of A in 
cell lysates, the same treatment conditions were chosen. Here, the cell lysates were 
collected  and  washed  with  ice-cold  PBS.  Then,  the  appropriate  lysis  buffer  (Tris, 
formic acid, 400 µl, chapter 2.1.4) was added to the probes and left to incubate for 15 
min. Cell debris was removed by centrifugation at 800 x g for 5 min, and cell lysates 
were  stored  until  assay  performance.  Before  performing  the  A ELISA,  standard 
dilutions from the reconstituted A solution given in the kit were freshly prepared and 
applied on the 96 well ELISA plate. Excess standard solutions could generally be 
stored at -80°C for several weeks, but a mix  of Lot numbers of ELISA kits is not 
recommendable. After thawing the probes, they were added to the 96 well ELISA 
plate and incubated overnight at 4-8°C without shaking. The next day, after washing 
the plates three times with the appropriate wash buffer provided in the kit, the primary 
antibody  dilution  was  added  to  the  plate  and  the  incubation  was  continued  for 
another 2h. It is noteworthy that in 2004, Biosource changed the assay protocol for 
the A1-40 ELISA: Here, the primary antibody was directly added to the probes and 
the mixture was incubated overnight as mentioned above. The rest of the protocol is 
identical to that of the A1-42 ELISA currently available. Then, the plate was again 
intensively washed three times before the addition of the secondary antibody. The 
incubation  was  continued  for  further  2h  followed  by  four  washing  steps.  Colour 
development is initiated by the addition of tetramethylbenzidine (TMB) forming a blue 
chromophore during the reaction. When 1 N HCl is added, the chromophore turns 
yellow, resulting in an absorbance at 450 nm. Absorbance was measured in a ELISA 
plate  reader  shortly  after  the  addition  of  1  N  HCl.  Sample  concentrations  were Materials and Methods
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calculated from the standard curve and A contents were calculated by the formula 
given for the standard regression in the Excel graph (Fig. 2.5).
Figure 2.5: A standard curve (example).
A standard dilution curve was performed in each experiment to exactly determine A contents of the probes by 
the resulting regression formula.
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2.2.5 Isolation of cytosolic and mitochondrial fractions
Cytosolic  and  mitochondrial  fractions  were  isolated  by  digitonin  permeabilization. 
Digitonin  depletes  cholesterol  from  the  plasma  membrane,  thus  causing  pore 
formation.  Mitochondria  generally posses less  cholesterol in the  outer  membrane. 
Consequently,  mitochondria  remain  intact  during  digitonin  treatment.  After  the 
establishment of optimal lysis conditions (Fig. 2.6), 5 x 10
6 cells were washed with ice 
cold phosphate-buffered saline (PBS) and were resuspended for 15 min on ice in 
permeabilization buffer containing 75 mM NaCl, 1 mM NaH2PO4, 250 mM sucrose, 1 
mM  PMSF,  additional  protease  inhibitors  (Complete
 mini,  Roche  Diagnostics, 
Germany), and 0.05% digitonin. To confirm the results, we checked successful lysis 
by trypan blue staining. Alternatively, we used the Clontech cell fractionation kit (BD 
Biosciences, Germany). Here, cells were treated with 200 µl lysis buffer provided in 
the  kit.  Following  a  centrifugation 
step at 800 x g at 4°C for 10 min, 
the  supernatant  was  separated 
from the pellet consisting of cellular 
debris.  The  crude  mitochondrial 
pellet  was  collected  by 
centrifugation at 13.000 x g at 4°C 
for  60  min.  The  supernatant 
containing  cytoplasm  proteins  was 
stored  at  –20°C  for  further 
investigation. 
Figure 2.6: Digitonin lysis of PC12 cells.
PC12  cells  were  treated  with  0.05%  digitonin  for  various  periods  of  time.  Membrane  permeabilization  was 
assessed by trypan blue staining. Blue cells bodies indicate successful permeabilization.Materials and Methods
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The  pellet  consisting  of  mitochondria  was  resuspended  in  0.1%  Triton  X  and 
mechanically lysed. Succesful separation of mitochondrial and cytosolic fractions was 
checked by western blot for COX-4. COX-4 (cytochrome c oxidase 4) is part of the 
electron  transport  chain  located  in  the  inner  mitochondrial  membrane.  Cytosolic 
fractions should be free of any mitochodrial components, like COX-4, namely. Before 
the  performance  of  western  blot  experiments,  the  total  protein  content  was 
determined  by  the 
method  of  Lowry 
(chapter  2.2.3)  and 
equal  amounts  of 
protein were loaded on 
the gel.
Figure 2.7: COX-4 western blot of cytosolic and mitochondrial fraction.
In the western blot of the mitochondrial fraction, COX-4 migrates at 17 kDa. Cytosolic fractions of APPsw and 
control cells are free from COX-4 protein.
2.2.6 Sample preparation of cell lysates
Equal amounts of cells were collected an resuspended in 4X NuPAGE SDS Sample 
lysis  buffer  (Invitrogen,  Germany).  After  sonification  for  30  min,  the  probes  were 
boiled at 95°C for 10 min, centrifuged at 10.000 x g for 5 min and then assayed by 
western blot. Alternatively, cells were lysed in STEN lysis buffer (chapter 2.1.4) for 15 
min on ice and crashed by exposure to liquid nitrogen followed by determination of 
protein content. The advantage of STEN lysis is the reduced viscosity of the lysate, 
which  faciliates gel  loading.  Furthermore,  protein levels  could  be detected  by  the 
method of Lowry (chapter 2.2.3) to assure correct and equal protein loading.
2.2.7 Sample preparation of medium probes
As mentioned above (chapter 2.2.4), for A ELISA and western blot experiments, 2-
5 x 10
6 cells ( 2 or 5 ml total volume of cell suspension) were seeded into culture 
dishes and left to settle overnight. The next day, depending on the assay design, 
treatment  was started.  After  incubation,  1  ml  of  the  medium  was  collected  and 
Mitochondrial fraction
Co
Cytosolic fraction
Co     APPsw
17 kDa COX4Materials and Methods
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centrifuged at 1000 x g for 5 min to remove cells and debris. Then, the protease 
inhibitor PMSF was added at a concentration of 1 µM to the medium of treated cells. 
Probes were frozen at –80°C until further usage. For western blot, samples were 
diluted  with  4X  NuPAGE  SDS  Sample  buffer,  boiled  at  95°C  for  10  min  and 
centrifuged at 10.0000 x g for 5 min.
2.2.8 Western Blot
2.2.8.1 Self-made tricine and glycine western blots
After  determination  of  the  total protein  content  by  the  method  of  Lowry  (chapter 
2.2.3), depending on the western blot to be performed, cell extracts, medium probes, 
cytosolic and mitochondrial fractions were loaded on acrylamide gels and examined 
by SDS-PAGE. Since the usage of gradient gels was first reduced to the application 
of the antibody W-02 detecting APP and A, we produced self-made glycine and 
tricine  western  blots  depending  on  the  protein  to  be  detected.  Generally,  we 
performed glycine or tricine western blot with acrylamid amounts ranging form 10 to 
18% at 90 V for 2-3h. For proteins with a molecular weight less than 30 kDa, tricine 
western blots (chapter 2.1.4) were more appropriate. The gels were prepared a day 
before SDS Page performance. High molecular weight proteins were separated on 
glycine western blots with acrylamide amounts ranging from 8-12%. Because of the 
intesnive  stripping  procedure,  proteins  were  then transferred  on Hybond  P  PVDF 
membranes  (Amersham  Biosciences,  Germany)  at  25  V  for  90  min,  being  more 
resistant to the treatment than nitrocellulose membranes. Membranes were saturated 
with 5% nonfat dry milk in TBST for one hour before antibody exposure. Then, the 
PVDF membranes were exposed to the corresponding antibodies overnight. 
2.2.8.2 Gradient gels
To detect APP and A on the same western blot, we used NuPAGE 4-12% gradient 
gels  (Invitrogen,  Germany).  The  proteins  were  transferred  on  Hybond  P  PVDF 
membranes  as  described  above  and  blocked  for  one  hour  with  Western  Breeze 
blocking solution, a comparable alternative to 5% nonfat dry milk. PVDF membranes 
were  incubated  with  mouse  anti-human  APP  W-02  (Abeta,  Germany).  The W0-2 Materials and Methods
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antibody is directed against amino acids 4-10 of the human A sequence, therefore 
detecting the mature and immature APP, sAPP, C83, C99 and A (Fig. 2.8). After 
treatment for 1h with the corresponding, horseradish peroxidase-coupled secondary 
antibodies  (Calbiochem,  Germany),  the  protein  bands  were  detected  by  ECL 
chemiluminescence reagent (Amersham, Germany). After detection, the membranes 
were  treated  with  stripping  buffer  for  2h  before  reprobing  with  distinct  antibodies 
(chapter 2.1.4).
Figure 2.8: Scheme of a gradient gel.
On the  left  side,  typical  bands  for  the  Marker  MagicMark
 (Invitrogen,  Germany)  are  shown.  The  marker is 
horseradish peroxidase-coupled. Via the chemiluminecent reaction with ECL, the bands of the marker appear on 
the film. On the right side, bands of A (4 kDa), CTF (C83, C99, approx. 6 kDa), sAPP (glycosylated forms, 96 
kDa) and full-length APP (glycosylated forms, 116 kDa). It is not possible to definitely differentiate between CTFs 
and A, since the protein bands are too close to each other on the gradient gel.
2.2.9 Quantikine M Cytochrome c ELISA
For  the  sample  preparation,  5  x  10
6 cells  were  plated  on  culture  dishes  the  day 
before  assay start.  The  next  day,  H2O2 (500  µM)  was  added  to  the  cells  to  start 
incubation. At the end of the incubation, cells were collected by centrifugation at 800 
x  g  for  5  min.  The  resulting  pellet  was  washed  with  ice-cold  PBS  and  again 
centrifuged at 800 x g for 5 min to remove the PBS wash buffer. In the following, cells 
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were  lysed  with  the  lysis  buffer  provided  in  the  kit  for  15  min  while  gently 
resuspending the pellet. Cell debris was removed by centrifugation at 800 x g for 5 
min and the samples were stored at –80°C for further investigation. The ELISA was 
performed according to the instructions given in the Cytochrome c ELISA kit by RnD 
Systems,  Germany.  The  assay  employs  the  quantitative  sandwich  enzyme 
immunoassay technique and was designed to replace cytochrome c western blot. A 
monoclonal  antibody  specific  for  cytochrome  c  has  been  pre-coated  onto  a 
microplate.  Samples  are pipetted  into  the wells  and  any  cytochrome  c  present is 
bound  by  the  immobilized  antibody  (Fig.  2.9).  After  washing  away  any  unbound 
substances,  an  enzyme-linked  monoclonal  antibody  specific  for  cytochrome  c  is 
added to the wells.  Following  four  wash  steps  to remove  any  unbound antibody-
enzyme reagent, a substrate solution (TMB) is added to the wells and colour (blue) 
develops in proportion to the amount of cytochrome c bound in the initial step. The 
colour  development  is  stopped  by  the  addition  of  1  N  HCl  and  the  intensity  is 
measured by a ELISA microplate reader.
Figure 2.9: Assay procedure Quantikine M Cytochrome c ELISA.
Add 100 µL probes/well
Incubate 2 hrs at RT
Aspirate and wash 4 times
Add 200 µL conjugate/well
Incubate 2 hrs at RT
Aspirate and wash 4 times
Add 200 µL substrate solution/well
Protect from light. Incubate 30 min
Add 50 µL stop solution/well
Read at 450 nm within 30 min
Correction wavelength 540 nmMaterials and Methods
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2.2.10 MTT-Assay
The assay is based on the cleavage of the yellow tetrazolium salt MTT to purple 
formazan crystals by metabolic active cells (Vistica, D. T., Skehan, P. et al., 1991; 
SLATER,  T.  F.,  1963).  This  cellular  reduction  involves  the  pyridine  nucleotide 
cofactors  NADH  and  NADPH  (Fig.  2.10).  The  formazan  crystals  formed  are 
solubilized and the resulting coloured solution is quantified using a scanning multiwell 
spectrophotometer (ELISA reader). 
Figure 2.10: Metabolization of MTT to a formazan salt.
5-10 x 10
5 (PC12, HEK, SY5Y) cells were seeded per well the day before treatment 
(Fig. 2.11). Two hours before the end of incubation, MTT reagent was added at a 
final concentration of 1.0 mg/ml. Incubation was continued for another 2h, and the 
formazan crystals were then solubilized by 100 µl of a 20% SDS/50% N,N-dimethyl-
formamide  solution.  After  complete  12h  of  solubilization,  the  absorption  was 
measured  at  550  nm  with  a  correction  wavelength  of  620  nm  using  an ELISA 
microplate reader.Materials and Methods
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Figure 2.11: MTT assay of SY5Y cells.
In order to establish the optimal conditions of the MTT assay for SY5Y cells, increasing cell numbers of SY5Y 
cells were plated on 96 well plates the day before assay start. Then, the assay was started by the addition of the 
MTT reagent. After solubilization, the absorption was measured at 450 nm with a correction wavelength at 620 
nm. Considering the total absorption values, 50.000- 100.000 cells/well were considered as optimal. One-way 
ANOVA p<0.0001; posthoc t test: ** p<0.01, ***p<0.001 vs 10.000 cells.
2.2.11 LDH assay
The  assay  principle  relies  on  the  fact  that  lactate  dehydrogenase  can  pass  the 
plasma membrane of damaged (necrotic or apoptotic) cells. Outside the cell, lactate 
dehydrogenase catalyses the oxidation of lactate to pyruvate and the reduction of 
NAD
+ to NADH+H
+ in the same time. NADH+H
+ reduces a yellowish tetrazolium salt 
resulting in a deep red formazan salt (Fig. 2.12). Consequently, the absoption of the 
formazan  correlates  with  lactate  dehydrogenase  activity.  Cells  were  plated  at  a 
density  of  1  x  10
5,  according  to  manufacturer´s  instructions  (Roche  Diagnostics, 
Germany) and the assay was started. After incubation, cells were centrifuged at 1000 
x  g, the supernatant was pipetted in a fresh 96 well plate, and LDH reagent was 
added. After half an hour, stop solution (1 N HCl) was added and absorption was 
measured  at  420  nm  with  a  correction  wavelength  of  620  nm  using  an  ELISA 
microplate reader.
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Figure 2.12: Test principle LDH assay.
2.2.12 Determination of ATP levels 
SY5Y cells were plated the day before at a density of 2 x 10
4 cells/well in a white 96 
well  plate.  SY5Y  cells  were  incubated  with  varying  concentrations  of  H2O2 for 
different periods of time. The kit is based upon the bioluminescent measurement of 
ATP. The bioluminescent method utilises an enzyme, luciferase, which catalyses the 
formation of light from ATP and luciferin. The emitted light is linearly related to the 
ATP  concentration  and  is  measured  using  a  luminometer.  The  bioluminescent 
method utilises an enzyme, luciferase, which catalyses the formation of light from 
ATP and luciferin according to the following reaction: 
Figure 2.13: Test priciple ATP assay.Materials and Methods
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2.2.13 -secretase activity assay
The  assay  detects  the  enzymatic  activity  of  the  -secretase  class  of  proteases 
associated with the cleavage of amyloid precursor protein (APP) from cell lysates 
using  a  fluorometric  reaction.  First,  cells  of  interest  are  lysed  to  collect  their 
intracellular  contents.  Principally,  protein  content  is  determined  by  the  method  of 
Lowry  (chapter  2.2.3)  allowing  to  always  apply  the  same  amount  of  protein. 
Generally, the applied volume of lysis buffer should be kept as low as possible to 
achieve  maximum  protein  contents.  The  cell  lysate  is  then  tested  for  secretase 
activity  by  the  addition  of  a  secretase-specific  peptide  conjugated to  the reporter 
molecules EDANS and DABCYL (Fig. 2.14).
Figure 2.14: Assay protocol for the -secretase activity assay.
In the uncleaved form, the fluorescent emissions from EDANS are quenched by the 
physical proximity of the DABCYL moiety which exhibits maximal absorption at the 
same  wavelength (495 nm) (Fig. 2.15). Cleavage of the peptide by the secretase 
physically  separates  EDANS  and  DABCYL  allowing  the  release  of  a  fluorescent 
signal. The substrate sequence provided with the kit corresponds to the amino acid 
sequence associated with -secretase cleavage of amyloid precursor protein (amino 
Victor
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acids 710-718) and includes the London mutation. The level of secretase enzymatic 
activity  in  the  cell  lysate  is  proportional  to  the  fluorometric  reaction.  Background 
controls are performed by reactions without addition of the substrate. Then, these 
values are  subtracted  from  the experimental results  prior  to calculating  the x-fold 
increase. 
Figure 2.15: Test principle of the -secretase activity assay.
In the uncleaved form, the fluorescent emissions from EDANS are quenched by the physical proximity of the 
DABCYL moiety which exhibits maximal absorption at the same wavelength (495 nm). Cleavage of the peptide by 
the secretase physically separates the EDANS and DABCYL allowing for the release of a fluorescent signal.
2.2.14 -secretase activity assay
First,  cells  of  interest  are  lysed  to  collect  their  intracellular  contents.  Principally, 
protein content is determined  by  the method  of Lowry  (chapter  2.2.3)  allowing  to 
always  apply  the  same  amounts  of  protein.  The  assay  principle  is  that  of  the  -
secretase activity assay. Generally, the applied volume of lysis buffer should be kept 
as  low  as  possible  to achieve  maximum  protein contents.  The cell lysate is then 
tested  for  secretase  activity  by  the  addition  of  a  secretase-specific  peptide 
conjugated to the reporter molecules EDANS and DABCYL. In the uncleaved form,
the fluorescent emissions from EDANS are quenched by the physical proximity of the 
DABCYL  moiety  which  exhibits  maximal  absorption at  the same  wavelength (495 
nm). Cleavage of the peptide by the secretase physically separates the EDANS and 
DABCYL allowing for the release of a fluorescent signal. A reconstituted -secretase Materials and Methods
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was provided within the kit as a positive control to assure the proper working of the 
test (Fig. 2.16).
Figure 2.16: Enzyme activity of reconstituted -secretase.
First, activity of reconstituted -secretase without substrate was determined. After the addition of substrate, -
secretase activity increases to the twofold. Addition of -secretase inhibitor completely blocks enzyme activity. 
One-way ANOVA p<0.001; posthoc t test: *** p<0.001 vs. -secretase (minus substrate/inhibitor); 
+++ p<0.001 vs. 
-secretase (plus substrate/inhibitor).
2.2.15 Statistical Analysis
Data are given as mean ± SEM. For statistical comparison, Students t-test, One-way 
ANOVA followed by Tukeys posthoc test, Repeated Measures ANOVA or Two-way 
ANOVA were used. p values less than 0.05 were considered statistically significant. 
For the statistical analysis, GraphPad Prism 3.0 software was used.
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
***
+ + +
substrate - + +
inhibitor - - +
f
l
u
o
r
e
s
c
e
n
c
e
 
u
n
i
t
sResults
81
3 RESULTSResults
82
3 Results
3.1 Characterization of APP processing and A secretion
3.1.1 Secretion of A in APPwt and APPsw PC12, HEK and SY5Y cells 
In order to investigate the effect of chronic APP expression and A production on 
oxidative stress-induced apoptosis, APP expression and A secretion levels of three 
different cell lines were determined. PC12 cells, rat pheochromocytoma cells, are of 
neuronal  origin  and  represent  a  convenient  model  for  the  investigation  of  neuro-
degenerative  diseases. Stably  APP-transfected  PC12  cells  suffering  from  chronic 
exposure  to  APP  and  A,  with  secretion  levels  in  the  picomolar  range,  mimic 
physiological  conditions  since  comparable  A1-40 levels  have  been  determined  in 
post-mortem dissected brains from patients suffering from sporadic AD. We could 
show that A1-40 levels of stably transfected PC12 cells bearing the Swedish double 
mutation are elevated to the twofold compared to control cells (p<0.05 vs. control), 
whith  APPwt  PC12  cells  secreting  20  pg/ml  less  A1-40 into  the  culture  medium 
compared to APPsw PC12 cells (Fig. 3.1). Furthermore, APPwt and APPsw clones 
express  similar  levels  of  APP  (Eckert,  A.,  Steiner,  B.  et  al.,  2001).  Culture 
supernatants  of  PC12  cells  were 
assayed for secreted A1-42, but due 
to  the  extremely  low  secretion 
levels  (approx.  <  15pg/ml),  the 
obtained  values  were  below  the 
detection  limit  of  the  A1-42 ELISA 
kit. 
Figure 3.1: Secreted A1-40 levels of PC12 cells.
Culture supernatants of 5 x 10
6 PC12 cells (APPwt, APPsw, Co) were collected after 24h incubation and assayed 
for A1-40 by ELISA. One-way ANOVA: ***p<0.0001, posthoc t test: *p<0.05 vs. control (Co). Data are shown as 
means ± SEM of 3-4 independent experiments. Inlay: APP expression levels of PC12 cells.
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HEK  cells, human  embryonic kidney  cells, are of non-neuronal  origin.  They were 
stably transfected with APPwt and APPsw and represent convenient models for the 
investigation of APP processing, A formation and secretion (Forman, M. S., Cook, 
D. G. et al., 1997). HEK control cells express low amounts of endogenous human 
APP (Fig. 3.2, Inlay) that is proteolytically processed resulting in measurable levels of 
secreted  A1-40 and  A1-42 (Fig.  3.2  A+B).  In  comparison  to  APPsw  PC12  cells, 
APPsw HEK cells secrete 30-fold higher levels of A1-40 and eightfold higher levels of 
A1-42, thus reaching the micromolar range. A1-42 levels of APPsw HEK cells were 
twentyfold lower than A1-40 levels (Fig. 3.2 A+B). APPsw HEK cells secrete tenfold 
more A1-40 (p<0.01 vs. APPwt control) and sevenfold more A1-42 (p<0.05 vs. APPwt 
control) than APPwt and control HEK cells (p<0.05, p<0.001 vs. control) (Fig. 3.2 A). 
APP expression, which does not alter between APPsw and APPwt PC12 cells, differs 
between HEK clones since APPsw HEK cells express more APP than APPwt HEK 
cells (Fig. 3.2, Inlay). Due to the characteristically high APP and A levels in APPsw 
HEK  cells,  they  serve  as  a  comparative  model  for  massive,  chronic  A
overproduction in contrast to chronically low exposure levels of A in PC12 cells.
Figure 3.2: Secreted A1-40 and A1-42 levels of HEK cells.
Culture supernatants of 5 x 10
6 HEK cells (APPwt, APPsw, Co) were collected and assayed for A1-40 (A) and 
A1-42 (B)  by  ELISA.  A)  Secreted  A1-40.  B)  Secreted  Aß1-42.  One-way  ANOVA:  ***p<0.001,  posthoc  t test: 
*p<0.05, *** p<0.001 vs. control (Co), 
+p<0.05, 
++p<0.01 vs. APPwt control. Data are shown as means ± SEM of 
3-4 independent experiments. Inlay: APP expression levels of HEK cells.
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SY5Y  cells, human  neuroblastoma  cells, represent a neuronal  cell line of human 
origin. The cell model of stably expressing APPwt clones closely mimics conditions in 
brains of patients suffering from sporadic AD. APPwt SY5Y cells secrete significantly 
(p<0.001) higher levels of A1-40 compared to control cells (Co).
Secretion  levels  of endogenous  A1-40  control  (Co)  SY5Y  cells are  roughly  in the 
range of control HEK cells (Fig. 3.3). Secreted A1-40 levels of APPwt SY5Y cells 
(approx. 210 pg/ml) are comparable to the levels of APPwt HEK (approx. 280 pg/ml) 
and. When compared to PC12 cells, APPwt SY5Y cells secrete sevenfold higher A1-
40 levels than APPsw PC12 and tenfold higher A1-40 than APPwt PC12 cells. 
Figure 3.3: Secreted A1-40 levels of SY5Y cells.
Culture supernatants of 5 x 10
6 SY5Y cells (APPwt, Co) were collected and assayed for A1-40 by ELISA. One-
way ANOVA: ***p<0.001, posthoc t test: ***p<0.001 vs. control (Co). Data are shown as means ± SEM of 3 
independent experiments. Inlay: APP expression levels of SY5Y cells.
3.1.2 Intracellular A levels of cell lysates
Recently,  it  has  been  shown  that in  a  model  of rat  cortical  neurons  intracellular, 
dimeric and oligomeric A forms are the key toxic species of neuronal cell death 
(Kienlen-Campard,  P.,  Miolet,  S.  et  al.,  2002).  There  is  only  little  known  about 
intracellular  A levels  in  stably  transfected  cell  lines.  We  determined  intracellular 
soluble  and  insoluble  A levels  in  HEK  cells  in  order  to  further  characterize  the 
situation in stably transfected cells and to compare the results with those obtained 
from  primary  cultures.  In  order  to  discriminate  between  soluble  and  insoluble  A
species, we performed particular extraction methods.
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Tris buffer lysis was  performed  for the extraction  of soluble  A and insoluble  A
species were extracted by formic acid (FA) lysis. 
The experiments were performed with HEK cells, because they secrete A in large 
quantities which lead us to the speculation that intracellular A might correlate with 
extracellular A reaching detectable levels. 
HEK control cells secrete low amounts of endogenous human A detectable by the 
ELISA kit. Nevertheless, intracellular, soluble A1-40 and A1-42 levels of HEK control 
cells were at the detection limit given in the ELISA kit (<15 pg/ml) (Fig. 3.4 A+B). 
Compared  to  secreted  extracellular  A1-40,  intracellular  A1-40 levels  are 
approximately more than hundredfold lower in APPsw, twentyfivefold lower in APPwt 
and tenfold lower in control HEK cells (Co). Secreted A1-40 levels are twentyfold 
higher  than  A1-42 levels.  Intracellular  A1-42 levels  are  in  the  same  range  like 
intracellular  A1-40 levels  (Fig.  3.4  B).  Nevertheless,  we  can  conclude  that 
intracellular, soluble A1-40 and A1-42 levels are of similar quantity (Fig. 3.4 A+B), 
with a tendency to higher soluble A1-40 and A1-42 in APPsw HEK cells, although not 
significant.
Figure 3.4: Intracellular soluble A1-40 and A1-42 levels of HEK cells.
Tris lysis was performed on 10 x 10
6 HEK cells (APPwt, APPsw, Co) and lysates were then assayed for A1-40 (A) 
and A1-42 (B) by ELISA. Data are shown as means ± SEM of 3 independent experiments.
For the detection of insoluble intracellular A species, a formic acid (FA) extraction 
was performed on HEK cells (Fig. 3.5 A+B). We observed a slight, but not significant 
increase  in  insoluble  A1-40 levels  of  APPsw  and  APPwt  HEK cells  compared  to 
control HEK cells (Fig. 3.5 A). 
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Intracellular, insoluble A1-42 was not detectable in APPwt and APPsw HEK cells. The 
FA extract of APPsw HEK cells contained approximately 60 ng/ml insoluble A1-42
(Fig. 3.5 B). Concluding we may state that in APPsw HEK cells, the ratio of A1-40
and  A1-42 is  shifted  in  favour  of  intracellular,  insoluble  A1-42 and  that  the 
accumulation of insoluble A species is a specific feature of APPsw HEK cells.
Figure 3.5: Intracellular insoluble A1-40 and A1-42 levels of HEK cells.
Formic acid lysis was performed on 10 x 10
6 HEK cells and lysates were then assayed for A1-40 (A) and A1-42
(B) by ELISA. One-way ANOVA: ns., posthoc t test: ns. Data are shown as means ± SEM of 3 independent 
experiments.
3.1.3 APP and mitochondria
In the recent years, there has been intensive discussion about APP processing and 
A generation and their impact on neuronal cell death. APP, besides its ER targeting 
domain  being  responsible  for  the  correct  post-translational  transport  of  APP, 
additionally  owns  a  mitochondrial-targeting  domain.  It  has  been  demonstrated 
recently that the accumulation of full-length APP in the mitochondrial compartment in 
a  transmembrane-arrested  form  causes  mitochondrial  dysfunction  and  impaired 
energy metabolism in rat cortical neurons (Anandatheerthavarada, H. K., Biswas, G. 
et  al.,  2003).  Using  confocal  laser  scanning  microscopy,  we  could  show  that 
mitochondria and APP are partly co-located in the cell  (Keil, U., Bonert, A. et al., 
2004). Full-length APP (116 kDa) was detected in the mitochondrial fraction of PC12 
cells by western blot (Fig. 3.6). In contrast to this, the purified cytosolic fraction is free 
from  APP,  indicating  that  in  this  fraction,  possible  impurities  from  the  plasma 
membrane  are  underneath  the  detection  limit.  The  cytosolic  fraction  is  free  from 
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cytochrome  c  oxidase-4  (COX-4,  14  kDa),  a  marker  for  the  inner  mitochondrial 
membrane, demonstrating the absence of mitochondrial debris. As expected, Actin 
(45 kDa),  the  major  intracellular  protein  component,  is found in the  cytosolic  and 
mitochondrial fraction.
ER-associated amyloid-binding protein (ERAB, 27 kDa), which we supposed to be 
located in the ER (Du Yan, S., Shi, Y. G. et al., 1999), was detected in the cytosolic 
fraction. Therefore, it seems  possible that ERAB  is associated  with  the outer  ER 
membrane, being easily removed by the fractionation procedure. From the outer ER 
membrane,  ERAB  might  be  transported  to  other  subcellular  compartments  under 
conditions of oxidative stress.
Figure 3.6: APP is present in the mitochondrial fraction of PC12 cells.
Mitochondrial and cytosolic fractions of 5 x 10
6 were subjected to western blot and analysed for the following 
proteins: full-length APP (116 kDa), Actin (45 kDa), ERAB (27 kDa) and COX-4 (14 kDa). Full-length APP is 
located in the purified mitochondrial fraction. Actin is found in both, cytosolic and mitochondrial fraction. ERAB is 
mainly located in the cytosolic compartment. COX-4, a crucial marker for the mitochodrial fraction, is found there 
exclusively.
In order to assess whether the presence of APP in mitochondria is a more generally 
observed  phenomenon  in  cell  culture,  we  submitted  mitochondrial  and  cytosolic 
fractions of APPwt, APPsw and control HEK cells to western blot analysis (Fig. 3.7). 
Since HEK cells are of non-neuronal origin, they are prone to show an intracellular 
full-length APP localization distinct from PC12 cells. We may also speculate that this 
effect is probably linked to the extremely high APPsw- and APPwt-load of HEK cells. 
Mitochondrial Fraction Cytosolic  Fraction
116 kDa APP
45 kDa Actin
14 kDa COX4
27 kDa ERAB
Co wt sw
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Indeed, full-length APP (116 kDa) was not only present in the mitochondrial but also 
in the cytosolic compartment of APPwt and APPsw HEK cells. It might be that the 
APP  found  in  the  cytosolic  fraction  has  been  associated  with  the  endoplasmatic 
reticulum and was separated by the fractionation procedure. C-terminal fragments 
(CTFs, 6 kDa), namely C99 and C83, are equally detected in the cytosolic fraction. 
Figure 3.7: APP is present in the mitochondrial fraction of HEK cells.
Mitochondrial and cytosolic fractions of 5 x 10
6 HEK cells were subjected to western blot and analysed for the 
following  proteins:  full-length  APP  (116  kDa)  and  CTF  (6  kDa).  Full-length  APP  is  located  in  the  purified 
mitochondrial fraction. CTFs are exclusively found in the cytosolic compartment.
3.1.4 A and mitochondria
In order to further characterize the intracellular localization of A in our cell models, 
we determined A levels of purified cytosolic and mitochondrial fractions of PC12, 
HEK and SY5Y cells by ELISA technique (Fig. 3.8 A-C). PC12 and SY5Y cells show 
very low cytosolic and mitochondrial A1-40 within the detection limit (Fig. 3.8 A+C). 
Hence,  mitochondrial  A1-40 of  APPsw HEK  cells  (38  pg/ml,  p<0.05  vs.  control, 
p<0.05 vs. APPwt control) was found in significantly elevated amounts compared to 
APPwt (< 10 pg/ml) and control cells (<10 pg/ml) (Fig. 3.8 B). APPsw HEK cells 
contain tenfold higher mitochondrial A1-40 levels than APPwt and control HEK cells. 
Due to fact that proteins are generally concentrated in the course of the fractionation 
procedure, A1-40 detected in mitochondrial fraction of APPsw HEK cells (approx. 38 
pg/ml) is higher than in Tris lysates (15pg/ml). 
Mitochondrial Fraction Cytosolic  Fraction
Co wt sw
HEK
Co wt sw
HEK
116 kDa APP
6 kDa CTFResults
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Figure 3.8: A1-40 is located in mitochondria of HEK cells.
A) A1-40 levels in mitochondrial and cytosolic fractions of 5 x 10
6 PC12 cells. B) A1-40 levels in mitochondrial and 
cytosolic fractions of 5 x 10
6 HEK cells. C) A1-40 levels in mitochondrial and cytosolic fractions of 5 x 10
6 SY5Y 
cells. One-way ANOVA: ***p<0.001, posthoc t test: **p<0.01 vs. control (Co), 
+p<0.05 vs. APPwt. Data are shown 
as means ± SEM of 2-4 independent experiments.
We  suggest  that  mitochondrial  fractions  were  enriched  in  protein  and  free  of 
proteases potentially being able to degrade A. In contrast, whole cell lysates contain 
multiple  A-degrading  proteases,  and  most  probably,  it  is  a question  of  protease 
inhibitor concentration that should be higher than the inhibitor concentration used in 
culture  supernatant  probes.  Notably,  cellular  debris  consisting  of  DNA  fragments, 
organelles and plasma membrane could potentially quench the A signal or interact 
with the detection and capture antibody. 
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3.1.5 Secretase activity in PC12 and HEK cells
In the preceding chapters, we could demonstrate that PC12, HEK and SY5Y cells 
revealed individually distinct APP expression and A secretion levels. It was found 
that -secretase expression is significantly increased in brains of AD patients (Shen, 
Y., Yang, L. B. et al., 2002; Fukumoto, H., Cheung, B. S. et al., 2002; Holsinger, R. 
M. D., Mclean, C. A. et al., 2004; Yang, L. B., Lindholm, K. et al., 2003c; Li, R., 
Lindholm,  K.  et  al.,  2004b) and  that  -secretase  activity  increases  with  aging  in 
human, monkey and mouse brain (Fukumoto, H., Rosene, D. L. et al., 2004). These 
findings indicate that -secretase expression and activity is of considerable in vivo 
relevance.  Moreover,  numerous  evidence  is  provided  that  the  APPsw  mutation 
promotes -secretase activity in APP transgenic mice. In order to characterize APPwt
and APPsw-transfected PC12 and HEK cells as suitable models for the investigation 
of AD-related alterations we determined the activity of the enzyme. 
Since  secretases  are  ubiquitously  expressed,  we  questioned  whether  HEK  cells 
show - and -secretase activity comparable to those of neuronal cells. The studies 
intended to characterize – and -secretase activity in the cell culture models of AD 
with special regard to the impact of the enzymes on A production. 
3.1.5.1 -secretase activity
The APPsw  mutation is  associated with increased -secretase-mediated cleavage 
leading to an early onset of Alzheimer’s Disease (Haass, C., Lemere, C. A. et al., 
1995b).  The  subsequent  -secretase  cleavage  results  an  enhanced  generation  of 
A1-40 and A1-42. We determined basal -secretase activity of PC12 and HEK cells 
(Fig. 3.9 A+B). In APPsw PC12 cells, baseline -secretase activity is increased to the 
twofold compared to APPwt (p<0.05 vs. APPwt) and control cells (p<0.05 vs. control) 
(Fig. 3.9 A). The same effect, even though less pronounced, was observed in APPsw 
HEK cells showing a significantly (p<0.05 vs. control) enhanced -secretase activity 
compared  to  control  HEK  cells  (see  Fig.  3.9  B).  The  demonstrated  data  are 
consistent  with  previously  reported  findings  of  other  groups,  since  -secretase  of 
APPsw transfected cells is significantly increased. Results
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Figure 3.9: Increased -secretase activity in APPsw PC12 and HEK cells.
Cell lysates of 5 x 10
6 cells were collected and assayed for -secretase activity. A) -secretase activity in PC12 
cells. B) -secretase activity in HEK cells. One-way ANOVA: ***p<0.001, posthoc t test: *p<0.05 vs. control (Co), 
+p<0.05 vs. APPwt. Data are shown as means ± SEM of 4 independent experiments. Dotted line represents 100% 
control.
3.1.5.2 -secretase activity
In contrast to the increasing evidence for the implication of enhanced -secretase 
activity in AD, little is known about AD-dependent alterations in -secretase activity. 
This might be due to the structure of -secretase representing a multimeric enzyme 
complex. It was reported that the isolation and reconstitution from human brain tissue 
homogenates was related to numerous methodical difficulties (Fraering, P. C., Ye, W. 
J. et al., 2004; Farmery, M. R., Tjernberg, L. O. et al., 2003; Edbauer, D., Winkler, E. 
et al., 2003). So far, six different -secretase complexes have been identified in the 
cell  (Shirotani,  K.,  Edbauer,  D.  et  al.,  2004),  and  evidence  is  provided  that 
intracellular  localization  and  environment  have  a  strong  impact  on  its  activity 
(Pasternak, S. H., Callahan, J. W. et al., 2004; Urano, Y., Hayashi, I. et al., 2005; Yu, 
W.  H.,  Kumar,  A.  et  al.,  2004).  We  assessed  whether  APPwt  and  the  APPsw 
mutation have an effect on baseline -secretase activity (Fig. 3.10 A+B). -secretase 
activity  was  significantly  (p<0.01)  increased  in  APPsw  PC12  cells  compared  to 
control cells (Fig. 3.10 A). In APPsw, APPwt and control HEK cells, comparable -
secretase activity levels were determined. Considering the results obtained from -
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secretase activity measurements with similar results in both cell culture models, we 
may conclude that -secretase activity is not simultaneously elevated in APPwt and 
APPsw HEK cells compared to APPwt and APPsw PC12 cells. On the one hand we 
speculate that -secretase activity may be at maximum levels in control HEK cells. 
HEK  control  cells  secrete  A levels  comparable  to  those  of  APPsw  PC12  cells 
(approx. 38 pg/ml), thus already leading to a maximum -secretase activity in control 
HEK cells. This implicates that the Swedish mutation does not prime for an increased 
-secretase activity per se. On the other hand, we may deduct that the APPwt and 
APPsw transfections do not have an impact on -secretase activity in non-neuronal 
cells. This would lead to the conclusion that the effect of the APPsw mutation on -
secretase  activity  is  a  typical  hallmark  of  neuronal  cell  lines.  In  a  more  abstract 
manner, we may rise the question whether alterations in composition and localization 
of the -secretase complex, rather than APP-related changes, modulate -secretase 
activity.
Figure 3.10: Increased -secretase activity in APPsw PC12 cells, but not in APPsw HEK cells.
Cell lysates of 5 x 10
6 cells were collected and assayed for -secretase activity. A) Delta values (%) of -secretase 
activity in PC12 cells. B) Delta values (%) of -secretase activity in HEK cells. One-way ANOVA: ***p<0.001, 
posthoc t test: **p<0.01 vs. control cells (Co). Data are shown as means ± SEM of 4 independent experiments. 
Dotted line represents 100% control under baseline conditions.
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3.1.5.3 Comparison of secretase activity
APPwt and APPsw HEK cells do not show significantly increased -secretase activity 
compared to control cells. Without specific substrate addition, fluorescence levels of 
HEK cells are comparable those of PC12 cells, indicating that increased, unspecific 
baseline fluorescence is not the reason for the astonishing results obtained for  -
secretase obtained in HEK cells.
One  consistent  observation  in  association  with  AD  is  that  -secretase  activity  is 
significantly elevated in cells (Haass, C., Lemere, C. A. et al., 1995a) and transgenic 
mice bearing the Swedish double mutation (Rossner, S., Apelt, J. et al., 2001) as well 
as in brains of patients suffering from sporadic AD (Tyler, S. J., Dawbarn, D. et al., 
2002; Li, R., Lindholm, K. et al., 2004a; Yang, L. B., Lindholm, K. et al., 2003a). In 
our cell model the APPsw mutation results in a markedly increased A1-40 secretion 
of APPsw HEK cells (2.6 pg/ml)  (Keil, U., Bonert, A. et al., 2004) and A1-42 (0.2 
pg/ml) compared to control HEK cells (A1-40: 0.35 pg/ml; A1-42: 14 pg/ml) . We could 
already demonstrate  that  these  high,  chronically  secreted  A levels initiated  early 
apoptosis as monitored by propidium iodide staining under baseline conditions (Keil, 
U., Bonert, A. et al., 2004). Here, we could demonstrate that the APPsw mutation 
leads to a significantly increased -secretase activity in HEK cells (APPsw: 164  15 
%  vs.  control:  100   32  %;  p<0.05)  under  baseline  conditions  (Fig.  3.11).  The 
increase  in  -secretase  activity  might  finally  result  in  an  increased  formation  of 
CTFs (C99, C-terminal fragments) and consequently to an increased A secretion. 
In  our  model,  we  did  not  observe  significant  alterations  of  -secretase  activity  in 
APPsw and control HEK cells under baseline conditions compared to -secretase 
activity.  Thus,  we  may  conclude  that  - and  -secretase  activity  are  not  directly 
interrelated. The most probable explanation  might be that the APPwt and APPsw 
transfection does not have an impact on -secretase activity in non-neuronal cells, 
while -secretase activity is equally elevated in neuronal (PC12) and non-neuronal 
(HEK) cells.Results
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Figure 3.11: Comparison of - and -secretase activity in APPsw and control HEK cells. 
- secretase and –secretase activity of APPsw and control HEK cells were compared. One-way ANOVA: p<0.05. 
posthoc t test revealed a significant increase in –secretase activity in APPsw (*p<0.05) vs. control HEK cells. All 
values represent the means  SEM from 3-4 experiments. 
3.2 Toxicity of different A species
It is still under investigation which kind of A species play the most prominent role in 
the course of AD. There is growing evidence that intracellular, dimeric or oligomeric 
A mainly contributes to the neuro-degenerative process (Kayed, R., Head, E. et al., 
2003).  The  aim  of  the  following  study  was  to  assess  whether  exposure  to 
extracellular or intracellular A leads to alterations in mitochondrial activity. To do so, 
various  settings  were  investigated.  First,  we  exposed  PC12  and  SY5Y  cells  to 
different A species (monomeric, dimeric, fibrillar) in order to characterize their effect 
on MTT reduction potential. In the next step, SY5Y K623C cells bearing a mutation in 
the APP gene which leads to the formation of intracellular dimeric APP and A were 
used to investigate  the  effect  of intracelularly  produced  A on  the MTT  reduction 
potential (Schmechel, A., Zentgraf, H. et al., 2003; Scheuermann, S., Hambsch, B. et 
al., 2001).
SY5Y  cells  producing  dimeric  A (SY5Y  K623C)  were  compared  to  APPwt-
transfected  and  control  SY5Y  cells  under  baseline  conditions  and  under  H2O2-
mediated oxidative stress by the MTT assay and the determination of ATP levels. 
The  measurement  of  the  MTT  reduction  potential  his  a  widely  used  and  well-
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established  method  for  the  investigation  of  viability  reflecting  metabolic  activity, 
function of mitochondria and cell death. 
3.2.1 Extracellular A: monomers vs. dimers and fibrils
We  exposed  PC12  and  SY5Y  control  cells  to  various  monomeric,  dimeric  and 
oligomeric/fibrillar  A forms.  Monomeric,  dimeric  and  A was  synthesized  and 
reconstituted  as  previously  described  (Schmechel,  A.,  Zentgraf,  H.  et  al.,  2003). 
Commercially available wild-type A1-42 (Bachem) was aggregated to form oligomers 
and/or  fibrills.  Previous  results  showed  that  aggregated  wild-type  A1-42 exhibits 
maximum toxicity at concentrations ranging from 10-100 nM (Leutz, S., Steiner, B. et 
al., 2002; Keil, U., Bonert, A. et al., 2004). Generally, PC12 and SY5Y cells were 
exposed to A isoforms (50, 100 nM) for 24h previous to the measurement of MTT 
reduction potential. PC12 and SY5Y control cells were first treated with aggregated 
wild-type A1-42.(Fig. 3.12 A+B). The treatment with oligomeric/fibrillar A1-42 (50,100 
nM) lead to a dose-dependent decrease in mitochondrial viability. In PC12 (50 nM: 
p<0.01; 100 nM: p<0.001 vs. control, Fig. 3.12 A) as well as in SY5Y cells (50,100 
nM: p<0.001 vs. control, Fig. 3.12 B) MTT reduction potential decreased for 40-50%, 
respectively. Briefly, the results confirmed former findings corroborating the theory 
that oligomeric/fibrillar aggregates basically contribute to A1-42-mediated toxicity.
Figure 3.12: Fibrillar wild-type A1-42 is toxic to PC12 and SY5Y cells.
The day before assay start, cells were plated on a 96 well plate at a density of 5 x 10
4 cells. A) Treatment of PC12 
control cells with oligomeric/fibrillar wild-type A1-42 for 24h. B) Treatment of SY5Y control cells with monomeric 
wild-type A1-42 for 24h. One-way ANOVA: ***p<0.001, posthoc t test: **p<0.01, ***p<0.001 vs. untreated control. 
Data are shown as means ± SEM of 5-6 independent experiments. Dotted line represents 100% baseline control.
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Exposure of PC12 and SY5Y cells to monomeric wild-type A1-42 (50,100 nM) for 24h 
did not result in a decrease in MTT reduction potential (Fig. 3.13 A+B). These data 
are consistent with earlier findings of other groups demonstrating that monomeric A
does not exhibit toxic effects in cell culture (Kayed, R., Head, E. et al., 2003). 
Figure 3.13: Extracellular monomeric wild-type A1-42 exhibits no toxicity to PC12 and SY5Y cells.
The day before assay start, cells were plated on a 96 well plate at a density of 5 x 10
4 cells. A) Treatment of PC12 
control  cells  with  monomeric  wild-type  A1-42 (A1-42 wt)  for  24h.  B)  Treatment  of  SY5Y  control  cells  with 
monomeric wild-type A1-42 for 24h. One-way ANOVA: ***p<0.001, posthoc t test: n.s. Data are shown as means 
± SEM of 5-6 independent experiments. Dotted line represents 100% control.
Exposure of PC12 cells and SY5Y to dimeric A1-40 (50,100 nM) for 24h lead to a 
decrease  in  MTT  reduction  potential  (Fig.  3.14  A+B).  In  PC12  control  cells, the 
decrease in MTT  reduction  almost  reached significancy  at an application 100 nM 
dimeric  A1-40 (p=0.06  vs.  control).  In  SY5Y  control  cells,  treatment  with  50  nM 
dimeric A1-40 nearly lead to a significant decrease in MTT reduction potential, while 
by  the  treatment  with  100  nM  dimeric  A1-40,  MTT  reduction  potential  decreased 
significantly  (p<0.05  vs.  control).  Concluding,  dimeric  A1-40 exhibited  less  toxic 
effects on MTT reduction potential of PC12 (100 nM: 32%) and on SY5Y cells (100 
nM: 10%) compared to fibrillar/oligomeric A1-42 (40-50%). This indicates that dimeric 
A1-40, although leading to a modest reduction of MTT reduction potential compared 
to monomeric wild-type A1-42, is less toxic than higher aggregated A species.
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Figure 3.14: Extracellular dimeric A1-40 is only slightly toxic to PC12 and SY5Y cells.
The day before assay start, cells were plated on a 96 well plate at a density of 5 x 10
4 cells. A) Treatment of PC12 
control cells with dimeric A1-40 for 24h. B) Treatment of SY5Y control cells with dimeric A1-40 for 24h. One-way 
ANOVA:  ***p<0.001,  posthoc  t test:  *p<0.05  vs.  control  (Co).  Data  are  shown  as  means  ± SEM  of  5-6 
independent experiments. Dotted line represents 100% control.
The exposure of PC12 and SY5Y cells to dimeric A1-42 (50,100 nM) resulted in a 
significant decrease of MTT reduction of both cell lines (Fig. 3.15 A+B). The extent in 
decrease is approximately 30% higher than the decrease in MTT reduction potential 
achieved by  exposure  to  dimeric  A1-40.  MTT  reduction  level  is  significantly 
decreased in PC12 (50 nM: 46%, p<0.001; 100 nM: 50%, p<0.001 vs. control, Fig. 
3.15 A) and SY5Y cells (50 nM: 29%, p<0.001; 100 nM: 31%, p<0.001 vs. control, 
Fig. 3.15 B). Dimeric A (A1-40, A1-42) species are more toxic than monomeric A
(A1-42):  the  MTT  reduction  achieved  by  the  treatment  with  dimeric  A1-42 is 
comparable to MTT reduction levels resulting from the exposure to fibrillar/oligomeric 
A1-42 (50-55%). Finally, we can conclude that neurotoxic effects, here monitored by 
MTT,  are  not  exclusively  dependent  on  the  A species  (A1-40,  A1-42),  but  also 
depend on the aggregation status of A species.
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Figure 3.15: Extracellular dimeric A1-42 is toxic to PC12 and SY5Y cells.
The day before assay start, cells were plated on a 96 well plate at a density of 5 x 10
4 cells. A) Treatment of PC12 
control cells with dimeric A1-42 for 24h. B) Treatment of SY5Y control cells with dimeric A1-42 for 24h. One-way 
ANOVA:  ***p<0.001,  posthoc  t test:  ***p<0.001  vs.  control  (Co).  Data  are  shown  as  means  ± SEM  of  5-6 
independent experiments. Dotted line represents 100% control.
3.2.2 Intracellular A: dimers
We investigated the MTT reduction potential and ATP levels of SY5Y cells bearing a 
dimer-forming APP mutation (APPK623C) in comparison to APPwt and control SY5Y 
cells. The formation  of  intracellular  APP  and  A species  has  been  demonstrated 
before  (Scheuermann,  S.,  Hambsch,  B.  et  al.,  2001).  Here,  we  focused  on  the 
characterization of functional viability parameters: APPwt and control SY5Y cells did 
show similar MTT reduction potential under baseline conditions, during exposure to 
0.1 mM H2O2 for 2, 4 and 6h and after exposure to H2O2 (0.001- 1.0 mM) for 6h (Fig. 
3.16  A+B).  MTT  reduction  was  significantly  reduced  in  APPK623C  SY5Y  cells 
compared to control SY5Y cells (control: 100%; APPK63C: 74%: p<0.001 vs. control) 
and compared to APPwt  SY5Y cells (APPwt: 92%; APPKC: 74%) under baseline 
conditions (Fig. 3.16 A+B). The exposure to H2O2 (0.1 mM) for 2, 4 and 6h did result 
in a similar decrease in MTT reduction potential of all clones (Fig. 3.16 A). After 4 and 
6h exposure, the decreased  MTT  reduction  potential  of APPK623C  cells  was  not 
significantly  different  from  the  values  obtained  for  APPwt  and  control  SYY  cells 
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compared to 2h treatment and baseline conditions (APPK623C: p<0.001 vs. control 
SY5Y, p<0.001 vs. APPwt SY5Y).
MTT reduction levels decreased significantly already after exposure to 0.01 mM H2O2
for 6h in all clones (Fig. 3.16 B). After exposure to 0.001 and 0.01 mM H2O2 for 6h 
and under baseline conditions, the MTT reduction potential of APPK623C cells was 
significantly  decreased  compared  to  APPwt  and  control  SY5Y  cells  (APPK623C: 
p<0.01 (baseline), p<0.05 (0.001 mM) vs. control SY5Y, p<0.01 (baseline), p<0.05 
(0.001  mM)  vs.  APPwt  SY5Y).  At  higher  concentrations  (0.1,  1.0  mM),  the  MTT 
reduction potential of APPK623C was not significantly different from that of APPwt 
and control SY5Y. 
Figure 3.16: Reduced mitochondrial viability in APPK623C SY5Y cells. 
A) APPK623C (APPKC), APPwt and control (Co) SY5Y cells were exposed to H2O2 (0.1 mM) for 2, 4 and 6 h 
and MTT reduction potential was assessed by an ELISA reader. One-way ANOVA: ***p<0.001, posthoc t test: 
***p<0.001 vs. control SY5Y cells (Co); 
+++p<0.001 vs. APPwt SY5Y cells. B) APPK623C, APPwt and control 
SY5Y cells were exposed to H2O2 (0.001-1 mM) for 6h. One-way ANOVA: ***p<0.001, posthoc t test: *p<0.051, 
**p<0.01 vs. SY5Y cells (Co); 
+p<0.05, 
++p<0.01 vs. APPwt SY5Y cells. Data are shown as means ± SEM of 4-6 
independent experiments. Dotted line represents 100% baseline control.
We have previously reported that PC12 cells bearing the Swedish double mutation 
show reduced ATP levels (Keil, U., Bonert, A. et al., 2004). Considering the fact that 
APPK623C SY5Y cells showed a significantly reduced MTT reduction potential under 
baseline  conditions  and  during  oxidative  stress,  we  determined  the  relative  ATP 
levels (%) compared to APPwt and control SY5Y cells under baseline conditions and 
expousre to H2O2 (0.1 mM) for 6h and to 0.001-1.0 M H2O2 for 6h (Fig. 3.17 A+B). 
Under  baseline  conditions,  APPK623C  show  significantly  decreased  ATP  levels 
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compared to APPwt and control cells (Control: 100%; APPK623C: 53%; p<0.001 vs. 
control)  and  compared  to  APPwt  SY5Y  cells  (APPwt:  93%;  APPK623C:  53%; 
p<0.001) (Fig 3.17 A+B). The exposure to H2O2 (0.1 mM, 2, 4, 6h) resulted in a time-
and concentration-dependent decrease in MTT reduction potential in all clones. After 
incubation with H2O2, the decrease of ATP-levels in APPK623C cells was similar to 
the decrease of APPwt and control SY5Y cells after 2, 4 and 6h. Additionally, SY5Y 
cells were incubated with various concentrations of H2O2 (0.001-1 mM) for 6h (Fig. 
3.17 A). The exposure to 0.01 and 1.0 mM H2O2 for 6h lead to drastically reduced 
ATP levels in all clones (Fig. 3.17 B). At the lower concentrations (0.001, 0.01 mM), 
APPK623C SY5Y cells show significantly decreased ATP levels compared to APPwt 
SY5Y (p<0.001 vs. APPK623C) and control SY5Y cells (p<0.001 vs. APPK623C). 
Figure 3.17: Reduced ATP levels in APPK623C SY5Y cells.
A) APPK623C (APPKC), APPwt and control (Co) SY5Y cells were exposed to H2O2 (0.1 mM) for 2, 4 and 6 h. 
One-way ANOVA: ***p<0.001, posthoc t test: ***p<0.001 vs. control SY5Y cells (Co); 
+++p<0.001 vs. APPwt SY5Y 
cells. B) APPK623C (APPKC), APPwt and control (Co) SY5Y cells were exposed to H2O2. (0.001-1 mM) for 6h. 
One-way ANOVA: ***p<0.001, posthoc t test: ***p<0.001 vs. control SY5Y cells (Co); 
+++p<0.001 vs. APPwt SY5Y 
cells. Data are shown as means ± SEM of 4-6 independent experiments. Dotted line represents 100% baseline 
control.
Resuming, we may state that the stably expressed K623C mutation is toxic to SY5Y 
cells  under  baseline  conditions,  as  monitored  by  the  decrease  in  MTT  reduction 
potential (Fig. 3.16 A+B) and strongly decreased baseline ATP levels under baseline 
conditions (Fig. 3.17 A+B). This implicates that intracellularly produced dimeric A is 
sufficient to cause impaired energy metabolism and reduced cellular viability in cell 
culture. The effect was so strong that there was no further increase by additional 
exposure to H2O2 – mediated oxidative stress.
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3.3 Characterization of mitochondria-dependent cell death 
pathways in APP-expressing cells
Proteins  of  the  Bcl-2  superfamily  are  important  players  in  the  regulation  of  the 
mitochondrial apoptotic pathway, modulating the release of numerous pro-apoptotic 
factors from mitochondria which in turn activate executioner caspases. In order to 
characterize the cell-type specific expression levels and subcellular localization, we 
submitted cell lysates of PC12, HEK and SY5Y cells to western blot analysis.
3.3.1 Bcl-2 family proteins and mitochondrial pro-apoptotic factors in 
PC12 cells
The analysis of cell lysates, mitochondrial and cytosolic fractions of PC12 cells (Fig. 
3.18) lead to the following result: The anti-apoptotic protein of Bcl-xL was expressed 
in moderate quantities in PC12 cells. Intracellularly, Bcl-xL is mainly located in the
mitochondrial fraction. Bcl-xL is decreased in the cytosolic fraction of APPsw and 
APPwt PC12 cells, which might contribute the increased vulnerability of APPwt and 
APPsw cells against oxidative injury. The expression of the pro-apoptotic protein Bax 
was unaffected in all clones. The protein is located in the mitochondrial and cytosolic 
compartment, with no difference in the distribution pattern of the clones. Bcl-2 is not 
expressed in PC12 cells. The result was confirmed by Celio Marques in our lab and 
by another working group analysing mRNA levels of Bcl-2 (Maroto, R., Perez-Polo, J. 
R., 1997; Marques, C. A., Keil, U. et al., 2003). Cytochrome c was expressed at 
comparable  levels  in  all  cell  types,  and  the  protein  was  mainly  located  in  the 
mitochondrial compartment under baseline conditions. Barely no cytochrome c was 
detected  in  the  cytosolic  compartment.  Similar  expression  and  distribution  was 
observed by the analysis of the pro-apoptotic mitochondrial factors Smac/DIABLO 
and  AIF.  Smac/DIABLO was  found  to  be  co-located  with  cytochrome  c  in  the 
mitochondrial intermembrane space (Adrain, C., Creagh, E. M. et al., 2001; Du, C., 
Fang, M. et al., 2000) and AIF was found to be mainly located in the mitochondrial 
compartment  (Cande,  C.,  Cohen,  I.  et  al.,  2002;  Daugas,  E.,  Susin,  S.  A.  et  al., 
2000).Results
102
Mitochondrial Fraction Cytosolic Fraction
Bcl-xL
Co wt sw 
Lysate
Bax
Smac
AIF 
Bcl-2
Co wt sw Co wt sw 
Cytochrome c
27kDa
20kDa
25kDa
14 kDa
57kDa
67kDa
Figure 3.18: Bcl-2 protein family members and mitochondrial pro-apoptotic factors in PC12 cells.
Subcellular fractions (mitochondria, cytosol) were isolated and subjected to western blot analysis as well as cell 
lysates. The resulting membranes were tested for the following proteins: Bcl-xL (27 kDa), Bax (20 kDa), Bcl-2 (25 
kDa), cytochrome c (14 kDa), Smac/DIABLO (57 kDa) and AIF (67 kDa).
3.3.2 Bcl-2 family proteins and mitochondrial pro-apoptotic factors in 
HEK cells
In the following, we investigated the expression and subcellular localization of Bcl-2 
family proteins and mitochondrial pro-apoptotic factors of HEK cells (Fig. 3.19). The 
anti-apoptotic  protein  Bcl-xL  was  expressed  in  HEK  cells,  and  slightly  reduced 
expression  levels  were  observed  in  APPwt  and  APPsw  cells.  Bcl-xL was  mainly 
found in the  mitochondrial fraction  of APPwt  and APPsw  HEK  cells, but  at lower 
levels than in control HEK cells. Only a minor part of Bcl-xL is located in the cytosolic 
fraction of APPsw, APPwt and control HEK cells. Bax was present in cell lysates of 
all  clones,  and  the  protein  is  equally  located  in  the  mitochondrial  and  cytosolic 
compartment. In contrast to the situation in PC12 cells, Bcl-2 was highly expressed in 
HEK cells. APPsw HEK cells express lower levels of Bcl-2 compared to APPwt and 
control HEK cells. This was confirmed by the analysis of the cytosolic fraction, as 
APPsw showed decreased Bcl-2 levels compared to APPwt and control cells. Also, 
we could demonstrate that Bcl-2 is mainly located in the cytosol. The mitochondrial 
fraction  is  free  from  the  protein  under  baseline  conditions.  Cytochrome  c  was Results
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expressed  at  comparable  levels  in  all  HEK  clones,  and  the  protein  was  mainly 
located  in  the  mitochondrial  compartment  under  baseline  conditions,  whith  only 
insignificant levels of cytochrome c in the cytosolic compartment. The pro-apoptotic 
mitochondrial factor Smac/DIABLO was abundantly present in the cytosol indicating 
its potential involvement in the increased apoptosis levels of HEK cells compared to 
PC12 cells under baseline conditions. AIF expression levels were unaltered in APPwt 
and APPsw  compared to control cells. Similar to PC12 cells, AIF was mainly located 
in mitochondria of HEK cells.
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Figure 3.19: Bcl-2 protein family members and mitochondrial pro-apoptotic factors in HEK cells.
Cell lysates and subcellular fractions were isolated as described above and subjected to western blot analysis. 
The resulting membranes were probed for the following proteins: Bcl-xL (27 kDa), Bax (20 kDa), Bcl-2 (25 kDa), 
cytochrome c (14 kDa), Smac/DIABLO (57 kDa) and AIF (67 kDa).
3.3.3 Bcl-2 family proteins and mitochondrial pro-apoptotic factors in 
SY5Y cells
The anti-apoptotic protein Bcl-xL was equally expressed in APPwt and control SY5Y 
cells (Fig. 3.20). In cell lysates, mitochondrial and cytosolic fractions, the expression 
levels of Bcl-xL were slightly decreased in APPwt compared to control SY5Y cells. In 
contrast to HEK cells, Bcl-xL was mainly found in the cytosolic fraction. Only a minor 
part of Bcl-xL is located in mitochondria of APPwt and control SY5Y cells. According Results
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to the previous findings in PC12 and HEK cells, Bax was found in cell lysates, and 
the protein is located in both mitochondrial and cytosolic compartments. Bcl-2 was
highly expressed in SY5Y cells, with APPwt cells showing decreased Bcl-2 levels 
compared  to control  cells.  In contrast to HEK  cells, Bcl-2 was  not present in the 
cytosolic fraction under baseline conditions, but notably present in the mitochondrial 
compartment. Cytochrome c was expressed at comparable levels in both APPwt and 
control SY5Y cells, with equivalent protein levels in the cytosolic and mitochondrial 
fraction.  Smac/DIABLO  was  found  in  the  cytosol,  which  is  in  consistent  with  the 
findings in HEK cells. APPwt and control SY5Y cells expressed equal amounts of 
AIF, and similar to PC12 and HEK cells, AIF was mainly located in mitochondrial 
fraction.
Figure 3.20: Bcl-2 protein family members and mitochondrial pro-apoptotic factors in SY5Y cells.
Cell lysates and subcellular fractions were isolated as described above and subjected to western blot analysis. 
The resulting membranes were probed for the following proteins: Bcl-xL (27 kDa), Bax (20 kDa), Bcl-2 (25 kDa), 
cytochrome c (14 kDa), Smac/DIABLO (57 kDa) and AIF (67 kDa).
Mitochondrial Fraction Cytosolic Fraction Lysate
Co wt Co wt Co wt
Bcl-xL
Bax
Smac
AIF 
Bcl-2
Cytochrome c
27 kDa
20 kDa
25 kDa
14 kDa
57 kDa
67 kDaResults
105
3.3.4 Bcl-2 family proteins in APP transgenic mice
Our previous findings indicate that decreased Bcl-2 and Bcl-xL expression might be 
implicated in the increased neurotoxicity mediated by chronic exposure to high levels 
of A. The next assays aimed at the demonstration of the in vivo relevance of the 
previous  findings  in  cell  culture.  Cell  lysates  of  dissociated  brain  neurons  of  3 
months-old APP transgenic mice were subjected to western blot analysis for APP 
(116 kDa), A (4 kDa), Bcl-xL (27 kDa), Bcl-2 (25 kDa) and Bax (20 kDa) (Fig. 3.21). 
3  months-old  APP  transgenic mice  exhibit significantly  increased  APP  expression 
levels  compared  to  non-transgenic  littermates.  Furthermore,  A was  scarcely 
detectable in both APP transgenic and non-transgenic mice. This is in accordance 
with  other  findings  showing  that  extracellular  A plaque  formation  is  significantly 
increased in 6 months-old APP transgenic mice. Bcl-xL expression levels of APP 
transgenic mice were decreased in comparison to non-transgenic littermates. Bcl-2 
and Bax expression was analogous in both groups.
Figure 3.21: Decreased Bcl-xL expression in APPtg mice.
Cell lysates of brain tissue of 3 months-old APP transgenic mice (n=3) and littermates (n=3) were generated by 
Tris lysis (5 mM). Probes were subjected to western blot for APP (116 kDa), A (4 kDa), Bcl-xL (27 kDa), Bcl-2 
(25 kDa) and Bax (20 kDa).
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3.3.5 Ratios of pro-and anti-apoptotic proteins of the Bcl-2 family
Altered  ratios  of  pro-(Bax)  and  anti-(Bcl-2)  apoptotic  protein  levels  are  generally 
considered to render cells more vulnerable to apoptotic cell death (Cheng, E. H. Y. 
A.,  Wei,  M.  C.  et  al.,  2001).  In  order  to  investigate  Bcl-2  family  proteins  and 
mitochondrial pro-apoptotic factors in more detail, we compared expression levels of 
Bcl-2, Bax and Bcl-xL in APPwt, APPsw, control HEK and APPwt, control SY5Y cells 
by densiometric analysis (Fig. 3.22 A-C). Bcl-2 expression is significantly higher in 
SY5Y control compared to HEK control cells (p<0.001 vs. HEK control) (Fig. 3.22 A). 
Furthermore,  Bcl-2  expression  is  significantly  decreased  in  APPwt  compared  to 
control  cells  (p<0.001  vs.  SY5Y  control). Although  SY5Y  control  cells  exhibited  a 
higher Bcl-xL expression, the increase was not significant (Fig. 3.22 B). Thus, Bcl-xL 
and Bax expression levels of HEK and SY5Y cells were at the same size (Fig. 3.22 
B+C), indicating that a shift in the ratio of pro- and anti-apoptotic Bcl-2 family protein 
levels might primarily be linked to altered expression levels of the anti-apoptotic Bcl-
2.Results
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Figure 3.22: Significantly decreased Bcl-2 expression levels in APPwt SY5Y cells.
Western blots of cell lysates of HEK and SY5Y cells for Bcl-2, Bcl-xL and Bax were densiometrically analysed. 
One-way ANOVA: p<0.0001; posthoc t test: ***p<0.001 vs. SY5Y control; 
+++p<0.001 vs. HEK control. Data are 
shown as means ± SEM of 3 independent experiments. 
As  mentioned above, the Bcl-2/Bax ratio is a generally accepted indicator for the 
vulnerability  against  apoptotic  cell death.  Consequently,  Bcl-2/Bax  and Bcl-xL/Bax 
ratios were calculated to relate them to baseline apoptosis process of HEK and SY5Y 
cells  (Fig.  3.23  A+B).  Although  no  significant  shift  of  the  Bcl-2/Bax  ratio  was 
monitored by the densiometric analysis of Bcl-2 in APPsw HEK cells compared to 
control cells, the Bcl-2/Bax ratio is significantly decreased in APPsw compared to 
control HEK cells (p<0.05 vs. control) (Fig. 3.23 A). The significantly elevated Bcl-
2/Bax ratio of control SY5Y cells (100% increase; p<0.001 vs. HEK control) clearly 
reflects increased Bcl-2 expression levels in control SY5Y cells. Notably, the Bcl-
2/Bax ratio of APPwt SY5Y cells is significantly decreased compared to control SY5Y 
cells ( APPwt: 0.9; control: 2.0; p<0.001).
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In turn, the Bcl-xL/Bax ratio of HEK cells was unaltered, while the Bcl-xL/Bax ratio of 
APPwt  SY5Y  cells  was  significantly  decreased  compared  to  control  SY5Y  cells 
(p<0.05 vs. control) (Fig. 3.23 B). Our findings are consistent with current studies 
pointing out that the Bcl-2/Bax ratio is a valuable indicator for apoptotic processes.
Figure 3.23: Significantly decreased Bcl-2/Bax and Bcl-xL/Bax ratios in APPwt SY5Y and APPsw HEK 
cells.
Western blots of cell lysates of HEK and SY5Y cells for Bcl-2, Bcl-xL and Bax were densiometrically analysed to 
calculate Bcl-2/Bax and Bcl-xL/Bax ratios. One-way ANOVA: p<0.0001; posthoc t test: *p<0.05,***p<0.001 vs. 
corresponding  control; 
+++p<0.001  vs.  HEK  control.  Data  are  shown  as  means  ± SEM  of  3  independent 
experiments. 
3.3.6 In-vivo relevance of altered Bcl-2, Bcl-xL/ Bax ratios
Western  blot  analysis  indicated  that  only  Bcl-xL  expression  was  altered  in  APP 
transgenic mice compared to non-transgenic littermates (Fig. 3.21). In the following, 
we subjected western blots for Bcl-xL and Bax to densiometric analysis to calculate 
Bcl-xL/ Bax ratios for APP transgenic mice and non-transgenic littermates (Fig. 3.24). 
Bcl-xL/Bax ratio were significantly (p<0.05 vs. littermate control) decreased in APP 
transgenic  mice.  Finally,  we  speculate  that down-regulation of  Bcl-xL levels is an 
early event in chronic exposure to increased APP and A levels.
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Figure 3.24: Significantly decreased Bcl-xL/ Bax ratio in APPtg mice.
Cell lysates of brain tissue of 3 month-old APP transgenic mice (n=3) and littermates (n=3) were generated by 
Tris lysis (5 mM). Probes were subjected to western blot for Bcl-xL (27 kDa) and Bax (20 kDa). Bands were 
evaluated densiometrically and Bcl-xL/Bax ratios were calculated in the following. One-way ANOVA: p<0.0001; 
posthoc t test: *p<0.05 vs. age-matched  littermate control.
3.3.7 Mitochondrial activity during oxidative injury in PC12, HEK and 
SY5Y cells
Preceding work of our group aimed at the characterization of caspase activation and 
mitochondrial  alterations  after  oxidative  injury  with  special  regard  to  the  APPsw 
mutation (Marques, C. A., Keil, U. et al., 2003; Keil, U., Bonert, A. et al., 2004). It was 
shown that initiator- and executioner caspases were activated in a time-dependent 
pattern  while  mitochondrial  membrane  potential  and  ATP  levels  decreased 
significantly during exposure to H2O2-mediated oxidative stress. In this setting, PC12 
cells were exposed to 500 µM H2O2 to investigate caspase-activation. Furthermore, it 
has  been  demonstrated  by  Celio  Marques  that  apoptosis  is  increased  to  the 
maximum after exposure to H2O2 at a concentration of 500 µM. Since the aim of this 
thesis  was  to  investigate  alterations  in  Bcl-2  family  members  and  pro-apoptotic 
mitochondrial factors to obtain a deeper knowledge of signal transduction during the 
course of apoptosis, we have chosen the same experimental conditions. First of all, 
we determined the MTT reduction potential during H2O2-mediated oxidative stress in 
order to compare the results to the time-dependent release of pro-apoptotic factors. 
This would enable us to determine whether changes in Bcl-2 family members, pro-
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apoptotic  mitochondrial  factors  or  MTT  reduction  potential  are  the  most  sensitive 
indicator of impaired cellular functions during oxidative stress-mediated apoptosis.
In order  to investigate  whether  wild-type  APP  and the APPsw  mutation  modulate 
cellular viability and mitochondrial activity during oxidative injury and under baseline 
conditions, we monitored the MTT reduction potential of APPwt and APPsw PC12 
cells after exposure to H2O2 (500 µM) for 0, 2, and 4h (Fig. 3.25). Under baseline 
conditions,  APPwt  and  APPsw  cells  revealed  a  reduced  MTT  reduction  potential 
compared to control cells (APPwt: 87%; APPsw: 69% vs. 100% baseline control). 
Exposure  to  H2O2 (500  µM)  resulted  in  a  significant  reduction  in  MTT  reduction 
potential after 2 and 4h (APPwt: p<0.001 vs. APPwt control; APPsw: p<0.001 vs. 
APPsw  control).  Furthermore,  MTT  reduction  potential  was  decreased  to  similar 
levels  in  APPwt  (2h:  13%;  4h:  3%)  and  in  APPsw  cells  (2h:  10%;  4h:  3%). 
Concluding,  the  APPsw  mutation  lead  to  a  more  pronounced  decrease  in  MTT 
reduction potential under baseline conditions compared to wild-type APP in PC12 
cells, while the massive exposure to H2O2 resulted in a drastic reduction of cellular 
viability in both cell types. These data were coherent with previous findings of our 
group (Marques, C. A., Keil, U. et al., 2003).
Figure 3.25: Decreased MTT reduction potential in APPwt and APPsw PC12 cells after oxidative injury.
APPsw  and  APPwt  PC12  cells  were  exposed  to  H2O2 (500  µM) fo  2  and  4h.  MTT  reduction  potential  was 
assessed in the following. One-way ANOVA: p<0.0001; posthoc t test: ***p<0.001 vs. corresponding untreated 
baseline control (APPwt, APPsw). Data are shown as means ± SEM of 3 independent experiments. Dotted line 
represents 100% baseline control.
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In the following, we exposed APPwt and APPsw HEK cells to H2O2 (500 µM) for 2 
and  4h  (Fig.  3.26).  Under  baseline  conditions,  APPsw  cells revealed  significantly 
reduced  MTT  reduction  potential  compared  to  APPwt  HEK  cells  (APPwt:  102%; 
APPsw:  79%  vs.  100%  baseline  control;  p<0.05  vs.  APPwt  control).  Exposure  to 
H2O2 (500 µM) resulted in a significant reduction in MTT reduction potential after 2 
and 4h (APPwt: p<0.001 vs. APPwt control; APPsw: p<0.001 vs. APPsw control). 
After  secondary  insult,  MTT  reduction  potential  of  APPsw  cells  was  significantly 
decreased compared to APPwt HEK cells (p<0.01 vs. corresponding APPwt probe). 
The  APPsw  mutation  not  only  lead  to  a  highly  pronounced  decrease  in  MTT 
reduction  potential  under  baseline  conditions,  but  also  lead  to  a  significantly 
decreased MTT reduction after oxidative injury compared to wild-type APP.
Figure 3.26: Decreased MTT reduction potential in APPwt and APPsw HEK cells after oxidative injury.
APPsw  and  APPwt  HEK  cells  were  exposed  to  H2O2 (500  µM)  fo  2  and  4h.  MTT  reduction  potential  was 
assessed in the following. One-way ANOVA: p<0.0001; posthoc t test: ***p<0.001 vs. corresponding untreated 
control; 
++p<0.01 vs.  APPwt.  Data  are  shown  as  means  ±  SEM  of  3  independent  experiments.  Dotted  line 
represents 100% baseline control.
We exposed APPwt and control SY5Y cells to varying concentrations of H2O2 (0.001-
1.0 mM) for 6h and to H2O2 (0.1 mM) for 2, 4 and 6h (Fig. 3.27 A+B). Under baseline 
conditions,  APPwt  cells  revealed  a  slightly  reduced  MTT  reduction  potential 
compared to control SY5Y cells (Fig. 3.27 A). Exposure to H2O2 (0.1 mM) resulted in 
a significant reduction in MTT reduction potential after 2 and 4h in both cell types 
(p<0.001 vs. untreated control). After secondary insult for 2 and 4h (H2O2, 0.1 mM) 
MTT reduction of APPwt and control SY5Y cells was at the same level.
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Figure 3.27: Decreased MTT reduction potential in APPwt SY5Y cells after oxidative injury.
A) APPwt and control SY5Y cells were exposed to H2O2 (0.001-1.0 mM) for 6h. B) APPwt and control SY5Y cells 
were exposed to H2O2 (0.1 mM) for 2, 4 and 6h. MTT reduction potential was assessed in the following. One-way 
ANOVA: p<0.0001; posthoc t test: **p<0.01, ***p<0.001 vs. corresponding untreated baseline control. Data are 
shown as means ± SEM of 3 independent experiments. Dotted line represents 100% baseline control.
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3.3.8 Subcellular localization of Bcl-2 family members and pro-apoptotic 
mitochondrial factors during oxidative injury
3.3.8.1 Bcl-xL
Bcl-xL is a Bcl-2 family protein bearing anti-apoptotic functions in the cell (Fig. 3.28 
A+B). Here, we investigated the intracellular distribution of Bcl-xL during exposure to 
oxidative  stress.  PC12  cells  were  exposed  to  H2O2 (500  µM)  for  2,  4  and  6h. 
Principally,  basal  levels  of  Bcl-xL  in  the  mitochondrial  fraction  are  unchanged  in 
APPwt and APPsw compared to control cells (Fig 3.28 A). During H2O2 treatment, 
mitochondrial  Bcl-xL  levels did  not  change.  In contrast to this,  cytosolic  Bcl-xL  is 
decreased  in  APPsw  and  APPwt  cells  compared  to  control  cells  under  baseline 
conditions  and  during  H2O2 treatment.  This  was  confirmed  by  the  densiometric 
western blot analysis of Bcl-xL (Two-way ANOVA: p<0.001 for cell type) (Fig. 3.28 
B),  indicating  that  after  oxidative  injury,  cytosolic  Bcl-xL  did  not  translocate  to 
mitochondria.Results
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Figure 3.28: Bcl-xL levels under baseline conditions and during exposure to H2O2 in PC12 cells.
A)  PC12  cells  were  exposed  to  H2O2 (500 µM) for 2,  4  and  6h.  Mitochondrial  and  cytosolic  fractions  were 
separated  and  subjected  to western  blot analysis.  B) Densiometric  analysis  of  Bcl-xL  bands of the  cytosolic 
fraction. Data represent means ± SEM of 3-6 independent experiments. Two-way ANOVA: p=0.0008 (cell type). 
Dotted line represents 100% control.
Increasing evidence is provided that Bcl-2 family proteins dimerize in order to exert 
their pro- or anti-apoptotic function. To investigate the dimerization potential of Bcl-
xL, we exposed PC12 cells to H2O2 (500 µM) for 2, 4 and 6h and treated cell lysates 
with  BMH  (5  mM),  a  commercially  available  chemical  cross-linker.  Cell  lysates 
assayed for Bcl-xL did not show any difference in total Bcl-xL content in APPsw, 
APPwt and control cells (Fig. 3.29). When subjected to cross-linking, heteromeric and 
dimeric  Bcl-xL  bands  (42,  54  kDa)  were  detected.  Nevertheless,  there  was  no 
change  in  heteromer/dimer  content  during H2O2 exposure  nor  were  there  any 
differences between the PC12 clones. Resuming, heteromerization or dimerization of 
Bcl-xL seems not to be a crucial step in oxidative injury-caused apoptosis.
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Figure 3.29: Bcl-xL forms dimers and heteromers.
PC12 cells were exposed to H2O2 (500 µM) for 2, 4 and 6h. After treatment with the chemical cross-linker BMH (5 
mM) for 1h, whole cell lysates were subjected to western blot analysis and assayed for Bcl-xL. 
3.3.8.2 Bax
Bax belongs to the pro-apoptotic members of the Bcl-2 family of proteins. Evidence is 
provided  that  Bax  is  a  pivotal  player  in  the  apoptotic  process.  It  is  still  under 
discussion  whether  Bax  insertion  and  oligomerization  in  the  outer  mitochondrial 
membrane forms pores itself by which mitochondrial factors are released into the 
cytosol or whether it induces PTP opening thus being the preliminary step to the 
release of pro-apoptotic, mitochondrial factors. First, we assessed the intracellular 
distribution of Bax under baseline conditions and after exposure to H2O2 (500 µM) for 
2, 4 and 6h. We could demonstrate that mitochondrial and cytosolic fractions contain 
equal amounts of Bax under baseline conditions and during oxidative injury (Fig. 3.30 
A+B).  Densiometric  analysis  of  the  cytosolic  fraction  revealed  a  slight,  but  not 
significant increase in Bax protein content after 4h followed by a slight reduction in 
cytosolic Bax contents to baseline levels after 6h exposure (Fig. 3.30 B).
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Figure 3.30: Bax slightly increases in the cytosolic compartment after 4h exposure to H2O2.
A)  PC12  cells  were  exposed  to  H2O2 (500 µM) for 2,  4  and  6h.  Mitochondrial  and  cytosolic  fractions  were 
separated and subjected to western blot analysis. B) Densiometric analysis of Bax bands of the cytosolic fraction. 
Data represent means ± SEM of 5-8 independent experiments. Dotted line represents 100% control.
It  has  been  described  before  that  Bax  oligomerizes  and  inserts  into  the  outer 
mitochondrial membrane during oxidative stress (Luetjens, C. M., Kogel, D. et al., 
2001). Here, we added BMH (5 mM) to cell lysates after exposure of PC12 cells to 
H2O2 (500  µM)  in  order  to  investigate  dimerization  (Fig.  3.31).  We  could  detect 
dimeric Bax under baseline conditions. After 4h exposure to H2O2, dimeric Bax levels 
increased. After 6h treatment, levels of dimeric Bax decreased slightly to baseline 
levels. This is consistent with previous data, as we could asses a slight increase in 
total cytosolic Bax after 4h treatment (Fig. 3.31 A+B). We suggest that increased 
dimer formation is initiated after 4h, potentially leading to transient pore formation or 
the opening of the membrane permeability transition pore in the outer mitochondrial 
membrane.
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Figure 3.31: Enhanced Bax dimerization after 4h H2O2 treatment.
PC12 cells were exposed to H2O2 (500 µM) for 2, 4 and 6h. After incubation of cell lysates with the chemical 
cross-linker BMH (5mM) for 1h, probes were subjected to western blot analysis and assayed for Bax. 
3.3.8.3 Cytochrome c
The release of cytochrome c from the mitochondrial inter-membrane space into the 
cytosol is known to be one crucial step of caspase-dependent apoptosis. It has been 
described before that only a minor part of cytochrome c is released into the cytosol 
while  the  main  part,  notably  cytochrome  c  bound to  the  electron  transport  chain, 
remains in the mitochondria.
As it has been shown in our group before that exposure to H2O2 leads to a time-
dependent activation of caspases, namely caspase-9 and caspase-3, as well as to a 
drop  down  of  mitochondrial  membrane  potential.  In  order  to  further  characterize 
mitochondrial changes during apoptosis, we again exposed PC12 cells to H2O2 (500 
µM) for 2, 4 and 6h (Fig. 3.32 A+B). Isolated cytosolic and mitochondrial fractions 
were assayed for cytochrome c. Exposure to H2O2 lead to a release of cytochrome c 
into the cytosol in a time-dependent manner (Two-way ANOVA: p<0.001 for time), 
with a maximum release at 6h of incubation. Under baseline conditions, only very low 
amount  of  cytosolic  cytochrome  c  was  detected.  After  6h incubation,  APPwt  and 
APPsw  cells  revealed  a  slightly  increased  release  of  cytochrome  c  compared  to 
control cells (Fig. 3.32 A). This result was confirmed by densiometric analysis of the 
cytochrome c western blot bands (Fig. 3.32 B). The cytosolic probes were subjected 
to a cytochrome c ELISA confirming the results achieved by densiometric analysis. 
Interestingly,  after  6h,  higher  values  were  achieved  by  ELISA,  indicating  that 
Co wt sw
0h
Co wt sw
2h
Co wt sw
4h
Co wt sw
6h
20 kDa monomeric Bax 
40 kDa dimeric BaxResults
118
saturation was reached in band intensity by densiometric analysis, resulting in lower, 
non-proportional increase in measured values.
Figure 3.32: Cytochrome c is released in a time-dependent manner after H2O2 exposure.
A) PC12 cells were exposed to H2O2 (500 µM) for 2, 4 and 6h. Cytosolic fractions were isolated and subjected to 
western blot analysis. B) Densiometric analysis of cytochrome c bands of the cytosolic fraction. Data represent 
means ± SEM of 5-10 independent experiments. Two-way ANOVA p<0.0001 (time). C) Cytochrome c ELISA of 
the  cytosolic  fractions.  Data  represent  means  ± SEM  of  3-4  independent  experiments.  Two-way  ANOVA: 
p=0.0113 (time). Dotted line represents 100% control.
3.3.8.4 Caspase/ JNK inhibition and cytochrome c release
Previously, it was demonstrated in our group that apoptosis is prevented by caspase 
and JNK inhibitors (Marques, C. A., Keil, U. et al., 2003). The release of cytochrome 
c in response to apoptogenic signals is downstream caspase-2 and -8, respectively. 
The interaction of JNK with the mitochondrial apoptosis signaling cascade through 
interaction with Bcl-2 family proteins. In order to investigate whether caspase-2 and -
8 or JNK inhibitors could prevent mitochondria-mediated apoptosis, we pre-incubated 
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control PC12 cells with specific enzyme inhibitors after induction of oxidative stress-
mediated apoptosis by H2O2 (500 µM) (Fig. 3.45). Indeed, as shown by western blot, 
caspase and JNK inhibition inhibited the release of cytochrome c into the cytosol. 
Moreover, cytochrome c detected in the cytosolic fraction of probes treated with the 
inhibitors, almost reached baseline levels.
Figure 3.33: Caspase- and JNK inhibition results in a decreased cytochrome c release
Control PC12 cells were exposed to H2O2 (500 µM) for 6h alone or in combination with the following inhibitors: 
Caspase-2 inhibitor (5 µM),  caspase-8 inhibitor (5 mM) and  JNK inhibitor (500  nM).  Cytosolic  fractions  were 
collected and analysed by western blot (n=1).
3.3.8.5 Smac/DIABLO
Second mitochondrial activator of caspases (Smac/DIABLO), is originally located in 
the  mitochondrial  inter-membrane  space  and  released  in  response  to  oxidative 
stress.  It  has  been  described  before  that  Smac/DIABLO  is  co-released  with 
cytochrome  c,  blocking  IAPs  (inhibitor  of  apoptosis  proteins),  thus  promoting 
apoptosis.  PC12  cells  were  exposed  to  H2O2 (500  µM)  for  2,  4  and  6h  and 
mitochondrial  fractions  were  analysed  by  western  blot.  Indeed,  a  time-dependent 
release of Smac/DIABLO was observed at various incubation time points H2O2 (Two-
way ANOVA: p<0.001 (time); p<0.05 (cell type) (Fig. 3.34 A+B)). Total amounts of 
mitochondrial Smac/DIABLO did not decrease during H2O2 treatment, indicating that 
Smac/DIABLO is not completely released into the cytosol as the major part remained 
in the mitochondrial inter-membrane space. This effect has also been observed for 
cytochrome c, and the previously postulated co-release of both pro-apoptotic factors 
could  be  confirmed  (Rehm,  M.,  Dussmann,  H.  et  al.,  2003).  We  suggest  that 
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Smac/DIABLO is released slightly earlier into the cytosol by APPwt and APPsw PC12 
cells  compared  to  control  cells.  These  results  were  confirmed  by  densiometric 
analysis of cytosolic Smac/DIABLO bands (Fig. 3.34 B).
Figure 3.34: Smac/DIABLO is co-released with cytochrome c during H2O2 exposure.
A) PC12 cells were exposed to H2O2 (500 µM) for 2, 4 and 6h. Cytosolic and mitochondrial fractions were isolated 
and subjected to western blot analysis. B) Densiometric analysis of Smac bands of the cytosolic fraction. Data 
represent  means ± SEM  of 5-9  independent  experiments.  Two-way  ANOVA  p<0.0001  (time),  p=0.0243  (cell 
type). Dotted line represents 100% control.
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3.3.8.6 AIF
Under  baseline  conditions,  apoptosis  inducing  factor  (AIF)  is  located  in  the 
mitochondrial matrix. In response to apoptotic stimuli, AIF is released into the cytosol 
from where it translocates to the nucleus (Arnoult, D., Gaume, B. et al., 2003). AIF 
induces  chromatin  condensation  and  nuclear  fragmentation  finally  leading  to 
apoptosis  (Daugas,  E.,  Susin,  S.  A.  et  al.,  2000).  AIF  is  part  of  the  caspase-
independent apoptosis thus caspase-activation is not required. Here, we wanted to 
asses the subcellular localization and the following translocation of AIF after oxidative 
injury. Hence, we treated PC12 cells with H2O2 (500 µM) for 2, 4 and 6h. After 6h 
exposure to H2O2, AIF accumulated in the mitochondrial compartment. Notably, the 
accumulation is highest in APPsw PC12 cells (Fig. 3.35), while AIF was not released 
into the cytosol at that time. Concluding we can say that the initial step of caspase-
independent apoptosis is the accumulation of AIF in the mitochondrial compartment.
Figure 3.35: Increased accumulation of AIF in mitochondria of APPsw PC12 cells after 6h H2O2 exposure.
PC12 cells were exposed to H2O2 (500 µM) for 2, 4 and 6h. Cytosolic and mitochondrial fractions were isolated 
and subjected to western blot analysis. Data represent means ± SEM of 4-5 independent experiments. 
We incubated the PC12 for 24h with H2O2 (500 µM) and assayed mitochondrial and 
cytosolic fractions for AIF. We observed an accumulation of AIF in APPsw, APPwt 
and control cells in the mitochondrial fraction after 24h treatment. In contrast to the 
6h incubation, no differences in mitochondrial AIF content were observed, indicating 
that AIF accumulated earlier in APPsw PC12 cells compared to APPwt and control 
cells (Fig. 3.36). Most interestingly, a cleaved fragment of AIF (57 kDa) was released 
into the cytosol after 24h H2O2 (500 µM) incubation (Fig. 3.36). It has been described 
before that the cleaved fragment of AIF translocates to the nucleus initiating nuclear 
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fragmentation  and  chromatin  condensation.  Our  data  corroborate  these  previous 
findings leading to the conclusion that apoptosis could be executed in a two-step, 
caspase-dependent and –independent manner.
Figure 3.36: H2O2 induces AIF fragmentation and the release of a cleaved fragment into the cytosol.
PC12 cells were incubated with H2O2 (500 µM) for 24h. Cytosolic and mitochondrial fractions were submitted to 
western blot analysis. After 24h incubation, AIF accumulates in the mitochondrial fraction, and a cleaved fragment 
is released into the cytosol. Data represent means ± SEM of 3 independent experiments. 
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3.4 Evaluation of disease-modifying strategies
3.4.1 -Secretase inhibitors
In  the  past,  large  collections  of  compounds  to  identify  molecules  that reduce  A
production  in  the  absence  of  overt  toxicity  have  been  screened  and  it  was 
determined  whether  - or  -secretase  activity  had  been  inhibited  by  secondary 
assays.  This  underlines  the  very  importance  of  - and  -secretase  as  potential 
targets  in  AD.  Here,  we  investigated  the  effects  of  two  - and  one   -secretase 
inhibitors on mitochondrial viability, APP expression and A secretion.
3.4.1.1 Mitochondrial activity
We could previously show that the functional -secretase inhibitor DAPT reconstitutes 
ATP levels in APPsw PC12 cells after 48h treatment. We additionally investigated the 
effect of -secretase inhibition by DAPT on MTT reduction potential of APPwt and 
APPsw PC12 and HEK cells (Fig. 3.37 A-B). Generally, APPsw and APPwt HEK and 
PC12  cells  revealed  a  slightly  reduced  MTT  reduction  potential  under  baseline 
conditions. The exposure of PC12 cells to DAPT (250-1000 nM) for 24h did not result 
in a significant increase of mitochondrial activity (Fig. 3.37 A). When the treatment of 
APPsw and APPwt PC12 cells to DAPT (0.25-1.0 µM) was continued for another 
24h, this resulted in a significant increase in MTT reduction levels of APPwt (0.5, 1.0 
µM; p<0.05 vs. untreated APPwt control) and APPsw (1000 nM; p<0.05 vs. untreated 
APPwt control) (Fig. 3.37 B). It should be explained that DAPT did not influence the 
MTT reduction potential of control cells. In order to prove that the results were not 
due to increased proliferation rates of APPwt and APPsw PC12 cells, cell numbers 
were counted after incubation (data not shown). The proliferation rates in the first 
three days were low, with similar results for all clones. But at an incubation for 5d, 
poliferation rates had to be taken into account for the calculation of the results. Results
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Figure 3.37: The -secretase inhibitor DAPT increases mitochondrial viability in PC12 cells.
A) PC12 cells were treated with DAPT (0.25-1.0 µM) for 24h. B) PC12 cells were treated with DAPT (0.25-1.0 µM) 
for 48h. Mitochondrial viability increases significantly in APPsw cells (1.0 µM), and in APPwt PC12 cells (0.5, 1.0 
µM) after 48h exposure to DAPT. One-way ANOVA: ***p<0.001, posthoc t test: *p<0.001 vs. APPsw baseline 
control, 
+p<0.001 vs. APPwt baseline control. Data are shown as means ± SEM of 3-5 independent experiments. 
Dotted line represents 100% baseline of control cells.
In order to exclude that the increase in MTT reduction potential is a cell-type specific 
process and not directly linked to DAPT, we treated APPwt, APPsw and control HEK 
cells  with  concentrations  ranging  from  0.25  to  1.0  µM  for  48h  (Fig.  3.38). 
Simultaneously, MTT reduction potential increased significantly in APPsw HEK cells 
(p<0.05 vs. untreated APPsw baseline control) after 48h treatment.
Figure 3.38: The -secretase inhibitor DAPT increases mitochondrial viability in APPsw HEK cells.
HEK  cells  were  treated  with  DAPT  (0.25- 1.0  µM)  for  48h  and  MTT  reduction  potential  was  measured. 
Mitochondrial viability increased significantly in APPsw cells (1.0 µM). One-way ANOVA: ***p<0.001, posthoc t
test: *p<0.001 vs. APPsw baseline control. Data are shown as means ± SEM of 5 independent experiments. 
Dotted line represents 100% baseline of control cells.
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The increase in MTT reduction potential could be directly linked to the A-reducing
properties  of  the  -secretase  inhibitor  DAPT,  which  indicates  tha  the inhibition  of 
enzymes  involved  in  the  processing  of  APP  are  promising  targets  for  AD.  The 
development of -secretase inhibitors lead to structurally distinct substances, all of 
which  possess  A-reducing  properties,  but  differ in  the  degree  of  their  toxic  side 
effects.  Thus,  a  structurally  distinct  -secretase  inhibitor,  L-685458,  was 
characterized by its effect on the MTT reduction potential (Fig. 3.39). L-685458 is 
widely described in literature as a transition-state analogue of -secretase, supposed 
to  bind  to  -secretase  in  a  highly  specific  manner  (Funamoto,  S.,  Morshima-
Kawashima,  M.  et al.,  2004;  Kornilova,  A. Y.,  Das,  C.  et  al.,  2003; Lewis,  H.  D., 
Revuelta, B. I. P. et al., 2003). In contrast to DAPT, we found a decrease in MTT 
reduction after L-685458 treatment.
Figure 3.39: The -secretase inhibitor L-685458 significantly decreases MTT reduction potential in HEK 
cells. 
Treatment with L-685458 (0.1-1.0 µM) for 48h. One way ANOVA: p<0.0001, posthoc t test revealed a significant 
decrease in MTT reduction in APPsw at 0.5 µM (**p<0.01 vs. APPsw baseline control) and 1.0 µM (*p<0.05 vs. 
APPsw baseline control) and in APPwt HEK cells at 0.5 µM (
++p<0.01) and 1000 nM (
+p<0.05) vs. untreated 
baseline control. Data are shown as means ± SEM of 5 independent experiments. Dotted line represents 100% 
baseline of control cells.
This result demonstrates that in the case of the -secretase inhibitor L-685458, the 
toxic  side  effects  monitored  by  a  decrease  of  the  MTT  reduction  potential  beat 
beneficial effects mediated by the reduction of A levels.
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3.4.1.2 Secreted A levels
The  functional  -secretase  inhibitor  DAPT  dose-dependently  reduces  A levels in 
plasma, CSF and brains of Tg2576 mice (Lanz, T. A., Himes, C. S. et al., 2003b) and 
in  rat  cortical  neurons  (Kienlen-Campard,  P.,  Miolet,  S.  et  al.,  2002).  In  order  to 
determine  A secretion  levels,  we  exposed  APPsw  and  APPwt  PC12  cells  to 
increasing  concentrations  of  DAPT  (0.1-1.0  µM)  for  24h  (Fig.  3.40  A+B).  Under 
baseline conditions, APPsw PC12 cells secrete significantly higher A1-40 levels than 
control cells (p<0.05 vs. control, Fig. 3.1) and APPwt PC12 cells (p<0.05 vs. APPwt 
control, Fig. 3.1). A1-40 secretion of APPsw PC12 cells decreased significantly in a 
dose-dependent  pattern  (p<0.01,  p<0.001  vs.  untreated  APPsw  baseline  control) 
(Fig. 3.40 B), while secreted A1-40 levels of APPwt PC12 cells remained unaffected. 
We speculate  that  this  is  due  to  the  very  low  A1-40 of  APPwt  PC12  cells,  thus 
rendering it impossible to achieve any further decrease in secretion levels by DAPT 
treatment (Fig. 3.40 A).
Figure 3.40: DAPT decreases secreted A1-40 levels in APPsw PC12 cells in a concentration-dependent 
manner.
PC12 cells were treated with increasing concentrations of DAPT (0.1-1.0 µM) for 24h. Culture supernatants were 
collected and assayed for A1-40 by ELISA technique. A) A1-40 levels of APPwt PC12 cells after exposure to 
DAPT (0.1-1.0 µM, 24h). B) A1-40 levels of APPsw PC12 cells after exposure to DAPT (0.1-1.0 µM, 24h). One-
way ANOVA: ***p<0.001, posthoc t test: **p<0.01, ***p<0.001 vs. APPsw baseline control. Data are shown as 
means ± SEM of 3 independent experiments. 
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Therefore, a similar experimental setting was used for APPwt and APPsw HEK cells. 
DAPT significantly decreased both secreted A1-40 and A1-42 in APPwt and APPsw 
HEK cells (Fig. 3.41 A+B, Fig. 3.42 A-D). 4h treatment with 0.25 µM DAPT did not 
lead to a decrease in A1-40 levels. The treatment  with 1.0 µM DAPT significantly 
reduced  A1-40 in  both  cell  lines  (p<0.001  vs.  corresponding  untreated  baseline 
control)  (Fig.  3.41  A+B).  Secreted  A1-42 was  not  detectable  after  4h  in  culture 
supernatants of APPwt and APPsw HEK cells. In more detail, we oberved a tenfold 
reduction in APPwt (Co: 112pg/ml vs. 15 pg/ml) and a 24fold reduction (Co: 486 
pg/ml vs. 22pg/ml) of secreted A1-40 in APPsw HEK cells after DAPT treatment (1.0 
µM).
Figure 3.41: DAPT treatment (4h) decreases secreted A1-40 levels in a concentration-dependent manner.
A) Treatment of APPwt HEK with DAPT (0.25, 1.0 µM) for 4h. B) Treatment of APPsw HEK with DAPT (0.25, 1.0 
µM) for 4h. Culture supernatants were collected after 4h incubation and assayed for A1-40 by ELISA technique. 
One-way ANOVA: ***p<0.001, posthoc t test: ***p<0.001 vs. control (Co), Data are shown as means ± SEM of 3 
independent experiments. 
In the following, we determined secreted A1-40 and A1-42 in APPwt and APPsw HEK 
cells after 24h exposure to DAPT (Fig. 3.42 A-D). Treatment of APPwt HEK cells with 
0.25 µM DAPT for 24h lead to a significant (p<0.01 vs. untreated baseline control) 
decrease in secreted A1-40 levels, while A1-42 levels remained unaltered (Fig 3.42 
A+B). APPwt HEK cells showed a significant (p<0.001 vs. untreated baseline control) 
reduction of both A1-40 and A1-42 at 1.0 µM DAPT. Generally, secretion of A1-40
was inhibited to a higher extent than the secretion of A1-42 in APPwt HEK cells. The 
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inhibition  of -secretase  by  DAPT  (0.25,  1.0  µM)  in  APPsw  HEK  cells completely 
abolished  both  A1-40 and  A1-42 secretion.  By  DAPT  treatment  for  another  24h, 
secreted A levels remained equally low in APPsw and APPwt HEK cells (data not 
shown).  Concluding,  the  -secretase  inhibitor  DAPT  blocks  A1-40 and  A1-42
secretion to a higher extent in APPsw than APPwt HEK cells. We may assume that 
the reduction of A1-40 and A1-42 secretion as an early event achieved by -secretase 
inhibition explains the increase in MTT reduction potential (Fig. 3.38).Results
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Figure 3.42: DAPT treatment (24h) strongly decreases secreted A1-40 and A1-42 levels in APPsw HEK 
cells.
A) Secreted A1-40 levels after treatment of APPwt HEK with DAPT (0.25, 1.0 µM) for 24h. B) Secreted A1-42
levels after treatment of APPwt HEK with DAPT (0.25, 1.0 µM) for 24h. C) Secreted A1-40 levels after treatment 
of APPsw HEK with DAPT (0.25, 1.0 µM) for 24h. D) Secreted A1-42 levels after treatment of APPsw HEK with 
DAPT (0.25, 1.0 µM) for 24h. Culture supernatants were collected after 24h incubation and assayed for A1-40 and 
A1-42. One-way ANOVA: ***p<0.001, posthoc t test: *p<0.05, **p<0.01,***p<0.001 vs. untreated baseline control 
(Co), Data are shown as means ± SEM of 3 independent experiments. 
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In order to further characterize the decrease in secreted A1-40 and A1-42 caused by 
-secretase inhibtion, the effects of the structurally distinct inhibitor L-685458 on A
secretion, APPwt and APPsw HEK cells were investigated. HEK cells were exposed 
to varying concentrations of L-685458 for 24h (Fig. 3.43 A-D). Most interestingly, L-
685458 induced a significant (p<0.05 vs. untreated baseline control) increase in A1-
40 and A1-42 at low concentrations (Fig. 3.43 A+B); A1-40 and A1-42 secretion was 
reduced  significantly  at  higher  concentrations  (0.25  µM:  p<0.05,  p<0.01;0.5  µM: 
p<0.001  vs.  untreated  baseline  control)  in  APPwt  HEK  cells.  Consequently,  the 
concentration-dependent  increase  in  secretion  was  more  pronounced  for  A1-42. 
Interestingly,  the  significant  reduction  of  secreted  A1-42 required  equal 
concentrations as for A1-40 reduction. In contrast to the situation in APPwt HEK cells, 
L-685458 did not induce enhanced secretion of both A1-40 and A1-42 in APPsw HEK 
cells (Fig. 3.43 C+D). A1-40 levels were significantly lowered at 0.25 µM (p<0.01 vs. 
untreated baseline control) and 0.5 µM (p<0.001 vs. untreated baseline control) (Fig. 
3.43 C). A1-42 secretion was more sensitive to -secretase inhibition by L-685458, as 
0.02 µM significantly reduced A1-42 secretion levels (p<0.001 vs. untreated baseline 
control) (Fig. 3.43 D). It was a very intriguing finding that the -secretase inhibitor L-
685458 differently modulates secreted A1-40 and A1-42 levels in APPwt and APPsw 
HEK cells. This would speak for distinct ways of APPsw and APPwt processing and 
A production thereof, a phenomenon which will need further discussion.Results
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Figure 3.43: L-685458 time- and dose-dependently decreases secreted A1-40 and A1-42 levels in APPsw 
and APPwt HEK cells.
A) Secreted A1-40 levels after treatment of APPwt HEK with L-685458 (0.02-0.5 µM) for 24h. B) Secreted A1-42
levels  after  treatment  of  APPwt  HEK  with  L-685458  (0.02-0.5  µM)  for  24h.  C)  Secreted  A1-40 levels  after 
treatment of APPsw HEK with L-685458 (0.02-0.5 µM) for 24h. D) Secreted A1-42 levels after treatment of APPsw 
HEK with L-685458 (0.02-0.5 µM) for 24h. Culture supernatants were collected after incubation and assayed by 
ELISA. One-way ANOVA: ***p<0.001, posthoc t test: **p<0.01,***p<0.001 vs. untreated baseline control (Co). 
Data are shown as means ± SEM of 3 independent experiments. 
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3.4.1.3 Intracellular APP, secreted APP, CTFs and A
It is generally  stated  that the  -secretase  inhibitor  DAPT  does not influence  APP 
expression and secretion in rat cortical neurons (Dovey, H. F., John, V. et al., 2001). 
Here, we show that high concentrations (1.0 µM, Fig. 3.26 A+B), in contrast to lower 
concentrations (0.25 µM, Fig. 3.44), modulate APP processing in stably transfected 
HEK cells. Cell lysates and culture supernatants of APPwt, APPsw and control cells 
were  collected  after  treatment  with  DAPT  and  subjected to western  blot analysis. 
Generally, intracellular CTFs (namely C83, 6 kDa) increased during DAPT treatment. 
Due to the sensitivity of the antibody W-02, secreted A (4 kDa) was detectable in 
the culture supernatants of APPsw HEK cells, but not in supernatants of APPwt and 
control HEK cells (Fig. 3.44, 3.45 A+B). Treatment of APPwt, APPsw and control 
cells with 0.25 µM DAPT for 24 and 48h did not affect the secretion of sAPP (96 
kDa). In contrast to this, A secretion was lowered markedly as no extracellular A
was  detected in  the  culture  supernatant  of  APPsw  HEK  cells.  Expression  of  full-
length APP (116 kDa) increased slightly in a time-dependent manner after 24 and 
48h DAPT treatment. 
Figure 3.44: DAPT treatment (0.25 µM) time-dependently increases intracellular APP and CTF levels.
APPwt, APPsw and control HEK cells were treated with DAPT (0.25 µM) for 24 and 48h. Culture supernatants 
and whole cell lysates were collected after incubation and subjected to western blot analysis. Intracellular full-
length APP (116 kDa) and CTFs increased, while secreted A levels decreased after 24 and 48h.
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We could show before that DAPT treatment (1.0 µM) significantly increased MTT 
reduction potential  of both PC12  and HEK cells. It was  of interest whether  other 
effects  on  APP  processing,  besides  the  inhibition  of  A formation  and  secretion, 
could  be  related  to  the  increase  in  MTT  reduction  by  DAPT  treatment.  After  4h 
exposure to DAPT (1.0 µM), secreted sAPP levels (96 kDa) slightly decreased in 
APPwt  and  APPsw  HEK  cells.  But  again,  it  came  to  a  slight  accumulation  of 
intracellular, full-length APP (116 kDa) (Fig. 3.45 A). Prolonged DAPT treatment for 
48h lead to reduction of secreted A and intracellular accumulation of CTFs. Of note, 
a drastic reduction not only of secreted sAPP (96 kDa), but also of intracellular full-
length  APP  (116  kDa)  was  observed  (Fig.  3.45  B).  These  findings  indicate  that 
altered  APP  processing,  in  a  more  generalized  manner,  might  be  modulated  by 
DAPT. Eventually, altered APP trafficking could result in alterations of full-length as 
well as secreted APP.Results
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Figure 3.45: DAPT modulates intracellular APP levels.
APPwt,  APPsw  and  control HEK  cells  were  treated  with  DAPT  (1.0  µM)  for  4h  (A)  and  48h  (B).  Culture 
supernatants and whole cell lysates were subjected to western blot analysis.
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3.4.2 -secretase inhibitors
3.4.2.1 Mitochondrial activity
It is widely known that peptidic -secretase inhibitors are toxic due to their unspecific 
side  effects  (Citron,  M.,  2002).  As  an  example  for  the  general  characteristics  of 
peptidic  -secretase  inhibitors,  we  chose  the  -secretase  inhibitor  II  in  order  to 
demonstrate that the MTT reduction potential mirrors the toxicity of the substance in 
cell culture. HEK cells were exposed to -secretase inhibitor II for 48h (Fig. 3.46). 
Concentrations of 2.5 µM and higher were exceedingly toxic to APPsw (p<0.001 vs. 
untreated baseline control) and APPwt (p<0.001 vs. untreated baseline control) HEK 
cells. Furthermore, we examined lower concentrations of the -secretase inhibitor II 
as well as shorter incubation periods without observing significantly increased MTT 
reduction levels in APPwt and APPsw HEK cells (data not shown).
Figure 3.46: The -secretase inhibitor II significantly reduces MTT reduction potential of APPwt, APPsw 
and control HEK cells.
Treatment of APPwt and APPsw and control HEK cells with -secretase inhibitor II (0.5-10 µM) for 48h. One-way 
ANOVA: p<0.001, posthoc t test revealed a significant decrease in MTT reduction at concentrations above 2.5 µM 
in APPsw  (***p<0.001)  and  APPwt (
+++p<0.001)  HEK  cells  vs. corresponding  untreated  baseline  controls. All 
values represent the means  SEM from 3-5 experiments, each experiment performed in triplicates. Dotted line 
represents 100% baseline of control.
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3.4.2.2 A secretion levels
HEK cells were exposed to -secretase inhibitor II for 24h and culture supernatants 
were assayed for secreted A1-40 and A1-42 (Fig. 3.47 A-C). Treatment of APPwt 
HEK cells exposed to -secretase inhibitor II (0.5-10 µM) revealed no effect on A1-40
secretion. Paradoxically, A1-42 levels significantly (p<0.001 vs. untreated baseline 
control) increased in a concentration-dependent pattern under the same treatment 
conditions (Fig. 3.47 B). In APPsw HEK cells, exposure to -secretase inhibitor II 
results in an unimportant increase in secreted A1-40 levels at concentrations ranging 
from 0.5-5 µM (Fig. 3.47 C). A similar effect was observed on A1-42 secretion levels 
at  0.5  µM  (Fig.  3.47  D).  But  also,  secreted  A1-40 was  significantly  (p<0.001  vs. 
untreated  baseline  control)  reduced  after  24h  treatment  with  10  µM  -secretase 
inhibitor II.Results
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Figure 3.47: Treatment of APPsw HEK cells with the -secretase inhibitor II (10 µM) leads to decreased 
secreted A1-42.
APPwt and APPsw HEK cells were treated with various concentrations of the  -secretase inhibitor II (0.5-10 µM) 
for 24h. Culture supernatants were collected and assayed by ELISA. A) Determination of secreted A1-40 levels in 
APPwt HEK cells. B) Determination of secreted A1-42 levels in APPwt HEK cells. C) Determination of secreted 
A1-40 levels in APPsw  HEK  cells.  D) Determination  of secreted  A1-42 levels in APPsw  HEK  cells. One-way 
ANOVA: p<0.0001, posthoc t test: p<0.001 vs. Co.All values represent the means  SEM from 3-6 experiments, 
each experiment performed in duplicates.
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3.4.3 Growth factor modulators
3.4.3.1 KP544 protects against oxidative injury
In order to investigate the effect of KP544 on cellular viability during oxidative insult, 
we treated PC12 cells with hydrogen peroxide (H2O2). Interestingly, already under 
baseline  conditions,  KP544  showed  protective  effects  on  APPsw  PC12  cells  by 
significantly increasing the cellular ability to reduce MTT (Fig. 3.48) suggesting that 
the  drug  is  able  to  protect  against  the  toxicity  of  chronic  A exposure.  After  6h 
treatment with H2O2 (500 µM), mitochondrial activity was very strongly decreased. 
Even under this condition of extreme disruption of MTT reduction, KP544 (0.01 µM) 
exhibited a significant protective effect on viability of control (p<0.05) as well as on 
APPsw (p<0.001) PC12 cells.
Figure 3.48: KP544 protects undifferentiated PC12 cells against H2O2 insult.
APPsw and control PC12 cells were treated with H2O2 (250 or 500 µM) in the presence or absence of KP544 
(0.01 µM) for 6 hours. Two-way ANOVA revealed a significant difference between cell types (p<0.001) and a 
significant effect of the KP455 treatment (p<0.001), posthoc t test: *p<0.05, **p<0.01 vs. corresponding control 
without KP544. All values represent the means  SEM from 3-4 experiments, each experiment performed in 
triplicates.
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3.4.3.2 KP544 protects differentiated cells against growth factor withdrawal
In order to investigate the effect of KP544 on cellular viability during trophic factor 
withdrawal, we treated PC12 cells with increasing concentrations of KP544 (0.001 
µM, 0.01 µM, 1.0 µM) for 3 days (Fig. 3.49 A-C). Notably, already under conditions in 
the presence of NGF (50ng/ml), KP544 did promote cellular survival of both, control 
and APPsw cells. This effect is strongest pronounced at a concentration of 1.0 µM, 
but is already present at a concentration as low as 0.001 µM indicating that KP544 
can enhance NGF activity on differentiated PC12 cells. Moreover, KP544 was able to 
enhance mitochondrial activity under conditions of NGF withdrawal in control as well 
as  in APPsw  cells (Fig. 3.49  A-C).  Again,  the  strongest  increase in the  ability  to 
reduce MTT was at a concentration of 1.0 µM KP544. In this experimental design, 
KP544  exhibited  an  1.7fold  increase  of  MTT  reduction  in  control  and  a  2.5  fold 
increase in APPsw cells thereby enhancing mitochondrial activity of these cells that 
suffer from NGF withrawal up to the level of control PC12 with NGF in the medium 
(Fig. 3.49 C). Again, APPsw cells seem to specifically benefit of the effects of KP544.Results
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Figure  3.49:  KP544  protects  fully  differentiated  PC12  cells  against  trophic  factor  withdrawal  in  a 
concentration-dependent manner.
Terminally differentiated PC12 cells were treated with increasing concentrations of KP544 - 0.001µM (A), 0.01 µM 
(B), 1.0 µM (C) - for 3 days in the presence or absence of NGF. A) Treatment with 0.001 µM KP544. Two-way 
ANOVA revealed a significant difference between cell types (p<0.05) and a significant KP544 treatment effect 
(p<0.001). B) Treatment with 0.01 µM KP544. Two-way ANOVA revealed a significant difference between cell 
types (p<0.01) and a significant KP544 treatment effect (p<0.001) C) Treatment with 1.0 µM KP544. Two-way 
ANOVA revealed a significant difference between cell types (p<0.001) and a significant KP544 treatment effect 
(p<0.001). A-C) posthoc t test: *p<0.05, **p<0.01, ***p<0.001 vs. corresponding control without KP544. All values 
represent the means  SEM from 4-7 experiments, each experiment performed in triplicates. 
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3.4.3.3 KP544 modulates the phosphorylation status of GSK-3 
Previously, it has been shown that NGF-induced neurite outgrowth of PC12 cells is 
about twofold enhanced with KP544 treatment (Fyfe, J. A., Beauchamp, L. M. et al., 
2004). Moreover, this study suggested that KP544 functions within the cell at a site 
that  is  downstream  from  or  independent  of  mitogen-activated  protein  kinases 
(MAPK), since expression levels of ERK1/2 did change after NGF treatment for 30 
min or 48h, but no additional effect of KP544 could be detected. In agreement with 
this observation, we did not find a specific effect of KP544 on expression levels of 
MEK1/2  (MAP-kinase-kinase),  which  acts  upstream  of  ERK1/2  (data  not  shown). 
Since evidence is provided that the PI 3-K-Akt-GSK-3 pathway is involved in and 
seems  to  be  even  more  important  for  neurite  extension  than  the  MAPK  pathway 
(Baki,  L.,  Shioi,  J.  et  al.,  2004),  we  investigated  GSK-3 expression  and 
phosphorylation. Therefore, we treated control and APPsw PC12 cells with NGF (50 
ng/ml) or with a combination of NGF and KP544 (1.0 µM) for 1 hour and for 48 hours 
(Fig. 3.50 A+B). In general, the expression and the phosphorylation status of GSK-3
were increased after 48 hours of incubation (Fig. 3.50 A). The expression levels of 
unphosphorylated  GSK-3 did  not  alter  between  APPsw  and  control  PC12  nor 
between  treatment  groups.  The  phosphorylation  at  Ser9  of  GSK-3 leads  to  an 
inactivation of the enzyme, resulting in the activation of pathways that are normally 
repressed  by  GSK-3.  GSK-3 activation  is  involved  in  neurodegenerative 
processes,  an  inactivation  of  this  enzyme  might  be  beneficial  to  mitochondrial 
acitivity, cellular viability and neurite growth. Of note, when cells were exposed to 
NGF for 1h, there was a slight increase in phospho- GSK-3 levels. Treatment with a 
combination  of  KP544  (1.0  µM)  and  NGF  (50  ng/ml)  for  1  hour  seems  to  have 
synergistic  effects,  specifically  in  APPsw  cells  phosphorylation  at  Ser9  increased 
significantly (p<0.05) compared to untreated APPsw control cells (Fig. 3.50 B). In 
addition, we observed an increased phosphorylation status (p<0.001) of GSK-3 of 
control cells and APPsw PC12 cells in all treatment groups after 48 hours compared 
to 1 hour exposure (Fig. 3.50 B), but no additional effects of KP544 to the action of 
NGF alone possibly due to the fact that maximum expression levels were reached. 
Interestingly, in all conditions, GSK-3 phosphorylation was significantly decreased in Results
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APPsw cells compared to control PC12 cells (Fig. 3.50 B) (Two-way ANOVA: p<0.05 
between cell types).
1 h 48 h
Co sw Co sw Co sw
A
Co sw Co sw
NGF NGF NGF
+
KP544
NGF
+
KP544
untreated
control
GSK 3ß 46 kDa
phospho-GSK 3ß 46 kDa
B
0
50
100
150
200
250
300
350
Co + K P 544
A P P sw + K P 544
*
Co
A P P sw
O
D
 
(
%
)
p
h
o
s
p
h
o
-
G
S
K
 
3
ß
NGF NGF NGF
+
KP544
NGF
+
KP544
untreated
control
1h 24h
Figure 3.50: Expression levels and phosphorylation status of GSK-3.
APPsw and control PC12 cells were treated with NGF (50 ng/ml) or NGF (50 nM) in combination with KP544 (1 
µM) for one hour and for 48 hours. A) Western blot analysis of GSK-3 and phospho-GSK-3 expression. B) 
Densiometric analysis of bands of phosphorylated GSK-3. Two-way ANOVA revealed a significant difference 
between cell types (p<0.05), posthoc t test: *p<0.05 vs. untreated APPsw control cells. All values represent the 
means  SEM. from 4-6 experiments.Results
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3.4.3.4 KP544 decreases the secretion of A1-40 in APPsw PC12 cells
Recent studies have shown that that GSK-3 interacts with and binds presenilin, a 
component of the high molecular weight -secretase complex that cleaves APP, in 
normal human brains and cells (De Ferrari, G. V., Inestrosa, N. C., 2000). Although 
GSK-3 is known to be involved in tau phosphorylation, its role in APP processing is 
poorly  understood.  Interestingly,  GSK-3 inhibitors,  like lithium,  abolished  GSK-3-
mediated A increase and reduced plaque burden in APP transgenic mice (Su, Y., 
Ryder, J. et al., 2004). In our cell model, the Swedish double mutation leads to a 
significantly increased secretion of Aß1-40 when compared to control cells (Keil, U., 
Bonert, A. et al., 2004). We treated APPsw PC12 cells with NGF (50 ng/ml), KP544 
(1.0  µM)  and  a  combination  of  both  for  48  hours  (Fig.  3.51).  A1-40 levels  were 
significantly  reduced  by  NGF  treatment  (p<0.05).  Of  note,  KP544  treatment  even 
reduced A1-40 levels to a higher extent (p<0.01) (NGF: 43% reduction; KP544: 57% 
reduction).  The  combined  treatment  with  KP544  and  NGF  showed  no  further 
reduction  of  A1-40 suggesting  that  NGF  and  KP544  act  synergistically  but  not 
additively on APP processing pathway in this experimental setting. Results
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Figure 3.51: KP544 reduces levels of secreted A1-40 in APPsw PC12 cells.
APPsw PC12 were treated with KP544 (1.0 µM), NGF (50 nM) or a combination of both for two days. Medium 
was  collected  and  analysed  by A1-40 ELISA.  One-way  ANOVA:  p<0.01,  posthoc  test:  *p<0.05,  **p<0.01  vs. 
untreated APPsw control. All values represent the means  SEM from 4-7 experiments.
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4 DISCUSSIONDiscussion
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4 Discussion
4.1 APP over-expression, intracellular A and APP localization, A
secretion and secretase activity
4.1.1 A secretion
Extracellular  addition  of A to cultured  neurons  or injection into  the brain  causes 
neurotoxic effects (Yankner, B. A., Dawes, L. R. et al., 1989; Geula, C., Wu, C. K. et 
al., 1998). However, it is difficult to discern cause-effect relationships from such data, 
especially in view of the nonspecific actions of the applied high-dosage A on cells or 
isolated mitochondria (Pereira, C., Santos, M. S. et al., 1998; Canevari, L., Clark, J. 
B. et al., 1999; Casley, C. S., Canevari, L. et al., 2002b). Concerning experiments on 
isolated mitochondria, one should not leave out of sight that interactions with other 
organelles,  which  might  be substantial  for  the investigated processes,  are lacking 
(cross talk of mitochondria and ER, e.g.). Hypothesizing that at low levels, A would 
seek  out  specific  cellular  targets  such  as  the  Receptor  for  Advanced  Glycation 
Endproducts (RAGE) as a multiligand receptor (Yan, S. D., Chen, X. et al., 1996b; 
Schmidt,  A.  M., Hori, O.  et al., 1996;  Yan,  S.  D., Chen,  X.  et al., 1996a), these 
specific interactions would not be detectable in isolated mitochondria.
Therefore, we used transfected cell lines expressing APPwt and APPsw as a model 
of investigation, offering the advantage to study chronic, dose-dependent effects of 
APP  and  A from  the  picomolar  to  the  nanomolar  range.  These  cell  lines,  first 
characterized by their A1-40 and A1-42 secretion levels, are a valuable tool to study 
AD-related alterations reflecting different stages of the disease. PC12 cells secrete 
low A levels reflecting the physiological situation in brains of patients suffering from 
sporadic AD (Scheuner, D., Eckman, C. et al., 1996; Selkoe, D. J., 2002). In contrast 
to this, APPsw HEK cells secrete extremely high, pathological levels of A which 
might reflect the situation of patients suffering from familial AD. Furthermore it has 
been stated by others that the transfection of APPsw in non-neuronal cells matches 
best with the expression of APPwt in neurons (Forman, M. S., Cook, D. G. et al., 
1997). Therefore, we additionally characterized SY5Y cells stably expressing APPwt 
as a model of reference. Since it is postulated that A can be re-internalized from the Discussion
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extracellular space into the cell body, it was surprising to find a strong variation in 
secreted A levels between the cell lines. Re-internalization of A might be partly 
dependent on the amounts secreted and might thus cause intracellular alterations in 
protein  expression  and  energy  metabolism  (for  further  discussion,  see  4.1.2). 
Consequently,  the  cell  lines  allow  us  to  study  cellular  alterations  linked  to  the 
presence of secreted A. Considering the fact that the biggest part of the AD patients 
are suffering from the sporadic form, most experiments were performed with this cell 
model.
4.1.2 Intracellular A
Most of the gene mutations that segregate with the inherited forms of AD result in 
increasing  the ratio  of  A1-42/  A1-40 production (Suzuki,  N.,  Cheung,  T. T.  et  al., 
1994). A1-42 also accumulates in neurons of AD patients (Wirths, O., Multhaup, G. et 
al.,  2004). First  evidence  for intracellular  A was  reported  by  Wertkin  et  al.  who 
observed intracellular A in a differentiated neuronal cell line (Wertkin, A. M., Turner, 
R. S. et al., 1993). A more detailed analysis of NT2N neurons showed substantial 
amounts of A1-40 and A1-42 at a ratio of 3 : 1 in cell lysates, whereas analysis of 
secreted forms yielded a ratio of 20 : 1 for A1-40: A1-42 (Turner, R. S., Suzuki, N. et 
al., 1996).
Intraneuronal A deposition in the hippocampus was described in transgenic mice 
expressing APP with the Swedish mutation (Shie, F. S., LeBoeur, R. C. et al., 2003). 
Takahashi  et  al.  used  immunoelectron  microscopy  to  determine  the  subcellular 
localization of A. They could show that intraneuronal A1-42 in APP-transgenic mice 
accumulated predominantly in multivesicular bodies (MVBs) within presynaptic and 
postsynaptic compartments, as well as in human AD brains. This accumulation was 
associated  with  an  altered  synaptic  morphology,  which  preceded  extracellular 
amyloid plaque deposition (Takahashi, R. H., Nam, E. E. et al., 2002). In accordance 
with these findings it has been previously shown that intraneuronal A accumulation 
precedes plaque formation in transgenic mice expressing mutant APP695 with the 
Swedish,  Dutch  and  London  mutations  in combination  with  mutant  presenilin-1. 
These mice displayed abundant intraneuronal A immunoreactivity in hippocampal 
and cortical pyramidal neurons (Wirths, O., Multhaup, G. et al., 2001). This was even 
more pronounced in a transgenic mouse model expressing the Swedish and London Discussion
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mutant  APP751  together  with  mutant  PS-1  (Blanchard,  V.,  Moussaoui,  S.  et  al., 
2003).  The  intraneuronal  immunoreactivity  declined  with  increased  plaque 
accumulation (Wirths, O., Bayer, T. A. et al., 2002). Moreover, the neuronal loss did 
not correlate with the amount of extracellularly deposited A, suggesting that high 
levels of intraneuronal A are linked to the neurotoxic effects (Schmitz, C., Rutten, B. 
P. F. et al., 2004).
A recent report described a new triple-transgenic mouse model expressing mutant 
APP in combination with mutant PS-1 and mutant tau-protein. These mice displayed 
early synaptic dysfunction before plaque or tangle deposition was evident, together 
with  early  intraneuronal  A immunoreactivity  preceding  plaque  deposition. 
Interestingly,  tau  and  A immunoreactivity  colocalized  in  hippocampal  neurons, 
implying that early intraneuronal A accumulation affects tau pathology (Oddo, S., 
Caccamo, A. et al., 2003a; Oddo, S., Caccamo, A. et al., 2003b).
A peptides are generated at different subcellular sites. Whereas A1-40 is generated 
solely  in  the  trans-Golgi  network  (TGN),  A1-42 is  generated  in  the  endoplasmic 
reticulum (ER) as well as Golgi compartments (Hartmann, T., Bieger, S. C. et al., 
1997; Xu, H. X., Sweeney, D. et al., 1997; Greenfield, J. P., Tsai, J. et al., 1999).
This  has  been  shown  by  the  retention  of  APP  in  the  endoplasmic 
reticulum/intermediate  compartment  (ER/IC),  which  leads  to  an  elimination  of 
intracellular  A1-40,  whereas  the  synthesis  of  intracellular  A1-42 was  not  affected 
(Cook, D. G., Forman, M. S. et al., 1997).Discussion
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Figure 4.1: The modified -amyoid cascade.
Scheme showing the current -amyloid hypothesis, which is based on biochemical, neuropathological, molecular-
biological and genetic evidence (taken from Wirths, 2004).
Altogether, these data strongly suggest that the neuronal production of A1-42 is a 
critical event in AD, and it has been speculated that intraneuronal A1-42 is toxic, but 
the toxicity has not been demonstrated. Kienlen-Campard et al. report that the long 
term  expression  of  human  APP  in  rat  cortical  neurons  induces  apoptosis.  They 
observed that although APP processing leads to production of extracellular A1-40
and soluble APP, these extracellular derivatives did not induce neuronal death. On 
the contrary, neurons underwent apoptosis as soon as they accumulated intracellular 
A1-42 following the expression of full-length APP or a C-terminal deleted APP isoform 
(Kienlen-Campard,  P.,  Miolet,  S.  et  al.,  2002).  Therefore  they  postulate  that  the 
accumulation  of  intraneuronal  A1-42 is  the  key  event  in  the  neurodegenerative 
process.  In  order  to  investigate  the  role of intracellular  A forms,  we  determined 
intracellular soluble and insoluble A1-40 and A1-42 in HEK cells. Generally, we found 
that intracellular A levels were extremely low in HEK cells, barely not detectable by 
the A ELISA kits used in our group (Fig. 3.4, 3.5). This fact should not be left out of Discussion
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sight during the interpretation of the following data. We observed that the amounts of 
soluble A1-40 and A1-42 were in the same range for all HEK clones (APPwt, APPsw, 
control), which could indicate a shift in the A1-42: A1-40 ratio in favour of A1-42 for 
intracellular,  soluble  A.  Intracellular,  insoluble  A1-40 was  detectable  in  APPwt, 
APPsw  and  control  HEK  cells,  whereas  insoluble  A1-42 was  only  detectable  in 
APPsw HEK cells. Thus, insoluble A1-40 and A1-42 was elevated in comparison to 
soluble  A1-40 and  A1-42 in  APPsw  HEK  cells.  Here,  the  A1-42:  A1-40 ratio  was 
clearly shifted in favour of A1-42, which lead us to the conclusion that A1-42 partly 
accumulates  intracellularly  and  forms  insoluble  aggegrates.  Furthermore,  we  may 
deduct that accumulation of intracellular, insoluble A1-42 is a pathogenic event, as it 
only occurs in APPsw HEK cells. Under baseline conditions, only APPsw HEK cells 
show decreased MTT reduction potential and decreased ATP levels (Keil, U., Bonert, 
A. et al., 2004; Bonert, A., Marques, C. et al., 2004; Marques, C. A., Keil, U. et al., 
2003) indicating  that  the  the  APPsw  mutation,  eventually  via  accumulation  of 
insoluble  intracellular  A1-42,  leads  to  disturbances  in  cellular  energy  metabolism 
resulting  in  cell  death.  This  would  be  in  accordance  with  previously  described 
findings  indicating  that  intracellular  A1-42 might  be  the  primary  toxic  species. 
Furthermore, one explanation for the low levels of soluble intracellular A1-40 and A1-
42 might  be  that  soluble  forms  do  not  accumulate  intracellularly  but  are  rapidly 
transported to the extracellular space, speaking for a relatively fast A turnover in all 
HEK cells. Discussion
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Figure 4.2: Model for the distribution of intracellular and secreted A1-40 and A1-42 in APPsw HEK cells.
Generally, intracellular soluble A1-40 and A1-42 are in the same range. In contrast to this, the A1-40/ A1-42 ratio is 
shifted in favour of A1-42 in APPsw HEK cells, and A1-40 is secreted to a higher extent than A1-42.
Besides intraneuronal A production, cellular uptake of A from the environment is a 
second  mechanism  that  contributes  to  intracellular  A accumulation.  Selective 
intracellular accumulation of A1-42 was reported in cells treated with synthetic A-
peptides. This internalization could be prevented under conditions that do not allow 
endocytosis  (Knauer,  M.  F.,  Soreghan,  B.  et  al.,  1992).  At  least  some  of  the 
internalized A accumulated in insoluble fractions and was resistant to degradation 
for  several  days  in cell  cultures  (Ida,  N.,  Masters,  C.  L.  et  al.,  1996).  This 
accumulation  and  degradation  resistance  seemed  to  be  specific  for  A1-42,  as 
internalized A1-40 and shorter peptides were eliminated with a half-life of about 1h 
(Burdick, D., Kosmoski, J. et al., 1997). The subcellular localization of internalized 
A1-42 seemed to be the endosomal/lysosomal system, where A1-42 induced a loss of 
lysosomal  impermeability  with  concomitant  membrane  damage  (Yang,  A.  J., 
Chandswangbhuvana, D. et al., 1998; Ditaranto, K., Tekirian, T. L. et al., 2001). 
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Figure 4.3: Alternative model for the distribution of intracellular and secreted A1-40 and A1-42 in APPsw 
HEK cells.
4.1.3 Mitochondrial APP and A
It  has  been  reported  recently  that  accumulation  of  full-length  APP  in  the 
mitochondrial compartment in a transmembrane-arrested form caused mitochondrial 
dysfunction  and  impaired  energy  metabolism.  APP  is  targeted  to  neuronal 
mitochondria under some physiological and pathological conditions, but its function in 
the  mitochondrial  compartment  is  still  unknown  (Anandatheerthavarada,  H.  K., 
Biswas,  G.  et  al.,  2003).  Furthermore,  as  mitochondria  may  trigger  the  abnormal 
onset of neuronal cell death in Alzheimer's disease, it is noteworthy that presenilin 1 
(PS-1), which is often mutated in familial forms of Alzheimer's disease, is located in 
mitochondria.  It  is  hypothesized  that  presenilin  mutations  may  sensitize  cells  to 
apoptotic stimuli mainly at the mitochondrial level. Also, dual targeting sequences (for 
endoplasmic  reticulum  and  mitochondria)  in  NCT  have  been  identified  by 
immunoelectron microscopy. NCT, together with APH-1, PEN-2, and PS-1 form a 
high  molecular  weight  complex  located  in  mitochondria.  -secretase  activity  in 
-secretase
-secretase
APP soluble
A1-40
soluble
A1-42
insoluble
A1-42
secreted
A1-40
secreted
A1-42
CellDiscussion
153
isolated mitochondria was demonstrated generating an APP intracellular domain, and 
the activity was inhibited by -secretase inhibitors (Hansson, C. A., Frykman, S. et al., 
2004). We could show in our own group by immunoelectron microscopy that APP is 
partly co-located with mitochondria (Keil, U., Bonert, A. et al., 2004). Here, we clearly 
demonstrated that indeed, full-length APP was present in the mitochondrial fractions 
of  PC12  and  HEK  cells.  Concluding,  our  data  corroborate  the  finding  of 
Anandatheerthavarada et al. that mitochondrial APP could potentially interact with 
transport proteins finally leading to mitochondrial dysfunction (Keil, U., Bonert, A. et 
al.,  2004;  Anandatheerthavarada,  H.  K.,  Biswas,  G.  et  al.,  2003).  As  mentioned 
above,  intracellular  A appears  to  accumulate  prior  to  the  appearance  of 
neurofibrillary tangles and senile plaques, and to be present in AD-affected areas of 
the brain. Furthermore, the toxic effects of intracellular A on cells has been shown, 
in certain cases, to exceed those of extracellular A (Kienlen-Campard, P., Miolet, S. 
et al., 2002).  These data  are  consistent  with  the relevance  of intracellular  A for 
disturbances of cellular function associated with AD. For this reason, we have sought 
possible intracellular targets of A. It was demonstrated by others that A is present 
in  the  mitochondria  of  AD  brains  and  in  brain  mitochondria  of  transgenic  mice 
(Lustbader,  J.  W.,  Cirilli,  M.  et  al.,  2004).  The  issue  is  extensively  discussed  in 
literature  since  it  has  been  demonstrated  that  A-binding  alcohol  dehydrogenase 
(ABAD) is a direct molecular link from A to mitochondrial toxicity. These data were 
consistent  with previous  work  (Yan,  S.  D., Roher, A.  et al.,  2000), demonstrating 
enhanced  expression  of  ABAD  in AD  brain  by immunoblotting  with an anti-ABAD 
antibody. A interacts with ABAD in the mitochondria of AD patients and transgenic 
mice. The crystal structure of A-bound ABAD revealed a substantial deformation of 
the  active  site  that  prevents  nicotinamide  adenine  dinucleotide  (NAD)  binding. 
Furthermore,  transgenic  mice  overexpressing  ABAD  in  an  A-rich  environment 
manifest exaggerated neuronal oxidative stress and impaired memory. 
The beneficial effects of ABAD on cellular functions under physiological conditions 
might be related to its sequestration of cyclophilin D in the mitochondrial matrix. By 
maintaining  cyclophilin  D  in  the  matrix  compartment,  this  chaperone  molecule  is 
unable to translocate to the inner mitochondrial membrane, where it could interact 
with  other  components  of  the  MPT  and,  potentially,  destabilize  mitochondrial 
function. Taken together, these data are consistent with cytoprotective properties of Discussion
154
ABAD in health and disease. In an environment rich in A, the protective properties 
of ABAD appear to be negated. Crystallographic studies demonstrated deformation 
of ABAD with loss of the NAD-binding site and a marked change in the enzyme’s 
catalytic  site.  These  structural  changes  were  associated  with  inhibition  of  ABAD 
activity towards its diverse substrates. This leads to the hypothesis that decreased 
ABAD activity has negative effects on brain energetics and, possibly, other functions. 
For  example,  decreased  ABAD  activity  might  result  in  accumulation  of  toxic 
metabolites  that  could  have  deleterious  effects.  In  addition,  ABAD–A interaction 
might displace cyclophilin D, resulting in its translocation to the inner mitochondrial 
membrane (Yan, S. D., Stern, D. M., 2005). Others have hypothesized that loss of 
ABAD’s  activity  as  a  hydroxysteroid  dehydrogenase  might  alter  metabolism  of 
estrogenic hormones involved in neuroprotection (He, X. Y., Merz, G. et al., 1999). 
These findings gave rise to the question whether full-length APP is further processed 
to A in the mitochondrial compartment. The orientation of APP in the mitochondrial 
membrane  leaves room  to the question  whether  A is released into  the cytosolic 
compartment or accumulates in mitochondria. Our results obtained by ELISA provide 
evidence that A1-40 is present in the mitochondrial compartment of APPsw HEK cells 
(Fig. 3.8). Analysis of mitochondrial fractions of SY5Y and PC12 cells did not show 
similar results, which is not surprising since secreted A1-40 levels are significantly 
lower than that of HEK cells. Thus, we may deduct that for PC12 and SY5Y cells, 
mitochondrial A is beyond the detection limit of the ELISA kit. The finding that A1-40
is found in the mitochondrial compartment of APPsw HEK cells is in accordance with 
the  above-mentioned  findings,  indicating  that  in  HEK  cells,  APP-processing 
secretases might be targeted to the mitochondria (Hansson, C. A., Frykman, S. et al., 
2004). Furthermore, it has been shown that the N-terminus of APP is directed to the 
mitochondrial  matrix,  allowing  secretases  to  correctly  process  APP.  As  a 
consequence, A could be located in the mitochondrial matrix, potentially interacting 
with ABAD thus further promoting the generation of oxidative stress and failure of 
mitochondrial energy metabolism.Discussion
155
Oxidative stress
cell death
Mitochondrion -secretase
A ABAD
APP
C-terminus
Figure 4.4: Hypothetical model for the impact of APP- and A-mediated mitochondrial dysfunction.
Evidence  is  provided  for  the  existence  of  -secretase  in  the  mitochondrial  fraction.  Thus,  mitochondrially 
processed A might interact with ABAD contributing to enhanced levels of oxidative stress and cell death.
4.1.4 A species and neurotoxicity
Genetic and pathological evidence strongly supports the amyloid cascade hypothesis 
of  AD,  which  states  that  A,  a  proteolytic  derivative  of  the large  transmembrane 
protein amyloid precursor protein (APP), has an early and vital role in all cases of AD. 
A forms  aggregates  that  are  thought  to initiate  the  pathogenic  cascade,  leading 
ultimately to neuronal loss and dementia (Hardy, J., Selkoe, D. J., 2002). Although 
A is constitutively produced, for a long time it was assumed that only A that is 
deposited in compact neuritic plaques is neurotoxic. Nevertheless, there is increasing 
evidence  that  A oligomers  contribute  significantly  to  the  pathological  alterations 
underlying  memory  failure  in  AD.  This  oligomerization  was  observed  to  occur 
intracellularly (Walsh, D. M., Klyubin, I. et al., 2002; Walsh, D. M., Tseng, B. P. et al., 
2000) and  A1-42 oligomers  turned  out  to  be  potent  neurotoxins  in  neuronal 
organotypic cultures at nanomolar concentrations (Lambert, M. P., Barlow, A. K. et Discussion
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al.,  1998).  These  oligomers  (also  referred  to  as  ADDLs,  for  A-derived  diffusible 
ligands)  are further  able  to inhibit hippocampal long-term  potentiation  and disrupt 
synaptic plasticity (Lambert, M. P., Barlow, A. K. et al., 1998; Walsh, D. M., Klyubin, I. 
et al., 2002). Using antibodies against synthetic A oligomers, these ADDLs have 
been found in brains of AD patients in concentrations up to 70fold higher than in 
control  brains  (Gong,  Y.,  Chang,  L.  et  al.,  2003).  These  A1-42 oligomers  were 
observed  within  abnormal  processes  and  synaptic  compartments  in  human  AD 
brains (Takahashi, R. H., Almeida, C. G. et al., 2004). Dimeric A peptides further 
rapidly accumulate in lipid rafts and were detected as sodium dodecyl sulfate soluble 
forms  in  brain  tissue  of  APP  transgenic  mice.  This  begins  as  early  as  memory 
impairments  become  obvious,  providing  a  further  link  to  the  assumption  that  A
oligomers are tightly linked to memory dysfunction in AD (Kawarabayashi, T., Shoji, 
M. et al., 2004). Investigating the formation of A dimers and oligomers, an important 
observation was that APP-APP interactions can occur via the carbohydrate domain 
of  the  amyloid  precursor  protein.  The  physiological  significance  of  APP-APP 
interactions remain to confirmed, since it is not understood whether and how APP 
dimerization  occurs  in  vivo  (Scheuermann,  S.,  Hambsch,  B.  et  al.,  2001).  It  was 
additionally found that cellular APP exists as homodimers matching best with a two-
site model. The generation of stabilized dimers by expressing mutant APP  with a 
single cysteine in the ectodomain juxtamembrane region and the mutation of Lys624 
to cysteine produced similar to 6-8fold more A than cells expressing normal APP. 
These results suggest that A production can in principle be positively regulated by 
dimerization  in  vivo  and  that  dimerization  could  be  a  physiologically  important 
mechanism  for  regulating the  proposed  signal  activity  of  APP  (Scheuermann,  S., 
Hambsch, B. et al., 2001). Moreover, biochemical data implicate that A dimers can 
easily  aggregate  into  fibrils  and  may  have  originated  from  APP-homodimers  by 
proteolytic processing (Schmechel, A., Zentgraf, H. et al., 2003). The presence of A
dimers  in  the  cortex  of  patients  with  AD  has  been  suggested  to  initiate  the 
accumulation of A in the human brain (Enya, M., Morishima-Kawashima, M. et al., 
1999). In APP transgenic mouse brain two forms of sodium dodecyl sulfate-stable A
homodimers  exist,  species  ending  at  A1-40 and  A1-42.  Spectroscopic  analyses 
showed  that engineered  dimeric  peptides ending  at  residue  42  displayed  a much 
more pronounced -structural transition than corresponding monomers (Schmechel, Discussion
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A., Zentgraf, H. et al., 2003). Nonfibrillar sodium dodecyl sulfate-stable dimers have 
been characterized as neurotoxic species (Lambert, M. P., Barlow, A. K. et al., 1998)
and  selectively  blocked  hippocampal  long-term  potentiation  in  the  absence  of 
monomers, protofibrils or fibrils (Walsh, D. M., Klyubin, I. et al., 2002).
A  very  interesting  model  was  proposed  by  Kayed  et  al.,  assuming  that  soluble 
oligomers  are  common  to  most  amyloids  and  may  represent  the  primary  toxic 
species of amyloids. They could show that all of the soluble oligomers tested (insulin, 
-synuclein, prion 106-126) display a common conformation-dependent structure that 
is unique to soluble oligomers regardless of sequence. The in vitro toxicity of soluble 
oligomers is inhibited by an oligomer-specific antibody. In human AD brain, soluble 
oligomers have a unique distribution that is distinct from fibrillar amyloid. Their results 
indicate that different types of soluble amyloid oligomers have a common structure 
and suggest they share a common mechanism of toxicity (Kayed, R., Head, E. et al., 
2003).Discussion
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Figure 4.5: Model of A-mediated neurotoxicity.
It has been found by several groups that dimeric as well as oligomeric A isoforms exhibit highly neurotoxic 
effects. Furthermore, it has been proposed that dimers and oligomers exhibit stronger neurotoxic properties than 
multimeric/fibrillar  A.  But  still  it  is  unknown,  how  dimeric,  oligomeric  or  multimeric  A isoforms  exert  their 
neurotoxic effects.Discussion
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Our data are in accordance with these previous findings since we could demonstrate 
that treatment with monomeric A1-42 did not lead to a decrease in MTT reduction 
potential,  which  implicates  that  the  monomeric  form  does  not  exhibit  neurotoxic 
effects  (Fig.  3.13).  In  contrast  to  this,  treatment  with  dimeric  A1-42 resulted  in  a
significant decrease in MTT reduction potential in both PC12 and SY5Y cells (Fig. 
3.15).  Furthermore,  the neurotoxic  effect  of dimeric  A1-42 was  comparable  to  the 
neurotoxic  effect  achieved  by  the  treatment  with  fibrillar  A1-42 (Fig.  3.12).  Most 
interestingly, treatment with dimeric A1-40 did only lead to a slight, but significant 
decrease in MTT reduction potential at 100 nM in SY5Y cells (Fig. 3.14). Again, this 
finding is in  accordance  with previous  data since it has  been  found that not only 
monomeric, but also dimeric A1-42 exhibits a higher neurotoxicity than monomeric or 
dimeric A1-40 does. At least, in our model, dimeric A1-42 and multimeric/fibrillar A1-
42 isoforms exhibit both the highest neurotoxic effects. Of note, we did not further 
characterize the critical components of multimeric/fibrillar A1-42, as this isoform was 
generated from commercially available A1-42. Thus, we can not definitely exclude 
that here, dimeric A1-42 is one of the major components. Moreover, we assessed the 
MTT reduction potential and ATP levels of APP and A dimer producing SY5Y cells 
(SY5Y K623C) under baseline conditions and under H2O2-mediated oxidative stress 
(Fig. 3.16, 3.17). These cells represent a valuable model for the investigation of the 
neurotoxic effects mediated by dimeric APP and dimeric A in comparison to control 
SY5Y cells. Under baseline conditions, we observed a decrease in MTT reduction 
potential  as  well  a  decreased  ATP  levels  in  SY5Y  cells  bearing  the  APP  dimer 
mutation. This is in accordance with previous findings since it has been reported that 
APP  dimer  formation  leads  to  a  six- to  eightfold  increased  A dimer  production 
(Scheuermann, S., Hambsch, B. et al., 2001). Increased A dimer production thus 
decreases cellular viablility under baseline conditions as monitored by MTT reduction 
and  a  drop-down  of  ATP  levels.  Exposure  to  oxidative  stress  lead  to  a  drastic 
decrease in MTT reduction potential and ATP levels in both APP dimer and control 
cells.  Finally,  we  may  conclude  that  not  only  extracellular,  but  also  intracellular 
dimeric A isoforms are neurotoxic. Our data further indicate that most probably both, 
intracellular and extracellular dimeric A is involved in neurotoxicity: First, intracellular
A dimers  lead  to  disturbances  in  mitochondrial  function  and  cellular  energy Discussion
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metablolism, rendering the cell more vulnerable to oxidative stress. In the next step, 
secreted dimeric A or extracellular A in general might lead to the generation of 
ROS itself or enhance oxidative-stress-mediated neurotoxicity.
4.2 APP processing, secretase inhibition and cellular viability
4.2.1 APP overexpression and secretase activity
APPsw  cells  (PC12,  HEK)  show  a  significant  increase  in  -secretase  activity 
compared to control cells, which is in accordance with previous findings indicating 
that the APPsw mutation leads to an increase in -secretase activity in cell culture 
(Haass, C., Lemere, C. A. et al., 1995b), a phenomenon which is probably also true 
for the situation in AD brain (Shen, Y., Yang, L. B. et al., 2002; Li, R., Lindholm, K. et 
al., 2004d;  Holsinger,  R.  M.  D.,  Mclean,  C.  A.  et al., 2002).  Of note, this  finding 
underlines the important role of APPsw-transfected neuronal and non-neuronal cells 
as  a valuable  model  for  the investigation  of -secretase-mediated  changes in  AD 
pathology. In contrast to this, it was a very intriguing finding that -secretase activity 
was  significantly  elevated  in  APPsw-transfected  PC12  cells  compared  to  control 
cells,  while  in  HEK  cells,  -secretase  activity  was  at  equal  levels  in  APPsw  and 
control cells (Fig. 3.10, 3.11). Thus, we conclude that a mutation-dependent increase 
in -secretase activity is an effect specifically observed in neuronal cell lines (PC12). 
In our experimental setting, we did not observe any significant differences in baseline 
values without the addition of - and -secretase-specific substrates, leading to the 
conclusion that these baseline values without substrate do not have an impact on -
secretase activity of PC12 and HEK cells, and that differences in secretase activity 
definitely result from the addition of secretase-specific substrates.
Regarding the A secretion of APPsw PC12 and HEK cells, it seems that increased 
-secretase,  but  not  -secretase  activity  is  responsible  for  the  increased  A
production and secretion. On the other hand, we may deduct that -secretase activity 
in control HEK cells under baseline conditions is at maximum level, due to the higher 
APP expression levels compared to PC12  cells. A further increase in the original 
substrate  as  monitored  by  APPsw-expression  in  HEK  cells  does  not  necessarily 
result in an increased -secretase activity.Discussion
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Figure 4.6: Proposed comparative model for - and -secretase activity in APPsw PC12 and HEK cells.
In both cell models, the APPsw mutation leads to a significant increase in -secretase activity. In APPsw PC12 
cells, the APPsw mutation additionally leads to a significant increase in -secretase activity. This effect was not 
observed in APPsw HEK cells, since -secretase activity is maximum in control HEK cells.
4.3 AD-relevant mitochondrial alterations
There  have  been  many  links  between  mitochondrial  function/dysfunction  and 
Alzheimer’s disease (AD) over the years (Arispe, N., Demazancourt, P. et al., 1994). 
Such a connection is rational, because meeting neuronal requirements for metabolic 
(especially energetic) homeostasis is a prerequisite for cognitive function. Defects in 
glucose utilization suggest possible abnormalities in mitochondrial function in AD. In 
support  of  this  possibility,  a  range  of  reports  have  shown  altered  mitochondrial 
properties  in  AD.  For  example,  decreased  activity  of  complex  IV  (cytochrome  c 
oxidase  or COX) has  been  observed in the  central  nervous  system,  and even in 
peripheral tissues, such as platelets, of patients with AD (Kish, S. J., Bergeron, C. et 
al., 1992; Mutisya, E. M., Bowling, A. C. et al., 1994; Parker, W. D., Parks, J. et al., 
1994; Maurer, I., Zierz, S. et al., 2000; Bosetti, F., Brizzi, F. et al., 2002). The latter is 
the most consistently noted mitochondrial abnormality in AD tissue. Indeed, studies 
with cybrids, in which mitochondria from patient tissue/cell samples (platelets) are 
transferred to a cell line depleted of mitochondrial DNA (thus, the only mitochondrial 
DNA is from the patient sample), have also demonstrated decreased COX activity 
(Khan, S. M., Cassarino, D. S. et al., 2000). These data are consistent with previous 
PC12
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APPsw -secretase activity  -secretase activity  A
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findings  of our  own  group indicating  that PC12  cells bearing  the  Swedish  double 
mutation suffer from reduced cytochrome c oxidase activity (Keil, U., Bonert, A. et al., 
2004). In addition, others have shown a decrease in the area of intact mitochondria in 
AD  brain,  vs.  control,  and  evidence  of  mitochondrial  morphologic  abnormalities 
associated  with  oxidative  modification  of  guanosine  (8-hydroxyguanosine)  and 
increased levels of nitrotyrosine (Castellani, R., Hirai, K. et al., 2002). Still, studies in 
cell  culture  demonstrating  a  role  for  proapoptotic  Bax  in  A-induced  apoptosis, 
mediated  via  Bax-induced  increased  permeability  of  the  outer  mitochondrial 
membrane,  caspase  activation  and cell death  (Giovanni,  A.,  Keramaris,  E.  et al., 
2000; Zhang, Y., McLaughlin, R. et al., 2002a), indicate that mitochondria remain 
important suspects as pathogenic contributors to A-mediated cellular dysfunction. 
The  counterpart  of  these  studies  on  patient  samples/intact  cells  are  experiments 
using  isolated  mitochondria  exposed  to  A.  For  example,  rat  brain  mitochondria 
incubated with A showed decreased state 3 and 4 mitochondrial respiration (Casley, 
C.  S.,  Canevari,  L.  et  al.,  2002a).  COX-4,  -ketoglutatrate  dehydrogenase  and 
pyruvate dehydrogenase activities were also diminished in mitochondria incubated 
with  A (Casley,  C.  S.,  Canevari,  L.  et  al.,  2002a).  In  another  study,  liver 
mitochondria exposed to A displayed a drop in membrane potential and increased 
susceptibility to matrix swelling, though brain mitochondria, by comparison, were less 
vulnerable to the effects of A (Moreira, P. I., Santos, M. S. et al., 2002). As might be 
expected from studies using intact cells, in which A can trigger apoptotic cascades 
(Loo, D. T., Copani, A. et al., 1993; LaFerla, F. M., Tinkle, B. T. et al., 1995; Mattson, 
M.  P.,  Partin,  J.  et  al.,  1998),  incubation  of  A with  brain  mitochondria  has been 
shown to cause cytochrome c release, as well as mitochondrial swelling (Kim, H. S., 
Lee, J. H. et al., 2002). The relevance of these results, from experiments in which 
isolated mitochondria were exposed to micromolar levels of synthetic A peptides, to 
the in vivo situation is yet to be determined. Taken together, these studies indicate 
the likelihood that there is an association of mitochondrial dysfunction with AD.Discussion
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4.3.1 Bcl-2 family proteins
Increasing evidence suggests that many neurons may undergo apoptosis in AD as 
high  levels  of  activated  pro-apoptotic  proteins  such  as  caspase-3  and  Bax  are 
present in particularly affected neurons (Mattson, M. P., Partin, J. et al., 1998). DNA 
damage  and  up-regulation  of  the  proapoptotic  proteins  p53  and  Bax  occur  in 
vulnerable neuronal populations at a relatively early stage in the disease process. 
Familial AD (FAD) mutations in presenilins render neurons vulnerable to apoptosis 
induced by A, trophic factor deprivation and other stimuli (Mattson, M. P., Partin, J. 
et al., 1998), consistent with an apoptotic mode of neuronal death in patients with 
these presenilin mutations. APP mutations are also sufficient to trigger apoptosis in 
cultured cells (McPhie, D. L., Coopersmith, R. et al., 2003; Eckert, A., Keil, U. et al., 
2003; Marques, C. A., Keil, U. et al., 2003). In our experiments, expression levels of 
mitochondrial pro-apoptotic factors differed markedly between PC12, HEK and SY5Y 
cells (Fig. 3.18, 3.19, 3.20). The most intriguing finding was that PC12 cells did not 
express  the endogenous anti-apoptotic  protein Bcl-2 (Fig.  3.18). This finding  was 
corroborated by additional data of our group, indicating that Bcl-2 mRNA levels were 
not  detectable  in  PC12  cells,  but  this  phenomenon  has  also  been  described  by 
others (Maroto, R., Perez-Polo, J. R., 1997). On the other hand, Bcl-xL is expressed 
in PC12 cells, and its intracellular distribution reveals that levels of cytosolic Bcl-xL 
are strongly reduced in APPwt and APPsw PC12 cells (Fig. 3.18, 3.28). This finding 
might be of in-vivo relevance since we observed a significant down-regulation of Bcl-
xL levels without alterations of Bcl-2 in APPsw transgenic mice (Fig. 3.21, 3.24). We 
might resume that Bcl-xL, as another anti-apoptotic player in the cell death scenario 
might  exert  similar  protective  functions  as  Bcl-2  under  certain  circumstances.  In 
contrast to the findings in PC12 cells, HEK and SY5Y cells, both of human origin, 
reveal  detectable  expression  levels  of  Bcl-2  (Fig.  3.19,  3.20).  Of  note,  Bcl-2 
expression levels were reduced in HEK cells bearing the Swedish double mutation as 
well as in SY5Y cells stably transfected with APPwt, leading to reduced Bcl-2/Bax 
ratios (Fig. 3.23). It has been found that for many but not all apoptotic signals, the 
balance between these competing activities determines cell fate (Adams, J. M., Cory, 
S.,  1998).  Most  interestingly,  APPwt  SY5Y  cells  exhibit  significantly  reduced  Bcl-
xL/Bax ratios (Fig. 3.23), indicating that reduced Bcl-xL levels are a characteristic Discussion
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feature of neuronal cells of over-expressing APP, as similar results were found in 
Thy-1 APP transgenic mice (Fig. 3.24). Concluding, we can say that a shift of Bcl-
2/Bax or Bcl-xL/Bax ratios in favour of Bax represents a characteristic hallmark of 
cells suffering from the over-expression of APP. Concluding, we may state that our 
data corroborate the involvement of Bcl-2 family proteins in A-mediated apoptosis. 
From a more general point of view, the role of Bcl-2 family proteins in AD-associated 
neurotoxicity  has  been  confirmed  by  former  findings  showing  that  Bcl-2  directly 
interacts with presenilin 1 (Alberici, A., Moratto, D. et al., 1999) and that presenilin 2 
and its mutations regulate the expression of Bcl-2 family proteins (Alves, d. C., Paitel, 
E.  et  al.,  2002).  Moreover,  several  groups  report  that  transfection  with  the  anti-
apoptotic Bcl-2 gene rescued PC12 cells from apoptotic death induced by A, and 
they suggest that NF-B plays a role in Bcl-2-mediated protection against A-induced 
apoptosis through augmentation of cellular antioxidant capacity (Jang, J. H., Surh, Y. 
J.,  2004).  Tan  et  al.  showed  that  Bcl-xL  significantly  inhibits  both  early-stage 
apoptosis and late-stage apoptosis/necrosis caused by A treatment, suggesting that 
Bcl-xL exhibits both anti-necrotic as well as anti-apoptotic roles in A-mediated cell 
death (Tan, J., Town, T. et al., 1999). Other groups could clearly demonstrate that 
intracellular A1-42 is selectively cytotoxic to human neurons through the p53-Bax cell 
death  pathway  (Zhang,  Y.,  McLaughlin,  R.  et  al.,  2002b).  Analysis  of  the  anti-
apoptotic factor Bcl-xL and the pro-apoptotic factor Bax in cytosolic and mitochondrial 
fractions of PC12 cells under baseline conditions and after oxidative injury induced 
by H2O2 lead to the following conclusions: Reduced cytosolic Bcl-xL levels in APPwt 
and APPsw PC12 cells compared to control cells as well as a shift in the Bcl-xL/Bax 
ratio  towards  Bax  under  baseline  conditions  might  be  involved  in  the  higher 
sensitivity of APPwt and APPsw cells to mitochondrial failure. During oxidative injury, 
cytosolic  Bcl-xL  levels  remained  unaltered  indicating  that  dyshomeostasis  in  Bcl-
xL/Bax ratio was not compensated by an increase cytosolic Bcl-xL levels (Fig. 3.28). 
Of  note,  there  was  no  alteration  of  baseline  mitochondrial  levels  of  monomeric, 
dimeric and heteromeric Bcl-xL in PC12 clones which remained unchanged during 
oxidative stress leading to the conclusion that mitochondrial Bcl-xL did not counteract 
apoptosis  induction  (Fig.  3.29).  Furthermore,  we  did  not  observe  a  baseline  up-
regulation of Bax nor did we observe alterations in cytosolic and mitochondrial Bax 
levels of APPwt and APPsw compared to control cells (Fig. 3.30). The temporary 
general increase in cytosolic Bax levels in all clones, namely dimeric Bax (Fig. 3.31), Discussion
165
might  pave  the  way  for  the  translocation  of  Bax  into  the  outer  mitochondrial 
membrane  leading  to  the  release  of  pro-apoptotic  mitochondrial  factors  into  the 
cytosol by PTP opening or by Bax pore formation. We finally conclude that moderate, 
chronic APP over-expression and exposure to A results in a shift of Bcl-xL/Bax ratio 
in favour of Bax thus increasing cellular vulnerability, but there was no evidence for a 
protective action of Bcl-xL during oxidative injury. It was rather difficult to compare 
our findings with that of other groups as most workers in the field investigate the 
effects of extracellular A on apoptosis in cells over-expressing Bcl-2, Bcl-xL or Bax. 
Naturally, it was found that Bcl-2 over-expression protects against secondary injury 
and  that  Bax-over-expression  results  in  increased  apoptosis  rate,  but  the  in-vivo 
relevance  has  to  be  questioned  as  these  models  are  not  close  to  physiological 
conditions. In contrast, PC12 cells as a model of moderate APP over-expression and 
A secretion levels in the physiological range could mimic the physiological situation 
in  an  early  stage  of  the  disease,  as  reduced  cytosolic  Bcl-xL  levels  precede  a 
reduction in Bcl-xL  expression  levels  observed  in cells  massively  over-expressing 
APP. Discussion
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Figure 4.4: A hypothetical role for Bcl-2 protein family members in oxidative stress-induced apoptosis in 
PC12 cells.
Increased cytososlic Bax oligomerization is implicated in apoptosis-induction in PC12 cells. Since Bcl-2 is not 
expressed in PC12 cells, Bcl-xL is the only pro-survival protein to counteract cytochrome c release as a trigger of 
the apoptotic cascade. Reduced cytosolic levels of Bcl-xL in APPwt and APPsw PC12 cells could be implicated in 
their increased vulnerablilty against oxidative stress.
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Furthermore,  previous  findings  of  our  group  describe  the  consequences  of  A-
induced mitochondrial dysfunction as follows: Under baseline conditions, the chronic 
low levels of intracellular A (picomolar range) in APPsw PC12 cells lead to reduced 
ATP  levels  and  reduced  metabolic  activity  (Keil,  U.,  Bonert,  A.  et  al.,  2004). 
Intriguingly, PC12 cells seem to counteract energy deficiency, since no enhanced 
baseline  apoptosis  has  been  observed.  If  this  adaptation  occurs  through  a 
upregulation of glycolysis needs to be determined e.g. by measuring the activation of 
the energy charge-sensitive AMP-activated protein kinase or the 6-phosphofructo-1-
kinase, the master regulator of glycolysis. This shift in the Bcl-xL/Bax ratio towards 
the pro-apoptotic Bax, and the energy deficiency conduct APPsw cells to be more Discussion
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vulnerable  against  mitochondrial  membrane  potential  changes  and  ATP  reduction 
after  oxidative  stress.  The  consequence  is an  activation  of  the intrinsic  apoptotic 
pathway, releasing cytochrome c into the cytosol, resulting in an activation of the 
apoptotic protease-activating factor-1/caspase 9 apoptosome complex.
4.3.2 Pro-apoptotic mitochondrial factors 
The release of pro-apoptotic factors from mitochondria into the cytosol is considered 
as  a  crucial  step  in  oxidative  stress-induced  apoptosis.  Indeed,  cytochrome  c, 
Smac/DIABLO  and AIF  are  time-dependently  released  upon  secondary  injury 
induced by H2O2 treatment. Our data are consistent with previous findings reporting 
that cytochrome c/ Smac/DIABLO co-release precedes the translocation of AIF from 
mitochondria into the nucleus (Fig. 3.32, 3.34, 3.36) (Arnoult, D., Parone, P. et al., 
2002).  Furthermore,  it  is  a  generally  accepted  that  Bax  oligomerization  and 
translocation  into  the  outer  mitochondrial  membrane  induces  the  release  of  pro-
apoptotic factors (Arnoult, D., Gaume, B. et al., 2003). This finding is corroborated by 
our  data  showing  an  increase  in  cytosolic  Bax  monomers  and  dimers  when  the 
release  of  cytochrome  c  and  Smac/DIABLO  into  the  cytosol  is  initiated  during 
oxidative injury (Fig. 3.30, 3.32, 3.34). Cytochrome c is released in a time-dependent 
pattern with a maximum release in APPwt and APPsw PC12 cells (Fig. 3.32). We 
speculate that APP over-expression, results in an increased cytochrome c liberation 
from the mitochondrion. Feedback amplification loops of pro-apoptotic factors and 
caspases have been described before: Caspase-3 potentiates activation of upstream 
caspases (-2, -6, -8) in this pathway and also participates in a feedback amplification 
loop involving caspase-9 (Creagh, E. M., Martin, S. J., 2001; Marzo, I., Susin, S. A. et 
al.,  1998;  Slee,  E.  A.,  Harte,  M.  T.  et  al.,  1999).  Here,  maximum  cytochrome  c 
release appeared shortly after maximum Smac/DIABLO release potentially leading to 
a mutual potentiation of their pro-apoptotic effect resulting in increased or prolonged 
caspase-3 activation, an effect potentially being enhanced by APP over-expression 
(Marques, C. A., Keil, U. et al., 2003). Our experiments additionally confirmed former 
findings as treatment with caspase-2 and -8 inhibitors and a JNK inhibitor diminished
cytochrome c release from mitochondria into the cytosol, eventually by interrupting 
the feedback amplification loop (Fig. 3.33). This indicates that caspase-2 and –8 as Discussion
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well as JNK act upstream mitochondria, and by their inhibition, cytochrome c release 
as a further crucial step in the apoptotic cascade, could be prevented.
Figure  4.7:  A  hypothetical  response  to  oxidative  stress  of  Smac/DIABLO  and  cytochrome  c  and  the 
implication of upstream caspases in the feedback amplification loop.
Increased release of Smac/DIABLO by APPsw and cytochrome c by APPwt and APPsw PC12 cells lead to an 
increased reponse to oxidative stress and the initiation of the apoptosis cascade. The feedback amplification loop, 
mediated by caspases upstream mitochondria, leads to an enhanced and prolonged apoptotic signaling.
The  release  of  AIF  independently  from  caspase-activation  is  still  controversely 
discussed (Penninger, J. M., Kroemer, G., 2003; Cande, C., Cohen, I. et al., 2002; 
Cande, C., Vahsen, N. et al., 2004). Nevertheless, AIF is involved in oxidative stress-
induced cell death in a two-step, time-dependent manner. Increased accumulation of 
AIF  in the  mitochondrial  compartment  has  been observed  to be part  of the  early 
events in apoptosis, similar to the relase of cytochrome c and Smac/DIABLO into the 
cytosol (Fig. 3.35). Of note, overexpression of the APPsw  mutations results in an 
increased  accumulation  of  AIF  compared  to  APPwt  and  control  cells.  Thus,  the 
APPsw mutation has an impact on caspase-dependent and independent apoptosis, 
but  it  is  open  to  discussion  whether  these  effects  might  be  finally  interrelated. 
Eventually,  increased  accumulation  of  AIF  in  the  mitochondrial  compartment  is 
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dependent  on  other  pro-apoptotic  factors  or  on  the  opening  of  PTP,  whereas  its 
release  finally  is  caspase-independent.  The  release  of  AIF,  accompanied  by  the 
cleavage of the protein, is a late event in apoptosis (Fig. 3.36). The occurence of a 
cleaved fragment in AIF release has been described before (Nicholson, D. W., 2001)
and  this  finding  gave  rise  to  the  question  whether  AIF  might  be  an  unidentified 
caspase  after  all,  since  inactive  pro-caspase-2  and  -9  are  located  in  the 
mitochondrion before induction of apoptosis and cleaved to their active form in the 
cytosol (Susin, S. A., Lorenzo, H. K. et al., 1999b; Susin, S. A., Daugas, E. et al., 
2000; Katoh, I., Tomimori, Y. et al., 2004). Moreover, as AIF is characterized as a 
functional oxidoreductase its janus-faced function in the modulation of apoptosis is 
focus of intensive investigation and its implication in Alzheimer´s disease is yet not 
fully elucidated.Discussion
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Figure 4.8: A hypothetical response to oxidative stress of the pro-apoptotic mitochondrial factor AIF.
Translocation of AIF into the mitochondrial compartment is generally considered as an early event of apoptosis. 
Accumulation of AIF is considered to be a caspase-independent process, but further investigation is required. 
Upon its release, cleaved AIF translocates to the nucleus where it initiates nuclear fragmentation and chromatin 
condensation.Discussion
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4.4 Disease-modifying strategies
4.4.1 Secretase inhibition
Most  of  the  worldwide  resources  for  anti-amyloid  therapy  have  focused  on  the 
inhibition  of  A production  through  secretase  inhibitors.  Since  1992,  it  has  been 
known  that  cells  that  endogenously  express  - and -secretase  enzymes  secrete 
significant quantities of A into the culture medium when they are transfected to over-
express APP (Haass, C., Schlossmacher, M. G. et al., 1992; Shoji, M., Hosokawa, M. 
et al., 1992). 
APP over-expressing HEK cells represent a valuable tool to study both the effect of 
modulation  of  APP  processing  and  secretase  inhibition  on  cell  survival 
(Vandermeeren, M., Geraerts, M. et al., 2001; Edbauer, D., Kaether, C. et al., 2004; 
Su, Y., Ryder, J. et al., 2004). Furthermore, it has been established recently that 
expression of APPsw in non-neuronal cells more closely mimics processing of APPwt 
in neurons (Forman, M. S., Cook, D. G. et al., 1997). Large evidence is provided in 
literature for the -secretase inhibiting effects of DAPT and L-685458 in cell culture 
and transgenic mouse models (Lanz, T. A., Himes, C. S. et al., 2003a; Dovey, H. F., 
John, V. et al., 2001). This is in accordance with our findings, in which we observed a 
drastic reduction of both A1-40 and A1-42 during DAPT treatment (Fig. 3.40-3.42) 
and a modest reduction of both A species for L-685458 (Fig. 3.43). Interestingly, at 
low  concentrations  (0.2  µM),  treatment  with  the  -secretase  inhibitor  L-685458 
resulted in a slight increase in secreted A1-40 and A1-42 levels in APPwt HEK cells. 
This effect has formely been described for other -secretase inhibitors, but the reason 
for that phenomenon requires further explanation (Lanz, T. A., Hosley, J. D. et al., 
2004).  For  DAPT,  we  did  not  observe  a  similar  effect.  Testing  the  -secretase 
inhibitor  II  for  its  A-reducing  activity  resulted  only  in  a  modest,  but  significant 
decrease  in  A1-40 and  A1-42 secretion  at  the  highest  concentration  (10  µM)  in 
APPsw  HEK  cells  (Fig.  3.47).  Treatment  with  the  -secretase  inhibitor  II  did  not 
decrease secreted A1-40 levels in APPwt HEK cells, and secreted A1-42 levels rose 
slightly during  exposure  to the inhibitor.  Inhibition  of  -secretase  by  commercially 
available, peptidic inhibitors did not result in an increase in MTT reduction potential. Discussion
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Of note, the -secretase inhibitor II exhibited highly toxic side effects as monitored by 
MTT assay after 48h treatment with 5 and 10 µM (Fig. 3.46), which we assume to 
reflect  side  effects  due  to  the  lack  of  enzyme  specificy.  Our  findings  further 
emphasize the need for more potent and less toxic -secretase inhibitors, as most of 
the commercially available -secretase inhibitors are of peptidic nature and do not 
meet the requirements for an effective drug-like enzyme inhibition. Thus, promising 
research is currently undertaken to inhibit -secretase cleavage by alternative non-
peptidic  structures  such  as  ribozymes  (Nawrot,  B.,  Antoszczyk,  S.  et  al.,  2003; 
Nawrot,  B.,  2004) or  small  inhibitory  RNA  interference  molecules  (Kao,  S.  C., 
Krichevsky, A. M. et al., 2004; Lavery, K. S., King, T. H., 2003) specifically targeting 
-secretase. L-685458 and DAPT differ in their nature of -secretase inhibition: L-
685458 is described  as  a highly  specific  transition-state  analogue  of  -secretase, 
directly binding to the active site of the enzyme (Li, Y. M., 2001). Originally, L-685458 
has been synthesized to mimick the amino acid sequence of APP in proximity to the 
-secretase  cleavage  site.  Although  it  has  been  hypothesized  that  the  substance 
would  exhibit  a higher inhibitory  potency  against -secretase, it showed  a loss  of 
activity in enzyme inhibition (Nadin, A., Owens, A. P. et al., 2003). Testing the L-
685458 inhibitor in HEK cells stably expressing APP and delta-Notch revealed a 
reduced  effect  on  cleavage  inhibition  of  both  substrates.  Furthermore,  a  non-
competitive mechanism of enzyme inhibition has been proposed for L-685458 (Tian, 
G. C., Ghanekar, S. V. et al., 2003). In contrast, DAPT is described as a highly potent 
functional  non-transition  state  analogue,  and  its  site  of  action  is  yet  not  fully 
characterized (Dovey, H. F., John, V. et al., 2001; Lanz, T. A., Himes, C. S. et al., 
2003b). Our data corroborate the previous findings since we observed in our model 
that DAPT dose- and time-dependently reduced secreted A levels (Fig. 3.41, 3.42) 
earlier and to a higher extent than L-685458 (Fig. 3.43). Although we can not finally 
exclude other mechanisms, the increased potency and rapid action of A secretion 
inhibition  by  DAPT  (1  µM)  might  result  in  the  significant  reconstitution  of  MTT 
reduction potential in APPsw HEK cells after 48h treatment (Fig. 3.38). This finding is 
in  coherence  with  the  formerly  observed  significant  increase  in  ATP  levels  and 
reconstitution of membrane potential during 48h DAPT treatment in APPsw  PC12 
cells (Keil, U., Bonert, A. et al., 2004). Furthermore, it has been reported that the 
inhibition of intracellular A1-42 formation by DAPT increases survival of rat primary Discussion
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cortical neurons, an effect which has not been achieved by the treatment with other 
secretase inhibitors (Kienlen-Campard, P., Miolet, S. et al., 2002). Consequently, we 
might deduct that DAPT could inhibit intracellular A formation to a higher extent than 
that of secreted A, since it has been reported that their formation is spatially distinct 
(Hartmann,  T.,  Bieger,  S.  C.  et  al.,  1997;  Xu,  H.  X.,  Sweeney,  D.  et  al.,  1997; 
Greenfield, J. P., Tsai, J. et al., 1999). Alternatively, it has been described by others 
in  photoaffinity  labeling  assays  that  DAPT  succesfully  competed  with  a 
photoactivatable  transition  state  analogue  at  high  concentrations  but  could  not 
displace the photoprobe at concentrations with which a transition state analogue can 
compete. This suggests that DAPT binds to the active site of -secretase, which is 
distinct but overlaps with the catalytic sites bound by the transition state analogue 
(Kornilova, A. Y., Wolfe, M. S., 2003). Others report differential effects of DAPT and 
L-685458 on A production from CTFs 1-48 and 1-49 transiently expressed in HEK 
cells, leading to the conclusion that the -secretase inhibitors have distinct binding 
sites on presenilins (Funamoto, S., Morshima-Kawashima, M. et al., 2004). We may 
assume that L-685458, by specifically inhibiting presenilins in other vital functions 
may cause a loss in cellular viability. We monitored a significant decrease in MTT 
reduction  potential  (Fig.  3.39) after  48h treatment  with  concentrations  significantly 
reducing A1-40 and A1-42 secretion levels (Fig. 3.43). This finding might indicate that 
L-685458  affects  other  presenilin-mediated  mechanisms  at  concentrations 
succesfully inhibiting -secretase, and that reduction of A levels per se does not 
necessarily result in a reconstitution of cellular viability. For example, it has been 
reported that presenilins are implicated in the PI3K pathway thus inhibiting GSK-3 
activation  and  tau  over-phosphorylation  (Baki,  L.,  Shioi,  J.  et  al.,  2004).  Others 
suggest that presenilins affect processing and nuclear functions of -protocadherins 
(Haas, I. G., Frank, M. et al., 2005) and contribute to calsenelin-mediated apoptosis 
(Jo, D. G., Chang, J. W. et al., 2003). It has been reported by some groups that APP 
is cleaved not only in the middle of the membrane (-cleavage) but also at alternative 
cleavage sites close to the membrane/cytoplasmic boundary (-cleavage), releasing 
APP intracellular domains (AICDs) (Gu, Y. J., Misonou, H. et al., 2001; Sastre, M., 
Steiner,  H.  et  al.,  2001;  Weidemann,  A.,  Eggert,  S.  et  al.,  2002).  In  a  general 
assumption,  -cleavage  precedes  A production  and  -cleavage  determines  the 
preference for the final A species. Funamoto et al. deduced from that observation Discussion
174
the presence of a novel enzyme being additionally involved in -cleavage, sensitive to 
L-685458, but insensitive to DAPT (Funamoto, S., Morshima-Kawashima, M. et al., 
2004). Concluding, we may assume that in the last years, considerable investigative 
efforts  have  been  accomplished  in  search  of  -secretase  inhibiting  substances. 
Recently, it has become clear that not all -secretase inhibitors block the active site of 
the enzyme in the same way. This is not surprising since -secretase is a multimeric 
enzyme complex  with potentially more than one active site, but distinct modes of 
inhibition might become crucial for the further drug design of -secretase inhibitors. -
secretase  inhibitors  structurally  similar  to  DAPT  might  be  favourable  since  a 
reconstitution of cellular viability has been observed by our group and by others (Keil, 
U., Bonert, A. et al., 2004; Bonert, A., Marques, C. et al., 2004; Kienlen-Campard, P., 
Miolet, S. et al., 2002). 
4.4.2 Pro-apoptotic mitochondrial factors: potential therapeutic targets 
in AD therapy?
Inhibition of caspases as a key and central component of the biochemical pathway 
that  mediates  apoptotic  cell  death  represents  an  attractive  therapeutic  strategy. 
There are efforts to induce caspase activation for the treatment of disorders where 
insufficient  apoptosis  occurs  (e.g.  cancer).  In  HIV  infection  efforts  to  activate 
caspases in infected cells exist e.g. gene therapy with a TAT-caspase-3 construct 
containing  a  HIV-protease  recognition  motif  selectively  induces  apoptosis  in  HIV 
infected cells only (Vocero-Akbani, A. M., Heyden, N. V. et al., 1999). Preliminary 
experiments  in  animal  models  using  non-selective  caspase  inhibitors  such  as  Z-
VAD(OMe)-CH2F, have shown in-vivo efficacy in ischemic and hypoxic brain injury 
(Cheng,  Y.,  Deshmukh,  M.  et  al.,  1998;  Daemen,  M.  A.,  van,  '.,  V  et  al.,  1999). 
Nevertheless,  the  development  of  selective  caspase-inhibitors  remains  a  big 
challenge in AD therapy. Recently, efforts have been undertaken inhibit pro-apoptotic 
factors up-stream  caspase-3 for the development  of anti-apoptotic  drugs. Several 
groups have focused on IAPs (inhibitor of apoptosis proteins) as the most promising 
target:  XIAP's  capacity  to  maintain  inhibition  of  caspase-9  within  the  Apaf-1 
apoptosome  is influenced  by  its ability  to  simultaneously inhibit  active  caspase-3, 
depending  on  the  apoptotic  stimulus,  inhibition  of  caspase-9  or 3 is  essential  for Discussion
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XIAP's anti-apoptotic activity (Bratton, S. B., Lewis, J. et al., 2002). Interestingly, only 
the  IAPs  have  been  demonstrated  to  be  endogenous  repressors  of  the  terminal 
caspase  cascade.  In  turn,  the  caspase  inhibiting  activity  of  XIAP  is  negatively 
regulated  by  at  least  two  XIAP-interacting  proteins,  XAF1  and  Smac/DIABLO.  In 
addition to the inhibition of caspases, recent discoveries from several laboratories 
suggest that XIAP is also involved in a number of other biologically significant cellular 
activities including modulation of receptor-mediated signal transduction and protein 
ubiquitination. The multiple biological activities of XIAP, its unique translational and 
post-translational control and the centrality of the caspase cascade make the control 
of  XIAP  expression  an  exceptionally  promising  molecular  target  for  modulating 
apoptosis.  Therapeutic  benefits  can  be  derived  from  both  the  suppression  of 
inappropriate cell death such as in neurodegenerative disorders and ischemic injury 
(Holcik,  M.,  Gibson,  H.  et  al.,  2001).  Thus,  it  seems  at  least  possible  that 
Smac/DIABLO might be a potential target for apoptosis-inhibition, since it selectively 
blocks the binding of IAP to the apoptosome. Recently, an essential serine protease 
with  pro-apoptotic  activity,  named  HtrA2/Omi,  was identified  to interact  with  A in 
yeast  two-hybrid  assays.  Co-immunoprecipitation  assays  further  confirmed  the 
interaction of A and the protease in cell culture experiments (Park, H. J., Seong, Y. 
M. et al., 2004). Considerung this fact, HtrA2/Omi-inhibiting substances could be of 
great interest for AD drug development 
Concerning  AIF,  a  recent  report  provides  new  insights  into  the  mechanisms  of 
neurodegeneration.  In  a  mouse mutant  with  progressive  cerebellar  and  retinal 
degeneration,  the  expression  of  the  apoptotic  protein  AIF  was  found  to  be 
downregulated leading paradoxically to apoptosis of neurons that is associated with 
an imbalance in free radical metabolism and cell cycle re-entry (Bonni, A., 2003). 
This  controversial  finding  indicates  that  intensive  investigative  efforts  have  to  be 
undertaken to elucidate the complex role of AIF in cell death decision before AIF 
inhibitors might be considered as potential therapeutic target in AD therapy.Discussion
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4.4.3 Growth factors in AD
The ability of neurotrophic factors to regulate developmental neuronal survival and 
adult  nervous  system  plasticity  suggests  the  use  of  these  molecules  to  treat 
neurodegeneration  associated  with  human  diseases.  Solid rationales  exist  for the 
use of NGF and neurotrophin-3 in the treatment of neuropathies of the peripheral 
sensory  system,  insulin-like  growth  factor  and  ciliary  neurotrophic  factor  in  motor 
neuron  atrophy,  and  NGF  in  Alzheimer's  disease.  Growth  factors  have  been 
identified  for  neurons  affected  in  Parkinson's  disease,  Huntington's  disease,  and 
acute brain and spinal cord injury. Various strategies are actively pursued to deliver 
neurotrophic factors to the brain, and develop therapeutically useful molecules that 
mimic  neurotrophic  factor  actions  or  stimulate  their  production  or  receptor 
mechanisms (Hefti, F., 1994). In a clinical trial with three patients, intrathecal NGF 
infusion resulted in a slight cognitive benefit, but also led to significant back pain and 
weight loss (Jonhagen,  M.  E.,  2000). Working on the  assumption  that  these  side 
effects could be avoided by delivering the factor to precise cellular targets, a small 
clinical Phase I trial of NGF gene therapy in AD was completed. The results were 
interpreted as being encouraging enough for larger, controlled trials of NGF gene 
delivery to commence (Tuszynski, M. H., Smith, D. E. et al., 1998; Tuszynski, M. H., 
Thal, L. et al., 2005). Nevertheless, NGF therapy for AD seems unlikely to produce 
clinical benefits as striking as described for glial cell line-derived neurotrophic factor 
infusion in Parkinson’s disease (Gill, S. S., Patel, N. K. et al., 2003), where only a 
localized  set  of  neurons  needs  protection/rescue.  Therefore,  efforts  are  currently 
undertaken to develop drug with NGF-like activity or with NGF-enhancing properties.Discussion
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4.4.4 NGF therapy
A is  reported  to  cause  a  loss  of  cholinergic  neurons  in  the  basal  forebrain, 
particularly in the nucleus basalis Meynert of AD patients. An up-regulation of p75
NTR, 
the  neurotrophin  affinity  receptor,  has  been  reported  to  correlate  with  - amyloid 
sensitivity in vitro and in vivo, suggesting an implication in A-mediated cell death. 
Blocking the interaction of A with p75
NTR by NGF abolished A-induced apoptotic 
cell death (Kuner, P., Schubenel, R. et al., 1998). As p75
NTR and TrkA receptors are 
expressed  in  PC12  cells,  it  is  noteworthy  that  APP  expression  and  secretion  is 
regulated by the binding of NGF to these receptors. NGF stimulates APP processing 
in favour of the sAPP secretory pathway in a dose-dependent pattern (Rossner, S., 
Ueberham, U. et al., 1998b). Consequently, it is generally supposed that treatment 
with  NGF  could  ameliorate  cortical  cholinergic  function  in  AD  (Rossner,  S., 
Ueberham, U. et al., 1998a). One AD treatment strategy is to protect or repair the 
neurons affected by the disease process, and neurotrophic factor treatments provide 
such  an  approach,  but  only  little  research  has  focused  on  the  application  of 
neurotrophin-like substances or growth factor enhancers in AD therapy.
4.4.5 Substituted pyrimidines as potential AD-relevant drugs ?
Substituted  pyrimidines  similar  to  KP544  have  modest  neurotrophin-like  activities 
(Awaya, A., Kobayashi, H. et al., 1993; Ikeuchi, T., Nakatani, A. et al., 1998) and their 
neuroprotective effect has been studied in models of cerebral ischemia, Parkinson 
and Huntington´s disease (Matsumoto, K., Yamamoto, K. et al., 2003; Fyfe, J. A., 
Beauchamp,  L.  M.  et  al.,  2004).  It  has  been  demonstrated  before  that  KP544 
promotes neurite outgrowth, but little investigative work has been done on the effect 
of  KP544  on  cell  viability  and  mitochondrial  activity.  Evidence  is  provided  that 
oxidative stress is an AD relevant secondary insult representing an early pathogenic 
key event of the disease. APPsw PC12 cells, besides their reduced mitochondrial 
activity under baseline conditions, showed a concentration-dependent decrease in 
the  cellular  ability  to  reduce  MTT  when  exposed  to  H2O2 for  6h (Fig. 3.48).  The 
significant protective effect of KP544 on APPsw PC12 cells under baseline conditions 
implicates that KP544 might rescue mitochondrial activity of PC12 cells suffering from Discussion
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chronic APPsw exposure in a NGF-independent pattern. After massive exposure to 
oxidative  stress (H2O2, 500 µM),  KP544  exhibited  significant protective  effects on 
APPsw and control cells while elevating MTT reduction of APPsw cells on the level of 
H2O2 -treated control cells (Fig. 3.48). 
In terminally  differentiated  PC12  cells,  KP544  significantly promoted  mitochondrial 
activity  (Fig.  3.49).  In  differentiated  PC12  cells  suffering  from  trophic  factor 
withdrawal,  the  protective  effect  was  most  pronounced  in  the  APPsw  clone  (Fig. 
3.49).  As  KP544  showed  protective  effects  in  undifferentiated  and  terminally 
differentiated APPsw cells, we supposed that that besides the promoting effect of 
KP544 on p75
NTR- and TrkA-mediated signaling, which is mainly tied to the presence 
of NGF, other enzymes involved in APP processing might be the original target of 
KP544. A recent study corroborated our theory revealing that KP544 functions within 
the cell at a site downstream or independent of MAPK and ERK1/2 pathway (Fyfe, J. 
A., Beauchamp, L. M. et al., 2004). As PI3K activation stimulates Akt which in turn 
phosphorylates  GSK-3,  a  multifunctional  serine/threonine  kinase  playing  a  pivotal 
role not only in the regulation of cell proliferation and neurite outgrowth, but also in 
APP  processing,  post-translational  modification  and  transport  (Doble,  B.  W., 
Woodgett,  J.  R.,  2003;  Aplin,  A.  E.,  Jacobsen,  J.  S.  et  al.,  1997).  GSK-3 is 
considered  to  be  the  connecting  link  between  the  two  main  hallmarks  of  AD,  as 
abnormal  tau  phosphorylation  as  well  as  altered  APP  processing  is  GSK-3-
mediated (Kaytor, M. D., Orr, H. T., 2002). In siRNA experiments, reduced GSK-3
protein expression levels  promote  A1-40 and A1-42 secretion, which is consistent 
with our data since we observed reduced GSK-3 expression in APPsw compared to 
control  cells,  while  A1-40 and A1-42 secretion is significantly increased in APPsw 
cells (Keil, U., Bonert, A. et al., 2004). Of note, GSK-3 expression levels were not 
affected  by  the  treatment  with  NGF  or  NGF/KP544  for  1h  or  48h  (Fig.  3.50). 
Moreover, after 1h treatment with NGF/KP544, the phosphorylation status of GSK-3
at Ser9 is significantly increased in APPsw cells compared to control cells (Fig. 3.50). 
In  contrast  to  this,  NGF  treatment  alone  resulted  in  a  slightly  increased  level  of 
phospho-GSK-3, while the combined treatment with KP544 resulted in a significant 
increase in phospho-GSK-3 compared to untreaed APPsw PC12 control. Lithium, a 
non-selective  GSK-3 inhibitor,  reduces  the  secretion  of  A1-40 and  A1-42 while 
promoting  the  -secretory  pathway  (Sun,  X.,  Sato,  S.  et  al.,  2002).  In  an  other Discussion
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experimental  setting,  GSK-3 linked  neuroprotection  by  17-estradiol  to  key  AD 
processes (Goodenough, S., Schafer, M. et al., 2003). Briefly, in a hippocampal slice 
culture  model  of  kainic  acid-induced  neurotoxic  cell  death  as  well  as  in  in  vivo 
models, estrogen caused phosphorylation and hence inactivation of GSK-3 having 
implications  for  estrogen  receptor  modulation  as  a  target  for  neurodegenerative 
disorders. In our setting, APPsw PC12 cells showed a significant reduction in A1-40
levels when exposed to NGF, KP544 or NGF/KP544 (Fig. 3.51). Of note, the early 
(1h) and significant increase in phospho-GSK-3 of APPsw cells could be one reason 
for the  strong effects of KP544 on A1-40 reduction,  which is  probably  due  to the 
influence of KP544 on GSK-3-mediated APP processing.
Refering to the results of Fyfe et al. (Fyfe, J. A., Beauchamp, L. M. et al., 2004), we 
resume that in our setting, KP544 acts additively but not synergistically on the APP 
processing  pathway.  However,  treatment  with  a  combination  of  KP544  and  NGF 
resulted in reduced A1-40 levels comparable to those achieved by the commercial -
secretase inhibitor DAPT. As presenilins directly interact with GSK-3 leading to a 
modulated  APP  processing  (Van  Gassen,  G.,  De  Jonghe,  C.  et  al.,  2000),  we 
suppose that an altered interaction of GSK-3 and the presenilins due to increased 
phosphorylation of GSK-3 might reduce secreted A1-40 levels.Discussion
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Figure 4.9: Proposed model for the impact of KP544 on APP processing and cellular viability.
In our model, treatment with KP544 results in a decreased activation of GSK-3. A decrease in GSK-3 results in 
decreased tau phosphorylation and an altered interaction between presenilins and APP, finally leading to reduced 
A levels.Summary
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5 Summary
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder marked 
by  progressive  loss  of  memory  and  cognitive  ability.  The  pathology  of  AD  is 
characterised by the presence of amyloid plaques, intracellular neurofibrillary tangles 
and pronounced cell death. The amyloid plaque is composed of amyloid beta (A) 
peptide. A is derived from the amyloid precursor protein (APP) through an initial -
secretase cleavage followed by an intramembraneous cut of -secretase. Autosomal 
dominant  forms  are  caused  by  mutations  in  APP,  presenilin  1  and  presenilin  2, 
mainly associated with the early onset of AD. These mutations alter APP processing 
with respect to an enhanced A production and are related to an increased vulnerability 
to  cell  death.  However,  the  underlying  mechanisms  responsible  for  the  massive 
neurodegeneration in the brain from AD patients are still not completely understood.
The aim of this thesis was to investigate pathways involved in the A cascade of 
neurodegeneration. Since novel findings indicate that already this A species exerts 
neurotoxic effects long before hyperphosphorylated tau, neurofibrillary tangles and 
extracellular A plaques appear, the investigations were accomplished with specific 
regard to the effects of intracellular A.
In the first part of this thesis, APP processing was studied in different in-vitro models 
of AD in order to characterize the cells with regard to APP expression, A secretion, 
intracellular A contents and distribution. For this purpose, PC12, HEK and SY5Y 
cells  stably  transfected  with  APP  wild-type  (APPwt)  or  APP  bearing the  Swedish 
mutation (APPsw) were investigated. The Swedish double mutation in the APP gene 
(K670M/N671L) results in six- to eightfold increased A production of both A1-40 and 
A1-42 compared to human wildtype APP cells (APPwt). Data obtaine from PC12 cells 
indicate that it is possible to specifically increase the A load without enhancing APP 
expression  levels.  The amount  of  secreted A1-40 followed  the  subsequent  order: 
HEK APPsw >> HEK APPwt = SY5Y APPwt > PC12 APPsw > PC12 APPwt. On the 
basis of these findings, it seemed possible to investigate dose-dependent effects of 
A in multiple experimental designs. These assay designs were created in order to 
mimick different in-vivo situations that are discussed to occur in AD patients: APPsw 
PC12 cells exhibit low physiological concentrations of A within picomolar range in Summary
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contrast to APPsw HEK cells, expressing A levels within the nanomolar range. Of 
note, the APPsw HEK cells showed a specific and highly significant increase in the 
intracellular accumulation of insoluble A1-42. Moreover, an intracellular accumulation 
of A and APP was found in the mitochondria of the HEK APPsw cells suggesting a 
direct impact on mitochondrial function on these cells. This effect might finally lead to 
disturbances  in  the  energy  metabolism  of  the  cell  or  to  increased  cell  death. 
Furthermore, baseline - and -secretase activity was assessed since these enzymes 
represent  promising  therapeutic  targets  to  slow  or  halt  the  disease  process.  As 
expected, -secretase activity was significantly elevated in all APPsw cell lines. This 
might be due to the proximity of the Swedish double mutation next to the N-terminus 
of  the  A sequence.  Interestingly,  -secretase  activity  was  similarly  increased  in 
PC12 APPsw cells. In addition, the toxicity of different A species was investigated in 
SY5Y  and  PC12  cells  with  regard  to  their  effect  on  cellular  viability  mirrored  by 
mitochondrial activity using MTT assay. Here, it turned out that not monomers, but 
already dimers  are neurotoxic  correlates.  Fibrillar  A species  showed  the highest 
toxicity.  In  the  next  step,  SY5Y  cells  forming  endogenous,  dimeric  APP  and  A
(SY5Y APPK623C) were investigated. In accordance with previous findings, these 
cells  showed  a  decreased  MTT  reduction  potential  in  comparison  to  APPwt  and 
control  SY5Y  cells reflecting  a decrease  of  cellular viability. The impaired energy 
metabolism of the cells was even more drastically mirrored by reduced baseline ATP 
levels.
In the second part of this thesis, the expression and intracellular distribution of Bcl-2 
family proteins and pro-apoptotic mitochondrial factors under baseline conditions and 
during oxidative stress were analyzed in the APPwt and APPsw bearing cells, since 
recent findings of our group indicate the pivotal role of mitochondria in A-induced 
cell death (Keil, U. et al., 2004; Marques, C. A. et al., 2003), Of note, these factors 
might potentially represent valuable therapeutic targets for the reduction of increased 
cell death  associated  with  the AD  progress.  The most  prominent finding  was  the 
reduction  of  expression  levels  of  the  anti-apoptotic  factor  Bcl-xL  in  the  cytosolic 
fractions of APPwt and APPsw PC12 cells. This might indicate that a lack of anti-
apoptotic factors or their altered intracellular distribution, rather than an increase in 
caspase-dependent  pro-apoptotic  factors,  could  be  responsible  for  the  increased 
vulnerability of APPwt- and APPsw-transfected PC12 cells against oxidative stress. 
Since total Bcl-xL expression was unaffected in PC12 cells, in contrast to APPwt and Summary
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APPsw-expressing  SY5Y  and  HEK  cells  revealing  significantly  decreased  Bcl-xL 
expression levels. Thus, alterations in Bcl-xL distribution seem to be an early event in 
the disease process. Increasing Bcl-xL expression might potentially be one promising 
strategy for AD modification.
In the last part of the thesis, disease-modifying strategies were assessed. PC12 and 
HEK cells bearing APPsw or APPwt were treated with the potent -secretase inhibitor 
DAPT. Of note, DAPT did not only efficiently block A production, but additionally led 
to  an  elevation  of  the  MTT  reduction  potential,  reflecting  an  increase  in  cellular 
viability. In contrast to DAPT, a structurally distinct -secretase inhibitor, L-685458, 
did  not  increase  MTT  reduction  potential,  but  rather  decreased  MTT  reduction 
potential  at  high  concentrations  indicating  that  under  these  conditions,  the  -
secretase  inhibitor  exhibits  toxic  side  effects  surmounting  the  potential  beneficial 
effect  of  a  decrease  in  A production.  The  development  of  -secretase  inhibitors 
similar to DAPT seems thus to be a promising strategy for AD therapy. Furthermore, 
cells  were  treated  with  the  -secretase  inhibitor  II.  Unfortunately,  the  -secretase 
inhibitor  II  did  block A production  only  at  extremely  high  concentrations  while 
exhibiting toxic side effects reflected by a decrease in MTT reduction potential. This 
indicates that the commercially available inhibitor is not suitable for therapeutic use.
As another disease-modifying strategy, several efforts are undertaken to ameliorate 
AD-relevant symptoms by the treatment with nerve groth factor (NGF). Since NGF is 
rapidly  degraded  and  is  not  able  to  cross  the  blood  brain  barrier,  it  seems  a 
reasonable  strategy  to  apply  substances  increasing  the  NGF  action  in  the  brain. 
Generally, it is known  that substituted  pyrimidines  have  modest  growth-promoting 
effects. Here, KP544, a novel substituted pyrimidine, was characterised. The exact 
mode of action of KP544 is not known. This drug increased MTT reduction potential 
in terminally differentiated and undifferentiated PC12 cells. Furthermore, treatment 
with  KP544  led  to  a  reduction  in  A40  secretion.  In  addition,  glycogen  synthase 
kinase-3 (GSK-3)  was  inactivated  in  the  presence  of  KP544.  This  is  very 
interesting  since  GSK-3 does  not  only  modulate  APP  processing,  but  is  also 
involved  in the hyperphosphorylation  of tau,  another pathological  hallmark  of AD. 
Thus, one may conclude that the target of KP544, GSK-3, represents a connecting 
link between the two main pathological hallmarks of AD and might thus be a very 
promising therapeutic target for AD.Zusammenfassung
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6 Zusammenfassung
Alzheimer  Demenz  (AD)  ist  die  häufigste  neurodegenerative  Erkrankung,  welche 
durch  einen  kontinuierlichen  Verlust  der  Gedächtnisleistung  und  der  kognitiven 
Fähigkeiten charaktersiert ist.
Typische  pathologische  Merkmale  der  Erkrankung  sind  Amyloid-Plaques, 
neurofibrilläre Bündel und gesteigerter Zelltod. Die Amyloid-Plaques bestehen aus 
Amyloid beta-Peptid (A), welches aus dem Amyloid-Vorläufer-Protein (APP) durch 
eine initiale -Sekretase-Spaltung, gefolgt von einem intermembranären Schnitt der 
-Sekretase, gebildet wird. Autosomal-dominante Formen werden durch Mutationen 
im  APP-,  Präsenilin-1- und  Präsenilin-2-Gen  verursacht.  Diese  Mutationen 
beeinflussen die APP-Prozessierung, so dass vermehrt A gebildet wird. Auerdem 
werden sie mit einer gesteigerten Empfindlichkeit von Neuronen gegenüber Zelltod in 
Zusammenhang gebracht. Bis heute jedoch sind die molekularen Mechanismen, die für 
die massive Neurodegeneration in Gehirnen von AD-Patienten verantwortlich sind, nicht 
vollständig aufgeklärt. 
Das Ziel dieser Arbeit war die Untersuchung zellulärer Signaltransduktionswege, die 
an der Amyloidkaskade beteiligt  sind.  Hier wurde  ein besonderes  Augenmerk  auf 
intrazelluläres A gerichtet, da neuere Ergebnisse belegen, dass diese A-Spezies 
neurotoxische Effekte auslöst, und zwar lange bevor hyperphosphoryliertes Tau und 
extrazelluläre A-Ablagerungen auftreten.
Im  ersten  Teil  der  Arbeit  wurde  die  APP-Prozessierung  und  A-Produktion  in 
verschiedenen  in-vitro-Modellen  untersucht.  PC12-,  HEK- und  SY5Y-Zellen,  die 
stabil  mit  der  Schwedischen  APP-Doppelmutation  (APPsw)  und  mit  wildtyp  APP 
(APPwt)  transfiziert  wurden,  dienten  als  Zellkulturmodelle.  Die  Schwedische 
Doppelmutation auf dem APP-Gen (K670M/N671L) führt zu einer sechs- bis achtfach 
erhöhten Produktion von A1-40 und A1-42 im Vergleich zu APPwt-Zellen. 
Anhand  der  Daten  aus  PC12-Zellen  konnte  abgeleitet  werden,  dass  durch  diese 
Mutation  die  sekretierten  A-Spiegel  ohne  Beeinflussung  der  APP-Expression 
gesteigert werden. Die sekretierten A-Spiegel nehmen in der folgenden Reihenfolge 
ab: HEK APPsw >> HEK APPwt =  SY5Y APPwt > PC12 APPsw > PC12 APPwt. Zusammenfassung
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Basierend auf diesem Ergebnis erscheint es zumindest möglich, dosisabhängige A-
Effekte  in  verschiedenen  experimentellen  Ansätzen  zu  untersuchen.  Diese 
Versuchsdesigns sollten möglichst authentisch verschiedene Stadien in Alzheimer-
Gehirnen abbilden: Beispielsweise dient das APPsw PC12-Zellmodell als Modell für 
niedrige physiologische A-Konzentrationen im picomolaren Bereich, im Gegensatz 
zu APPsw HEK-Zellen, die A-Spiegel im nanomolaren Bereich zeigen. APPsw HEK-
Zellen zeigten eine spezifische und hochsignifikante Anreicherung von unlöslichem 
A1-42 im intrazellulären Kompartiment. 
Auerdem wurde eine Akkumulation von A und APP in Mitochondrien von APPsw 
HEK-Zellen  beobachtet.  Dies  lät  eine  direkte  Beeinflussung  mitochondrialer 
Funktionen  vermuten,  welche  letztendlich  zu  Störungen  im  Engergiehaushalt  der 
Zelle und zu gesteigertem Zelltod führen könnte. Desweiteren wurden die basalen 
Aktivitäten der - und -Sekretase untersucht, da diese Enzyme vielversprechende 
therapeutische  Angriffspunkte  darstellen,  um  den  Verlauf  der  Erkrankung  zu 
verlangsamen bzw. aufzuhalten. Erwartungsgemä war die -Sekretase-Aktivität in 
allen  APPsw-Klonen  erhöht.  Dies  lät  sich  durch  die  Nähe  der  Schwedischen 
Doppelmutation zum N-Terminus der A-Sequenz erklären. Interessanterweise war 
die -Sekretase-Aktivität in PC12-Zellen ebenfalls signifikant erhöht.
Die Toxizität verschiedener A-Spezies wurde in SY5Y- und PC12-Zellen im Hinblick 
auf  die  zelluläre  Viabilität,  dargestellt  durch  die  Messung  der  mitochondrialen 
Aktivität im MTT-Assay, untersucht. Hier zeigte sich, dass nicht Monomere, sondern 
Dimere  erste  toxische  Korrelate  darstellen,  und  dass  fibrilläres  A die  höchste 
Toxizität aufweist.
Im nächsten Schritt wurden SY5Y-Zellen untersucht, die dimeres APP und A (SY5Y 
APPK623C) bilden. In Übereinstimmung mit anderen Daten besaen diese Zellen im 
Vergleich  zu  APPwt  und  Kontroll-Zellen  ein  erniedrigtes  MTT-Reduktionspotential 
und somit eine reduzierte zelluläre Viabilität. Der gestörte Energiehaushalt der Zellen 
konnte durch erniedrigte basale ATP-Spiegel noch drastischer dargestellt werden.
Im zweiten Teil der Arbeit wurde die Expression und die intrazelluläre Verteilung von 
Proteinen  der  Bcl-2-Familie  und  pro-apoptotischer  mitochondrialer  Faktoren 
untersucht. Die Proteine wurden unter basalen Bedingungen und unter oxidativem 
Stress  in  APPwt  und  APPsw  Zellen  untersucht,  da  neuere  Ergebnisse  unserer 
Arbeitsgruppe  eine  zentrale  Rolle  der  Mitochondrien  bei  A-vermitteltem  Zelltod Zusammenfassung
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zeigten (Keil, U. et al., 2004; Marques, C. A. et al., 2003). Diese Faktoren könnten 
potentiell  wichtige  therapeutische  Angriffpunkte  zur  Reduktion  des  gesteigerten, 
Alzheimer-assoziierten Zelltods darstellen.
Interessanterweise sind die Expressionsspiegel des anti-apoptotischen Faktors Bcl-
xL in zytosolischen Fraktionen von APPwt und APPsw Zellen erniedrigt. Dies könnte 
darauf  hinweisen,  dass  ein  Mangel  an  anti-apoptotischen  Faktoren  oder  ihre 
veränderte  intrazelluläre  Verteilung,  eher  noch  als  eine  Erhöhung  caspase-
abhängiger,  pro-apoptotischer  Faktoren,  für  die  gesteigerte  Empfindlichkeit  der 
APPwt- und APPsw-transfizierten Zellen gegenüber oxidativem Stress verantwortlich 
ist. Da die Bcl-xL-Expression in APPsw PC12-Zellen, im Gegensatz zu APPsw HEK 
und  APPwt  SY5Y  unverändert  war,  könnten  Veränderungen  in  der  intrazellulären 
Bcl-xL-Verteilung  ein frühes  Ereignis  im  Krankheitsverlauf  darstellen.  Somit  würde 
eine  Erhöhung  der  Bcl-xL-Expression  eine  potentielle  krankheitsmodulierende 
Strategie darstellen. 
Im  letzten  Teil  der  Arbeit  wurden  krankheitsmodulierende  Strategien  untersucht. 
PC12- und  HEK-Zellen  wurden  mit  dem  potenten  -Sekretase-Inhibitor  DAPT 
behandelt. Die Behandlung mit DAPT führte nicht nur zu einer effizienten Hemmung 
der A-Produktion, sondern auch zu einer Steigerung des MTT-Reduktionspotentials, 
welche eine gesteigerte zelluläre Viabilität wiederspiegelt. Im Gegensatz zur DAPT-
Exposition erhöhte die Behandlung mit einem strukturell verschiedenen -Sekretase-
Inhibitor,  L-685458,  das  MTT-Reduktionspotential  nicht.  Im  Gegenteil,  L-685458 
führte  zu  einer  Reduktion  der  zellulären  Viabilität,  bedingt  durch  toxische 
Nebeneffekte,  welche  die  protektiven  Eigenschaften  der  -Sekretase-Inhibition 
überlagerten.  Die  Entwicklung  von  DAPT-ähnlichen  -Sekretase-Inhibitoren  könnte 
somit eine vielversprechende Strategie in der Behandlung der Alzheimer Demenz 
darstellen.  Auerdem  wurden  Zellen  mit  dem  -Sekretase-Inhibitor  II  behandelt. 
Unglücklicherweise hemmte der -Sekretase-Inhibitor II die A-Produktion nur in sehr 
hohen Konzentrationen,  bei  denen massive  toxische  Nebeneffekte  im  MTT-Assay 
beobachtet wurden. Somit scheint dieser kommerziell erhältliche Inhibitor nicht zur 
therapeutischen Anwendung geeignet zu sein. 
Es wurden schon einige Versuche unternommen, AD-relevante Symptome durch die 
Behandlung mit Nervenwachstumsfaktor (NGF) zu behandeln. Da NGF sehr rasch 
abgebaut wird und die Blut-Hirn-Schranke nicht passieren kann, erschien es sinnvoll, 
Substanzen zu entwickeln, welche die NGF-Wirkung im Gehirn fördern. Zusammenfassung
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Es  ist  allgemein  bekannt,  dass  substituierte  Pyrimidine  wachstumsfördernde 
Eigenschaften besitzen. In dieser Arbeit wurde KP544, ein neuartiges substituiertes 
Pyrimidin,  näher  charakterisiert.  Der  genaue  Wirkmechanismus  von  KP544  ist 
unbekannt.  Die  Behandlung  mit  KP544  führt  zu  einer  Steigerung  des  MTT-
Reduktionspotentials in undifferenzierten und differenzierten PC12-Zellen sowie zu 
einer  verminderten  A1-40-Sekretion.  Zusätzlich  wurde  eine  Inaktivierung  der 
Glykogen-Synthase-Kinase-3 (GSK-3)  in  Gegenwart  von  KP544  beobachtet. 
Dieser  Befund  ist  sehr  interessant,  da  GSK-3 nicht  nur  die  APP-Prozessierung, 
sondern  auch  die  Hyperphosphorylierung  von  Tau,  einem  weiteren  Merkmal  der 
Alzheimer Demenz, moduliert. Daher könnte man schlussfolgern, dass das Target 
von  KP544,  GSK-3,  ein  Bindeglied  zwischen  den  zwei  Hauptmerkmalen  der 
Alzheimer  Demenz  darstellt  und  somit  ebenfalls  ein  sehr  interessanter 
therapeutischer Angriffspunkt darstellt. References
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ABAD A-binding alcohol dehydrogenase
ADAM A disintegrin and metalloproteinase
ADAPT Alzheimer´s disease prevention trial
ADDL A-derived diffusible ligands
ADP Adenosine diphosphate
AGE Advanced glycation end products
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APH Anterior pharynx
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Apo E Apolipoprotein E
APP Amyloid precursor protein
APPK623C dimeric APP
APPsw APP bearing the Swedish mutation
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A Amyloid beta
ATP Adenosine triphosphate
BACE
-secretase, -site amyloid precursor 
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BSA Bovine serum albumne
°C degree Celsius
cdk Cyclin-dependent kinase
Ced-4
Caenorhabditis elegans protein-4, pro-
apoptotic
COX-1/-2 Cyclooxygenase 1/2
COX-4 Cytochrome c oxidase
CSF Cerebrospinal fluid
CT Computer toograhy
CTF C-termina fragmentAbbreviations
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N
6,2’-O-dibutyryladenosine 3’:5’-cyclic 
monophosphate
Delta-1 delta-like protein-1
DMEM Dulbecco´s modified eagle medium
DMSO Dinethylsulfoxide
DNA Desoxyribonucleic acid
DSM-IV
Diagnostic and Statistic manual of 
mental disorders
DTT Dithiothreitol
ECL Enhanced chemoluminescence
EDTA Ethylenediaminetetraacetate
ELISA Enzyme-linked immunosorbent assay
EOAD Early-onset AD
ER Endoplasmatic reticulum
ERAB
Endoplasmatic reticulum-associated 
amyloid beta binding protein
ErbB4
v-erb-a erythroblastic leukaemia viral 
oncogene homologue-4
ERK Extracellular signal-regulated kinase
ETC Electron transport chain
FA Formic acid
FAD Familial Alzheimer´s disease
FADH2 Flavine adenine dinucleotide
FCS Fetal calf serum
FDA Food and drug administration
g Gram
g gravitation
G418 Geneticine sulfate
GSK-3 Glycogen synthase kinase-3
GTP Guanyl triphosphate
h Hours
H2O2 Hydrogen peroxide
HEK Human embryonic kidney Abbreviations
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HIV Human immunodeficiency virus
IAP Inhibitor of apoptosis proteins
IDE Insulin-degrading enzyme
Jag-2 Jagged-2
JNK c-Jun N-terminal kinase
KP544
[2-amino-5-(4-chlorophenylethynyl)-4-
(4-trans-
hydroxycyclohexylamino)pyrimidine]
l Litre
LDH Lactate dehydrogenase
LOAD Late-onset Alzheimer´s disease
MAP Microtubule-associated protein
MAPK Mitogen-activated protein kinase
min Minutes
ml Millilitres
MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide)
NaCl Sodium chloride
NAD Nicotinamide adenine dinucleotide
NFkB Nuclear factor kB
NGF Nerve growth factor
NIA National institute of aging
NIH National institute of health
NINCDS-ADRDA
National Institute of neurologic and and 
communicative disorders and stroke-
alzheimer´s disease and related 
disorders association
NMDA N-methyl-D-aspartate
NSAIDs Non-steroidal anti-inflammatory drugs
p75
NTR Low affinity neurotrophin receptor
PBS Phosphate buffered saline
PC12 Rat pheochromocytoma
PCR Polymerase chain reactionAbbreviations
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PEN-2 Presenilin enhancer-2
PET Positron-emission tomography
PHF Paired helical filaments
PI3K Phosphoinositide-3 kinase
PMSF Phenoylmethysulfonylfluoride
PPAR-
Peroxisome proliferator activated 
receptor-
PS Presenilin
PTP Permeability transition pore
RNA Ribonucleic acid
ROS Reactive oxygen species
sAPP soluble APP
SDS Sodium dodecyl sulfate
SDS-PAGE
Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis
sec Seconds
Smac
Second mitochondrial activator of 
caspases
SY5Y Human neuroblastoma
t Time
TACE
Enzyme cleaving members of the TNF 
receptor family
Trk Tyrosine kinase
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